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Chapter 1 
Introduction 
L Normal hematopoiesis 
Blood cell formation in adult mammalians takes place in the bone marrow. The 
parental cells in the bone marrow responsible for the blood cell formation are the so-
called hematopoietic stem cells. These primitive precursor cells are capable of self-
renewal but may also differentiate into the distinct committed hematopoietic 
progenitor cells [1-3], which may finally develop into the individual blood cell types, 
e.g. erythrocytes, neutrophilic granulocytes, monocytes, platelets, or B- and T-
lymphocytes [1, 4, 5] (Figure 1). There is considerable amplification in the system: 
one stem cell may be capable of producing 106 mature blood cells after 20 cell 
divisions. As the cells differentiate they lose adhesion to the bone marrovv stroma and 
enter the blood circulation. 
Stem and progenitor cell differentiation depends largely on hematopoietic growth 
factors (HGF) (Figure 1 ). HGFs regulate proliferation, differentiation and survival of 
progenitor cells, and may also influence the function of mature blood cells (6]. HGFs 
sometimes act locally at the site where they are produced, but they may also circulate 
in the plasma. The major sources for HGFs are T -lymphocytes, monocytes, 
endothelial cells, and fibroblasts [7]. The HGF erythropoietin (EPO) is synthesised in 
the kidney [8], whereas thrombopoietin (TPO) is mainly produced in the liver [9, l 0]. 
The biological effects of HGFs are mediated through specific receptors on target cells. 
Upon binding of a HGF to its specific receptor, a cascade of signals is transmitted 
through the cytoplasm to the nucleus resulting in activation of DNA synthesis and 
regulation of transcription and translation of genes that are critical in development. 
The existence of primitive multipotential precursors and separate committed 
progenitor cells has been demonstrated in vitro by using semi-solidified colony 
culture techniques. The type of precursor that is grown in these cultures mainly 
depends on the growth factors added. HGFs that may stimulate multilineage growth 
of primitive murine bone marrow progenitor ceils, either aJone or in -;:ombination with 
other cytokines are e.g. TPO, Stem cell factor (SCF) and Interleukin 3 (IL-3 ). 
Primitive stem cells may develop into precursor cells that are committed to a 
particular differentiation lineage. Colonies containing neutrophils develop in cultures 
supplemented with granulocyte-colony stimulating factor (G-CSF}. Macrcphage 
colonies develop in the presence of macrophage-CSF (M--CSF), vd:ereas erythroid 
precursors differentiate upo!1 EPO stimulation (Figure l ). 
H. Leukemia 
Errors may occur m the process of hematopoietic development, as the result of 
mutations _in the DNA of hematopoietic precursor cells, sausing inappropriate 
expression of genes critical in blood cell development. These genetic lesions may lead 
to overactivaticn of genes (proto-oncogenes), inactivation of genes (tumour 
suppressor genes) or expression of aberrant gene products (e.g. fusion proteins). The 
consequences of these defects may be multiple, e.g. increased rate of proliferation, 
alterations in cell survival or a block in differentiation of particular hematopoietic 
lineages. The combination of different genetic lesions in a specific hematopoietic 
progenitor may ultimately result in the development of leukemia. Leukemia is 
characterised by an accumulation in the bone marrmv of non-tlE1ctional blood cells 
arrested at a particular stage of differentiation. 
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Figure 1. Hematopoiesis. 
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After a number of cell divisions and differentiation steps a pluripotent stem cell gives rise to a common 
lymphoid stem cell, as \vel! as to a series of progenitor cells for three main marrow cell lines: (a) 
erythroid, (b) granulocytic and monocytic, and (c) megakaryocytic. These processes are mediated by 
hematopoietic growth factors (IL = interleukin: TPO = chrombopoietin; GM-CSF = 
granulocyte/macrophage-colony stimulating factor; EPO = erythropoietin: M-CSF = macrophage-
colony stimulating facwr; G-CSF = granulocyte-colony stimulating factor). In virro these progenitor 
cells can be identified by in semi-solid culture medium by the type of colony they fonn. (BFUE =burst-
fanning unit, erythroid; CFU =colony fanning unit GM =granulocyte-monocyte). 
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Ha. Leukemia: classification by morphology 
Chronic as well as acute leukemias exist, which are both subdivided into myeloid or 
lymphoid fonns. In acute myeloid leukemia (AML), primitive myeloblasts pile up in 
the marrow, whereas in acute lymphoblastic leukemias (ALL), immature B-lymphoid 
(B-ALL) or T-lymphoid cells (T-ALL) accumulate in the hematopoietic system. 
Among the chronic leukemias we recognise various types, e.g. chronic myeloid 
leukemia (CML), chronic lymphocytic leukemia (CLL), hairy cell leukemia, 
prolymphocytic leukemia and various leukemia/lymphoma syndromes. 
Myeloid leukemias can be distinguished from lymphoid disease by morphologic 
analysis, immunophenotyping, cytogenetics and/or molecular diagnosis (see next 
paragraph). Acute myeloid leukemias may be classified according to the varying 
degrees of granulocytic, monocytic, erythroid or megakaryocytic differentiation of the 
leukemia cells. AML is subdivided into 8 variants based on morphology and 
cytochemistry (F AB-classification, M0-M,) [ll, 12]. 
Patients with CML present with a high amount of granulocytic cells in marrow and 
blood. In the majority of CML patients this chronic phase will be followed by an 
acute phase with high numbers of primitive myeloid cells in blood and marrow. 
Another group of diseases that frequently develop into AML is formed by the 
myelodysplastic syndromes (MDS). MDS is commonly found in the elderly and 
characterised by bone marrow failure. Most cases occur de novo, but an increasing 
number arises because of previously given chemo-or radiotherapy. CML as well as 
MDS are examples of myeloid diseases that following variable time intervals may 
transform into acute leukemia indicating that leukemia may be a multigenetic disease 
and that at least two events are required to obtain full AML. Development towards 
AML may also occur in patients suffering from particular hematopoietic disorders, 
such as neutropenia with underlying G-CSF-receptor mutations [13], Diamond-
Blackfan anemia [14, 15], or the autosomal recessive disorder Fanconi Anemia (FA) 
[16]. Patients are at high risk to developing myeloid leukemia, again suggesting that 
multiple genetic defects in those patients give rise to clinically apparent leukemia. 
The ident~fication of the genetic lesions that are responsible for dysregulation of 
hematopoiesis in humans and in animal models has been one of the main subjects in 
leukemia-research in the past two decades and forms the central theme o.fthis thesis. 
For this purpose a large panel of retrovirally induced leukemias was generated, 
which were class(fied using m01phological and immunological analyses (Chapter 2). 
The ultimate goal of these studies was the identification and cloning of novel disease 
genes (Chapters 3 and 4). 
Hb. Cytogenetics and molecular analysis of disease genes 
Leukemia is the result of disordered expression of genes leading to imbalanced 
proliferation, differentiation, and/or survival of hematopoietic precursor cells. Certain 
defects may result in abnonnal expression of a particular gene (proto-oncogenes), 
whereas due to hi-allelic inactivation so-called tumour suppressor genes may be 
turned down. Another class of cancer susceptibility genes consists of DNA repair 
genes, which are involved in maintaining genomic stability [17-20]. 
A number of aberrant gene products in human leukemias have been identified and 
isolated by chromosomal breakpoint cloning. Leukemias are frequently characterised 
by the appearance of non-random chromosomal translocations. In translocations, part 
of one chromosome is aberrantly fused to another chromosome, often resulting in the 
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generation of a fusion-gene and the subsequent expression of an aberrant fusion-
transcript and -protein. Cytogenetic abnormalities provide useful parameters for the 
distinction of leukemias with distinct prognosis. Patients carrying translocations 
t(l5; 17), t(8;21) or inv(l6)/del(l6) are among the so-called good-risk AML cases, 
whereas AML cases with a abnormality involving chromosome 3q26, 11 q, 17p, 20q, 
2lq, or with a translocation t(6;9) or t(9;22) represent the bad-risk group [21-23]. 
Among the group of bad-risk AML cases are also the ones with monosomy 7 or a 7q-, 
monosomy 5 or a 5q-, and patients with a complex karyotype (more than three 
cytogenetic abnonnalities in a leukemic cell) [21, 24]. Genes that may be aberrantly 
expressed in these latter leukemias are currently unknown. AML cases with 
cytogenetic abnormalities other than the ones described so far (e.g. +8, -Y, +6, 
del(12p)) or patients without any apparent cytogenetic abnormality have an 
intermediate-risk [22, 23, 25]. The most frequent chromosomal abnonnalities in AML 
and the genes involved have been summarised in Table 1. Besides the cytogenetic 
abnormalities that frequently result in the expression of specific breakpoint related 
fusion genes, a number of more subtle genetic alterations have been identified. 
Among these are point mutations, deletions or insertions in various genes that may be 
critical in hematopoietic development e.g. AMLI, c/EBPo.,p53 or RAS [26-29]. 
Table 1: Translocations in AML. 
translocation genes involved leukemia subtvpe fusion protein reference 
1(8;21 )( q22;q?2) AMLJIETO AML-M2 AML!-ETO [30] 
t(l6;21 )(q24;g22) AMLJIMTG16 AML AML1-MTG16 [31 J 
t(3;21)(q26;q22) AMLJIMDSJ AML AMLl-MDSl [32] 
AMLJIEVIJ AMLl-EVll [33] 
AMLJIEAP AMLl-EAP [34] 
1(3;3) (g2l;g26) EVIJ/Riboforin AMLIMDS EVll [35, 36] 
inv(3)(q2l;q26) EVIJ/Ribo(orin AMLIMDS EVll [35, 36] 
1(3; 12)(p13;g26) EVIl/TEL AML ETV6-EVII [37] 
1(1 ;3 )(p36;g21) MEL/Ribo/Orin AML MEL! [38] 
inv( l6)(p 13;q22) CBF{JIMYHJJ AML-M4ou CBF@-MYH!l [39] 
1(15; 17)(q22;g21) PMLIRARa AML-M3 PML-RARa [40] 
I( 11; 1 7)(g23 ;g21) PLZFIRARa AML-M3 PLZF-RARa [ 41 J 
1(5; 17)(q35;g21) NPMIRARa AML-M3 NPM-RARa [42] 
1(4;ll)(g21 ;g23) AF4/lvfLL mixed lineage MLL-AF4 [43] 
1(9;11 )(p22;q23) MLLT3/J'v!LL AML-M4.s MLL-AF9 [44] 
1{10;11 )(pl2;g23) MLLTJO/A1LL AML-M4.s MLL-AFlO [45] 
t(ll ;15)(q23;g14) MLLIAF15 AML-M4.s MLL-AF15 [46] 
1(7; ll)(p 15;p 15) HOXA9/NUP98 AML NUP98-HOXA9 [47] 
1(16;21 )(pll ;q22) FUS/ERG AML FUS-ERG [48] 
1(6;9)(p23;g34) DEKICAN AML DEK-CAN [49] 
1(9;22)(q34;g ll) ABLIBCR AML BCR-ABL [50] 
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It is of interest that many of the genetic aberrations in leukemia involve genes that 
normally encode transcriptional regulators, e.g. AMLJ, CBF/3, RARa, MLL, EVIl, or 
c/EBPa. Transcription factors play a critical role in the initiation of transcription and 
selectively attract RNA polymerase molecules to specific promoters [6]. In most of 
the translocations the mutated counterpart of these genes will function as a repressor, 
thereby interfering with the normal function of the non-mutated gene-products [51]. 
This interference may cause abnormal expression of downstream target genes of these 
transcription regulators ultimately influencing development of the hematopoietic cells 
expressing these mutated transcription regulators. Therefore, it is not only of interest 
which genes may be mutated in leukemia, but also which down-stream target genes 
are affected in leukemias carrying one of the frequently occurring cytogenetic 
abnormalities. 
The ident(fication ofnovel transfOrming genes as described in the studies presented in 
this thesis may serve seven:;/ goals. Novel disease genes ident{fied using our leukemia 
models may represent 1) breakpoint genes nor previous(v identified, 2) disease genes 
that may be abnormally expressed in human leukemia as the result ~(mutations other 
than chromosomal trans/ocations, 3) genes that are downstream ~f any of the 
abnormally expressed genes in AML or 4) genetic lesions that are spec(fic for virus 
induced mouse leukemias. 
HI. Identification of disease genes by means of retroviral insertional 
mutagenesis 
Since leukemia is believed to be a multigenetic disease, abnorrnai c:xpression of a 
particular gene is assumed to be one event among multiple defective genes within a 
certain leukemia. Therefore, even in cases in which a disease gene h<~s b:::cn identified, 
it is mo:ot likely that other genetic defects resulting in aberrant gene expression are 
required to obtain fuli leukemic transfonnation [52, 53]. Furthermore, m 
approximately 50% of the clinically diagnosed myeloid leukemias no cytogenetic 
abnormalities have been detected, whereas iTl r: c;t!1er cases ''1Y'1 do carry a 
cytogenetic abnormality the genes located near the bl·,2akpoints are ., Lcnknown [54-
56]. An alternative approach to find as yet undisclosed leukemia di:o, ·~se genes is the 
identification and cloning of common virus integration sl 1:es (VIS). Tl1is approach has 
proven to be a sensitive tool to identify novel proto-o:·,.::ogencs (e.g. N-myc, Evil [57, 
58]) as weli as tumour suppressor genes (e.g.p53, Nfi' i.- ]). 
[n fact, a number of genes located on chromosomal breakpoints or othenvise 
aberrantly expressed in human hematopoietic malignancies have been identified 
through ret;:oviral inse1iional mutagenesis in murine k:1. ·.~~las. Examples of these are 
Evil [58, 60], Evi2(Nfl) [61-63], Evi6(Hoxa9) [64, 65], BcU(Cyciin Dl) [66, 67], N-
Myc [57, 68], and Erg [69]. 
The molecular basis of rctroviral insertional mutagenesis in the development of 
leukemias is the activation of proto-oncogenes or inactivation of tumour suppressor 
genes as a result of proviral integration into the host genome. In mice the 
development of lymphoid, myeloid or erythroid leukemias is dependent on the 
combination of mouse strain and retrovirus. Friend MuLY gives rise to mainly 
erythroid leukemias [70], whereas Moloney Mul V in Balb/c mice is able to induce 
mainly lymphoid leukemias [71]. Although Cas-Br-M Mul V is able to generate all 
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Figure 2. Retroviral insertional mutagenesis of host genes. 
A. Stmcture of the proviral genome. The retrovims contains gag. pol, and env genes, flanked by a 
long tenninal repeat (L TR) on both sides. The L TR includes the regulatory sequences, and is 
constmcted from a U3 (containing a promoter and a poly-A signal), an R, and a U5 region. 
B. Mechanisms of activation by retroviral inse1iion: 
1. Activation by promoter inse1iion: transcription initiates from the viral promoter in either the 5' 
or 3' LTR, thereby replacing the function of the nonnal promoter. 
2. Activation by enhancement: transcriptional enhancement is probably the most frequent 
mechanism of gene activation by insertional mutagenesis. Activation by enhancement allows 
more flexibility with respect to the proviral orientation, and distance between provirus and 
target gene. 
3. Activation by mRNA truncation: this is possible by removing mRNA destabilising sequences 
in the 3 'UTR, or by integration of the provirus into the coding sequence of a gene. 
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three leukemic phenotypes in NIH-Swiss mice [72], the majority of the leukemias are 
of myeloid origin. 
Generally, expression of proto-oncogenes located in the vicinity of an inserted 
provirus is elevated by retroviral promoter or enhancer sequences. However, retroviral 
integration within the protein-coding region of a cellular target gene resulting in the 
expression of truncated proteins has also been reported. Provirus that is integrated into 
the host genome may subsequently activate a proto-oncogene or inactivate a tumour 
suppressor gene. This may occur by promoter insertion, enhancement, removal of 
mRNA destabilising motifs, or by transcription termination. Transcriptional 
enhancement is probably the most frequent mechanism of gene activation by 
insertional mutagenesis, whereas tennination of transcription is the least frequent [73] 
(Figure 2). 
The cloning of common V!Ss is an attractive approach leading to the identification of 
leukemia disease genes. Until recently the cloning of VISs consisted of time-
consuming and laborious procedures of genomic cloning, Southern blotting and 
complicated strategies to identify potential target genes within a locus. The isolation 
of common V!Ss and potential disease genes on large scale requires a more efficient 
strategy. In Chapters 3 and 4 we developed and used two PCR based methods to 
clone large numbers of virus integration sites in retrovirally induced myeloid 
leukemias. The availability of sophisticated databases allows for a rapid 
identification of target "disease" genes. 
IV. Models to study the effect of disease genes on myeloid development 
Most of the genes that we have found by retroviral insertional mutagenesis in the 
studies presented in this thesis had not previously been identified as disease genes in 
leukemia. To investigate the role of each of those genes in normal development and in 
transformation representative in vitro and in vivo models could be useful. 
IVa. In vitro models 
Study of genes of interest in vitro requires cellular models with full capability to 
differentiate. The 32D murine myeloid differentiation system is a suitable cell line 
that allows for investigating gene expression in myeloid transformation in vitro. The 
cells are fully growth factor (IL-3) dependent and in the presence of the G-CSF-
receptor, they are capable of terminal differentiation towards neutrophils [74]. Thus 
the introduction of a candidate disease gene, the effect of that gene on growth factor 
dependent proliferation, cell survival or neutrophilic maturation may be assessed. For 
instance introduction of a tnmcated G-CSF -receptor, representative of a preleukemic 
genetic abnormality, into 32D cells showed that the cells no longer developed towards 
neutrophils following G-CSF stimulation [75]. Other genes that were successfully 
introduced into 32D cells and converted a leukemic phenotype are e.g. Evil, DR-
nm23, CBFf3, and Notch] [76-79]. 
Another growth factor dependent in vitro model is the erythroid mouse cell line I/11 
[80, 81]. In analogy with 32D cells, these erythroid precursor cells are maintained in 
culture at an immature stage using a combination of two growth factors EPO and SCF 
and will differentiate when stimulated with EPO alone. Whether genes may easily be 
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introduced into these cells to study leukemic transformation in vitro has not been 
studied yet. 
In vitro differentiation models, such as 32D or I/11 may also be of use to study 
normal expression of genes during differentiation. Genes normally expressed in 
normal immature progenitors, but tumed down during differentiation may become 
transforming when they are aberrantly regulated. For instance, the identification of 
genes expressed in primitive cells but not turned down during differentiation cause a 
differentiation block and lead to leukemia. Genes which specific maturation stage 
dependent expression pattems and located in a common VIS may represent disease 
genes involved in the block of myeloid differentiation. 
Comparative eDNA was isolated and prepared ji-om Jill cells unstimulated versus 
stimuloted tvith EPO and SCF and used for hybridisation of Atlas™-.filters. to identifY 
genes or gene-combinations spec{fic for certain d{fferentiation stages. The gene 
nm23-M2 H·as ident?fied as a virus integration in a retrovirally induced myeloid 
leukemia (Chapters 4 and 5). In Chapter 6 it is shmvn that normal expression of the 
mn23-M2 gene in Jill cells is regulated by grmvth factors. Moreover, the gene 
appeared to be highly expressed in primitive cells but it was downregulated during 
differentiation. A potential novel mechanism of expression regulation is discussed. 
IVb. In vivo models 
To detennine the effect of overexpression of a gene in question on hematopoiesis in 
vivo and to investigate its possible role in hematopoietic malignancies, transgenic 
mice may be generated. Since expression of the gene should occur at a specific stage 
of the cellular developmental pathway, a proper choice of promoter should be made. 
To study the role in hematopoietic development, the promoter of the Sea-l (Ly-6E.l) 
gene may be suitable. Genes controlled by regulatory elements of the Sea-l gene are 
expressed in primitive hematopoietic cells, as has previously been shown for LacZ 
[82, 83]. Transgenic mice have been created for the proto-oncogene Evil [84], in 
which the trans gene was under the control of this Sea-l promoter. Although the 
presence of E vi 1 trans gene product was demonstrated, it was concluded that after a 
follow-up of more than one year these mice did not develop leukemia. In fact similar 
findings were reported for studies using Amll-Eto mice [85]. 
Since leukemia development is believed to be a multigenetic disease, it is not 
unexpected that these animals did not develop any disease. Several pieces of evidence 
have been put forward to show that additional hits were required to obtain full 
leukemic transfonnation. Injection of Evil transgenic mice with Cas-Br-M MuLV 
demonstrated that significantly more transgenic mice developed leukemia than vims 
treated controllittennates [84]. Amll-Eto mice did not generate leukemia either unless 
exposed to secondary stimuli [86]. A model in which mice develop a myeloid 
proliferative disease is the PmliRar transgenic, with the trans gene under the control of 
Cathepsin-G promoter. Interestingly, these animals show increased abnonnal myeloid 
development when the reciprocal Rar!Pml fusion gene is expressed as well [87]. 
These studies demonstrate that transgenic models are valuable tools to identify 
additional disease genes that may cooperate with any gene of interest. 
In Cas-Br-M induced leukemias virus integrations were fi·equently found in the gene 
encoding the peripheral cannabinoid receptor Cb2. In Chapter 7 we describe the 
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generation of two Cb2-transgenic lines, with the transgene under the control ofSca-1 
promoter. The effect of the transgene on hematopoiesis and the role in /eukernia 
development was studied using retroviral treatment of the transgenic mice. 
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Abstract 
Cas~Br-M murine leukemia vims (MuLV) is a slow-transforming retrovirus, which 
potently induces leukemias in mice and is therefore well suited for retroviral insertional 
mutagenesis. We used Cas-Br-M MuL V in NIH/Swiss mice to establish a new panel of 
mainly myeloid leukemias. All tumours found in leukemic animals were classified by 
gross pathology, morphology, immunophenotype as well as the incidence of known 
common vinrs integration sites (VISs) in MuLV -inducedmyeloid malignancies, i.e., Evil, 
Evill/Cb2, Evil2, FlU and c-Afyb. Interestingly, male mice were more susceptible than 
females to the inductionofleukemia by Cas-Br-M MuLV. Seventy-fourofthe Cas-Br-M 
MuL V -inoculated mice developed a severe splenomegaly, sometimes in association with 
a thymoma. Although most of the immunophenotyped Cas-Br-M MuL V tumours were 
of myeloid origin (58%), numerous T-cellleukemias (21%) and mixed myeloid/T-cell 
leukemias (21 %) were found. The myeloid leukemias and myeloid compmiment of the 
mixed leukemias were further characterised by immunophenotyping with stem cell-, 
myeloid- and erythroid-specific antibodies. The known Cas-Br-M MuLV common VISs 
Evil, Evili!Cb2 and Evil2 were demonstrated in 19%, 12% and 20% of the cases, 
respectively, while no Flil and c-Myb rearrangements were found. Integrations into Evil 
were restricted to myeloid leukemias, whereas those in Evil l/Cb2 and Evil2 were 
identified in myeloid as well as T -lymphoid leukemias. This panel of well-characterised 
Cas-Br-M MuLV -induced hematopoietic tumours may be useful for the isolation and 
characterisation of new proto-oncogenes involved in myeloid or T -cell leukemias. 
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Introduction 
Slow-transfonning retrovimses that do not contain oncogenes in their genome induce 
tumours by means of insertional mutagenesis [ 1-3]. The identification of common vims 
integration sites in retrovirally-induced tumours provides a powerful strategy to isolate 
novel transfonninggenes from leukemias and lymphomas [1-3]. Moreover, genes located 
on chromosomal breakpoint regions or aberrantly expressed in human hematopoietic 
malignancies have frequently been identified through retroviral insertional mutagenesis in 
murine leukemias, e.g., Evil [4, 5], Evi2 (NFl) [6-8], Evi6 (Hoxa9) [9, 10], Bell 
(CyclinDl) [ll, 12]. N-Myc [13, 14] and Erg [15, 16]. The molecular basis ofretrovira1 
insertional mutagenesis in the development of leukemias is the activation of proto-
oncogenes or inactivation of tumour suppressor genes as a result of proviral integration 
into the host genome. Generally, expression of proto-oncogenes located in the vicinity 
of an inserted provims is elevated by retroviral promoter or enhancer sequences. 
However, retroviral integration within the protein-coding region of a cellular target gene 
resulting in the expression of tnmcated products has also been observed [2, 3]. 
Cas-Br-M MuLV leukemia vims (also refetTed to as Cas-Er-E MuLV) is a naturally 
occurring ecotropic vims that induces a wide variety of hematologic diseases in NFS mice 
[17] and non-E, non-T-celi leukemias in NIH/Swiss mice [18]. A number of recurrent 
targets have been observed: Evil [5, 19, 20], Evill!Cb2 [21], Evil2 [22] and Flil [ 18] or 
for Moloney and Friend MuLV, i.e., c-Myb [23-25]. Evil encodes a zinc-finger 
transcription factor [5] and overexpression of Evil has been shown to interfere in 
granulocytic [26] as well as erythroid differentiation [27]. Evill and Evil2 are two 
relatively novel common VISs that we recently identified in Cas-Br-M MuLV-induccd 
IL-3 dependent myeloid cell line NFS 107 and the Cas-Br-M MuLV-induced primary 
tumours described in this manuscript [21, 22]. Evil I is located on mouse chromosome 
4 and the target proto-oncogene in this locus is the gene encoding the hematopoietic 
peripheral cannabinoid receptor Cb2 [21]. The candidateproto-oncogenein Evi12, vvhich 
was mapped on mouse chromosome I 0 [22], is cunentlyunknown. The ets-transcription 
factor Fli I was originalty identified by cloning proviral insertions fi·om Friend MuL V-
induced erythroid leukemias [28], but pro viruses in Flil were later also shown in non-B, 
non-T-ceH leukemias [18]. The transcription factor c-Myb is one of the best-studied 
proto-oncogenes in myeloid disease [29] and has been shown to be a target for proviral 
insertions in myeloid leukemias [3]. 
To isolate novel common VlSs and identify new target proto-oncogenes and cooperating 
proto-oncogenes [22] involved in myeloid leukemia development, we have generated a 
novel panel of Cas-Br-M MuLV-induced leukemias in NIH/S·wiss mice. We have 
characterised the hematologic malignancies by gross pathology, cytology and 
immunophenotyping using a panel of monoclonal antibodies directed to cell surface 
antigens of various blood cell lineages. Seventy-four of the 91 animals, presenting with 
a hematopoietic disease were leukemic, manifested by a splenomegaly and/or a th)'lnoma. 
\Vhile the majority of the leukemias were of myeloid migin (59%), a significant number 
of the leukemias expressed a T -cell phenotype (21 %) or a mixed myeloid/T -cell 
phenotype (21 %). We also determined the frequencies of proviral inse1iion in loci that 
have previously been shown to be recunent targets in myeloid malignancies for Cas-Br-
M MuLV. Here we demonstrate frequent retroviral inse1iion in Evil, Evil I and Evi 12, 
but not in FlU and c-Afyb. Retroviral insertion in relation to the immunophcnotypeof the 
Cas-Br-M MuLV -induced leukemias has been investigated. 
This well characterised panel of retrovirally-induced leukemias provides a powerful 
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source for the isolation of nove] transfonning proto-oncogenes involved in myeloid and 
T -cetl leukemia development. 
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Figure 1. 
Immunophenotyping of Cas-Br-M MuLV -induced primary CSL tumours. 
Representatives of leukemias with a T-cellphenotype (Thyl·+ and CDJ"'._) (A. CSL38) and with a non-T-
cell phenotype(CD3- and Thy l-or-) (B. CSL60). CSL60 is a typical example of a leukemia type IV (Table 
5), i.e., blasts with granulocytic and monocytic differentiation. 
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Materials and Methods 
Mice, viruses and pathology of tumours 
NIH/Swiss mice were obtained from Harlan(Horst, The Netherlands). Cas-Br-M MuLV-
producing NIH 3T3 cells (donated by Dr. Janet W. Hartley from the National institutes 
of Health, Bethesda, MA) [30] were cultured in Dulbecco's modified Eagle's mediwn 
(DMEM) (GIBCO, Gent, Belgium) containing 10% fetal calf serum (FCS). To obtain 
virus a 70% sub-confluent culture of Cas-Br-M MuLV-producing NIH 3T3 cells was 
incubated in 5 ml of culture medium for 18 hours at 37 ° C, in a 75cm2 culture flask. 
Newborn NIH/Swiss mice were subcutaneously injected with 100 f..ll of viral supernatant, 
made cell free by filtration (pore size, 0.22 ~m; Nucleopore Corp., Pleasanton, CA). 
Leukemias appeared 5 to 13 months after inoculation, with mice sacrificed when 
moribund. Leukemic mice had enlarged spleens, frequently accompanied with gross 
thymus enlargements. Diagnosis was based on gross pathology, cytological staining with 
May-Griinwald Giemsa and ±low-cytometric analysis using monoclonal antibodies 
directed to membrane surface antigens (Table 1 ). Leukemias were also characterised for 
DNA rearrangements within immunoglobulin heavy chain (IgH) genes. Cells were cryo-
preserved in aliquots of 50 x 106 cells in 7.5% DMSO and 20% FCS using a controlled 
freezing apparatus, and storage in liquid nitrogen. 
Table 1: Monoclonal antibodies. 
Antibody Antigen Specificity Rethences 
ER-MP54 ER-MP54 Ag myeloid cells [31] 
ER-MP58 ER-MP58 Ag myeloid cells [31] 
Ml/70 Macl non-fixed macrophages [32] 
granulocytes 
natural killer cells 
F4/80 F4/80 Ag macrophages [33) 
RB6-8C5 Grl granulocytes [34! 
ER-MP21 Transferrin Receptor cells in cycle [35] 
e hroid cells 
TER119 Glycophorin A mature erythroid cells [36] 
59-AD2.2 Thy! T-cells [37] 
hematopoietic stem cells 
m eloid cells 
KT3 CD3 mature functional T-cells [38] 
RA3 6B2 B220 B-cells [39] 
mveloid cells 
Ell 16!-7 Seal hematopoietic precursors [40] 
T-cells 
Labelling of cells with monoclonal antibodies and jlow-cytometry 
Cells were labelled sequentially with rat monoclonal antibodies (I'AoAbs) followed by 
Ga.Ra (Goat anti Rat)-FITC (Nordic, Tilburg, The Netherlands). All incubations were 
carried om 30 minutes on ice in phosphate buffered saline supplemented with 1% bovine 
serum albumin. The specifications of the MoAbs used in this study are described in 
Table 1. Cell surface fluorescence was analysed using a F ACScan flow cytometer (Becton 
Dickinson, Mountain View, CA). A sample was considered positive for a particular 
marker when 30% or more of the cells showed positive fluorescence (Figure I). In the 
case of Thyl expression, a disc1imination between ~nterrnediate positive (Thyl +; not 
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more than 1 log difference in fluorescence intensity between positive and the negative 
control) and strongly positive (Thyl++; 2 log difference or more between positive and 
negative) (Figure 1) was made. 
DNA isolation, Southern blot analysis and probes 
Isolation of genomic DNA and Southern blot analysis was carried out exactly as described 
previously [21]. The immunoglobulin heavy chain region was analysed with an EcoR!-
Bglll (2.5 kb) Jh probe from clone H24 [41] (a gift from Dr. T.Honjo, Kyoto University, 
Japan). The T-cell-receptorB-chaingene was analysed with a 4 kbHindlll 1,11 probe [42]. 
Rearrangements in the Evil locus were detected using the 535 bp eDNA fragment that 
we recently described [ 16], while those in the Evill/Cb2 locus were studied with a 1.2 
kb EcoRi-BamHI Cb2 eDNA fragment[21}. Evil2 rearrangements were studied with the 
503 probe obtained with a RT-PCR based strategy to isolate complementary DNA 
fragments flanking retrovirus integration sites [ 16]. Rearrangements in the c-1\1yb gene 
were determined with a 450 bp Ncoi-EcoRI and a 500bp Pstl-Psti eDNA probe spanning 
cxons 3,4,5 and 6 of the gene [43}. Flil insertions were studied using a 1.7 kb EcoRI 
eDNA probe [28]. 
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Figure 2. 
females 
males 
Survival curves of male(-) and rc:male (---)NIH/Swiss mice developing leukemia allcrinoculation with 
Cas-Br-M MuLV. 
A log-rank test was perfotmed, based on Kaplan Meier analysis. Males died significantly earlier than 
females (p<O.OOl). The x-axis represents the time at which the mice developed leukemia after injection 
with the Cas-Br-M MuLV. 
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Results 
Leukemia development and gross pathology 
Tumour incidence, gross pathology and histology - Newborn NIH/Swiss mice were 
inoculated with Cas-Br-M MuLV-containingculture supematant. Ninety-one of the 116 
mice inoculated developed hematologic malignancies, with 74 of these becoming severely 
sick with signs of splenomegaly and/or a thymoma (Table 2). The other 17 mice 
developed a mild disease, with a moderate increase (two-fold) in spleen size. Eighteen of 
the 25 mice without evidence of hematological disease died of unlmown causes. The 
remaining 7 mice (females) were sacrificed at the end of the experiment, i.e., after 394 
days, without signs of leukemia or any other disease. 
Table 2: Frequency of Cas-Br-M MuL V-induced leukemias in NIH/Swiss mice. 
~o. of mice No. of leukemias Frequency(%} 
Males 54 41 76 
Females 62 ]] 53 
Total 116 74 64 
Cytological analysis of mice with splenomegaly alone revealed inunature blast cells 
(46%), myeloblasts with granulocytic features (27%) or lymphocytes (27%). In 82% of 
the mice with a thymoma histology the presence of a high percentage of lymphocytes 
was observed, whereas the remaining ( 18%) contained itmnature blast cells without signs 
of granulocytic differentiation. 
Differences between male andjf:malemice- In this study we focused on the 74 cases with 
severe hematologic malignancies. Interestingly, only 33 out of 62 (53%) female mice 
developed severe leukemia, whereas tumour fonnation in male mice was evident in 41 of 
54 (76%) cases. Furthennore, male mice developed leukemia more rapidly then female 
mice (Figure 2). Thus, male NIH/Swiss mice appear to be more susceptible to leukemia 
induction by Cas-Br-M MuL V than female animals. In contrast, gross pathology revealed 
no significant differences between sexes in the leukemia types found (Table 3). Thirty-
one out of41 male mice (71 %) and 24 out of33 females (73%) manifested leukemia with 
a major spleen enlargement, while in 10 of 41 males (24%) and 7 of 33 females (21 %) the 
mice also developed a thymoma. Two females developed thymoma without 
splenomegaly. 
Table 3: Gross pathology of Cas-Br-M MuL V-induced leukemias. 
Sex Gross pathology :'\lo. of % Latency period mean 
mice (days days) 
Male 31 76 166-799 215 
0 0 
splenomegaly and thymus 10 24 137-236 197 
enlaro-ement 
total 41 100 ll7-299 211 
Female selenomegaly ?4 73 170-394 ?63 
thymus enlargement ? 6 175-224 
splenomegaly and thymus 7 21 177-314 245 
enlargement 
total 33 100 170-394 245 
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Phenotype of Cas-Br-M lvfuL V-induced leukemias 
Leukemic cells from spleen, thymus or bone marrow of 63 of the 74 cases with severe 
disease could be immunophenotyped by flow-cytometry using monoclonal antibodies 
(Table 1). 
T-ee!! leukemias- Thirteen cases displayed a solely T-cell phenotype, i.e., CD3+-,-/ 
Thy!++ (II cases), CDr+; Thy!· (one case) or CD3-/ Thy!+- (one case), without 
expression of myeloid markers (Figure 1 and Table 4). In ten of those mice the T-cell 
origin of the leukemia was substantiated by the presence of a thymoma (Table 4). In 13 
cases the leukemic cells expressed T -cell as well as myeloid markers, with eight of these 
displaying a thymus enlargement as welL 
Myeloid leukemias- A CDY/Thyl· or CD3-;Thyl +non-T-cell phenotype (Figure I and 
Table 4) was found in 37 cases. Thirty-six of those 37 cases displayed a major spleen 
enlargement without a thymoma. These leukemias and the non-lymphoid compartment 
of the 13 mixed leukemias, containing both CD3~/Thyl ~and CD3- cells, were further 
immunophenotyped using the complete panel of monoclonal antibodies (Table 1 ), which 
revealed heterogeneity among the cases. Six cases (5 non-T-cell and 1 mixed leukemia) 
showed an immature myeloid phenotype, i.e., hnm+ (Sea+, Thy I+, ER-MP58+ and/or 
ER-MP54+), Gr!-. Macr and F4/80-(Table 5). Four cases revealed a myeloid phenotype 
with neutrophil characteristics, i.e., Im1r/, Gr+, (Macl+) but F4/80-. Myeloid leukemias 
expressing monocyte/macrophage differentiation markers, i.e., lmm+, F4/80+, Macl+, but 
Gr1- were identified in 16 (11 non-T-celland 5 mixed leukemias)cases. Twelve (9 non-T-
cell and 3 mixed leukemias) cases expressed monocytic as well as granulocytic 
differentiation markers, i.e., hnm_,_, F4/80-'--, Macl_,_ and Grl+. In 10 cases myeloid and 
erythroid differentiation markers (ER-MP21- and Terll9+) were identified. In 2 out of 
the 37 non-T-cellleukemia cases, mainly B220+ lymphocytes were found. Although 
these data suggest that these leukemias are ofB-1ymphocyte origin, no rearrangements 
in the immunoglobulin heavy chain genes were found using a Jh-probe on EcoRl digested 
genomic DNAs of these cells (data not shown). In fact, no rearrangements in the lgH gene 
were found in any of the other cases (data not shown). 
Retroviral integrations in Cas-Br-Ji;f MuLV induced leukemias 
Cas-Br-M MuLV-associatedcommon V!Ss- Loci previously shown to be targets for Cas-
Br-M provims are Evil [5, 19, 20, 44]. Evill/Cb2 [21]. Evil2 [22] and Fli I [18] while 
Moloney- and Friend MuLV also target c-Myb [23-25]. To study the frequencies of 
rearrangements in these loci, Southem blot analysis was carried out on spleen and/or 
thymus DNA obtained from the 74 mice with severe disease. Rearrangements in Evil, 
Evill or Evil 2 were found in 28 cases (Figure 3). No abnonnalitiesin Flil or c-lvfyh were 
observed. In 48 out of 74 cases no retroviral inse1iions in any ofthese regions could be 
identified. 
Evil- Rearrangements in the Evil gene were found in 14 out of74 cases (Figure 3 and 
4A). Those novel retroviral insertions in the Evil locus are situated in the same region of 
the Evil locus, as the previously described Cas-Br-M MuLV Evil insertions (Figme4B) 
[16, 20, 45]. Evil rearrangements were demonstrated in non-T-een or mixed lineage 
leukemias, and not in T -celi leukemias (Table 6). Two leukemias expressed an imrnamre 
immunophenotype, one leukemia showed monocytic differentiation. a fourth leukemia 
expressed granulocytic markers and two other leukemias coexpressed monocytic as well 
as granulocytic characteris;:ics. interestingly, 5 leukemias showed an erythroid 
phenotype, i.e., the cciis .... ,., .. ere ER-MP21 and TER119 positive ~:Table 5). Three mice, 
from which the tumours afterwards were shown to have Evil rearrange:;nems.died before 
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Table 4. Immunophenotypingof Cas-Br-M MuL V-inducedleukemias:T -cell versus non-T-cellleukernias. 
imrnunophenotvpe Seienomegaly 
T -cell leukemias CD3 "/Th f 3' 
Non-T -ccD leukemias " CD3"/Tirrl·"'·' 36 
Mixed leukemias CD3 '/Thyl ' and 5 
CD3"/Th r"'-
Ncl evaluable ll 
Total 55 
"Mice ·with 2. thymoma i:;clude c2.ses with or without a splenomegaly. 
bIn one case (CSL 70) CDl'"'"tfhy 1· lymphocytes were found. 
'In one case (CSL54) CD3-/Thyr' lymphocytes were observed. 
"CD3. non-T-ceii leukemias Thy or Thyl but not Thy I_,_ cclis. 
'fhymom::t. 'J:otall 
10' 13 
l 37 
8 l] 
0 
" 
19 7-:1 
0 Mixed leukemias CO!"it.:.:n c:;;,. '/Thyi 'I :-lymphocytes 2.1; -,vel] as CD?" !eukemis celL. 
,·o•=-~-~. ~----· -·-· =~~-=~~·=~==-===-~=-==--===-=""'""'~=-~-
Err~mlJDOphenoty~tf'" ~:"H>-T-cdl 11:1!ixed Evil-+ 
leukemias leukemias/ leukemias ~--,~--~-~~--~---.,.---.,.---.,.---.,.---.,.-==:,;:_-==~="""-"-
l;mnatur.?. blast cells Grl , F4/80·, Mac:- 5 2 
and Imm' 
IG 
IV 
Blasr;; , .. llr. 
ncl'tr0i i!ic 
differ::n :uLi.or .. 
B~asts \Vith 
monocy1'ic 
di cleremwti o,·. 
Blast::; with 
granulocytic and 
monocyt1c 
ditfere.1tid,or. 
Blasts \Vith myeloid 
anC erythroid 
differentiation 
G.-~-'-·;.:'4.:'80-, (Mac+)' 
.c-.;: G. Im1r/ 
G1l . F4180~, Macl 
and Jmnt 
Grl_,_, ~4/80. Mac!'' 
and lmm-
ll 
9 
ER-l\tlP2I"'·TERlJS+, 6 
Imm 1 .(M<!c!') 
(F4/RO-) and (Grl-) 
B770" 'InC. otnef 7 
37 
G 
5 
3 
0 
13 
Q 
ll 
Leukemias \Ve"e immunopnenotvped using the rnonoclonal;;:ntibodies indicated in Table l. 
"(l_mm ') iaci;cate,; tbat cdb may express r. combination v-1 Seal, ER-lvl?58, ER-MP5t-, m1d /or Thyl. 
1
' lviixed kul~·.:m\;_•,-.,: com:o,d -1· ·lympf,ocytic as wei! as ncn T -cellleLl;cc,?Jiz._ cells. In this case rh(! nVll-T-
cell compai"t;~·.cn~ is analysed .. , cxptcssion nE:rl;ers bc1-·Neei: brnc:cns may be positive or negati'JC 
any viable cell could be hz.rvested s.11d immunophenotyped. 
Evi ;:]/Cb]- The target gene in EviJ! bas bee'-1 shoyvn to be Cb2. Ret~·ovira! insertions in 
Cb1 occur e:tbe:r :::' or 3' of t)Je protein-coding region [2:, 22]. Rcanangements i~1 
Evi,~I!Cb2 \v-;:;re {mnd ins- of the 74 cases studied (Figw·c 3). The exact positions of 
thes;;; Evil 1 retrovirai insertion sires have been donnnented recently [22_1· Evil i 
rcmTangements Vi/ere founc1 in T -ceU, myeloid or mixed leukemias (Table 6). Three Evil I 
rearrangement~ \vere found in leu.kemic spleens obtained from mice that died before 
immunological ancdysis could be canied out. Interestingly, i~1 addition to the 9 l~ukcmic 
cases, SoLtfhcr:: bbt s_;;alys.is reveaied rearrangcmems it: th~ Evil j/Ch2 locus in splenic 
DT'-Ti\ ft,·on:: c.. (:r ~:·J;::. :'7 cases w~lb a r:lii-='~ dise:as-.::. LC. C:St74 and c:SL75. 
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Evil2- Evi12 rearrangements occurred in 15 of the 74leukemic cases (Figure 3). Those 
proviral insertions are all present in a relatively small 1600 bp region, located upstream 
of the Tral !Grp94 gene and have been described recently [22]. The target gene in Evil2 
is currently unknown. As with Evill/Cb2 rearrangements, retroviral insertions in Evi12 
have been found in T -cell (3 cases), non-T -cell (2 cases) and mixed leukemias ( 4 cases) 
(Table 6). Out of the 74 mice that developed a severe leukemia, 5 died before any viable 
cell could be harvested. Interestingly, all five mice carried a retroviral insertion in Evil2. 
Tumours with multiple rearrangements - Coincidence of Evil with other integrations 
appeared to be rare: Evil andEvill /Cb2 in 1 case, Evil and Evil2 in 2 cases, while Evi 1, 
Evill/Cb2 and Evil2 was also observed in 1 case (Figure 3). Interestingly, six of the 
Evil l/Cb2 rearranged cases also harboured£vil2 vims integrations(Figure 3). These data 
may suggest cooperation in leukemia development between Cb2 and the target gene in the 
Evil2 locus. Only three of those cases could be analysed phenotypically. One leukemia 
had aT-cell phenotype (CSL14) and 2 mixed leukemias expressed T-cell as well as 
myeloid markers (CSL12 and -16). 
Table 6. Common virus integration sites in Cas-Br-M MuLV-induced tumours: immunologic 
characterisation. 
Leukemia tvpe Evil Evi1l!Cb2 Evil2 
T -cell leukemia 0 2 3 
Non-T- non-8-cellleukemia 9 l 2 
Mixed leukemia" 2 3 4 
Deadn 3 3 5 
Total 14 9 15 
" Mixed leukemias contain T lymphocytic as well as non T -cell leukemia cells. 
b Immunophenotype could not be determined due to the high percentage of dead cells 
14/74 9/74 
Evi1 Evi11/Cb2 
Figure 3. 
15/74 
Evi12 
CSL63 and -105 
CSL 11,-15, -17, -35, 
-60, -85, and -89 
CSL 12, -14, -16, -27, 
and -97 
CSL13 
CSL29 and -93 
CSL30, -41,-46,-57,-
78,-94,-95,-99,-117, 
and-123 
Common virus integration sites Evil, Evill/Cb2 and Evil2 in primary CSL tumours 
Diagram representing the different provirus insertions in Evil, Evill!Cb2 and Evi12 in the primary CSL 
tumours. Overlapping boxes symbolise coincidence ofprovims insertions in two or three common VISs, 
i.e., Evil, Evil! /Cb2 and/or Evi 12. The CSL leukemia numbers are depicted. The y-axis represents the 
sum of the leukemias. 
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Figure 4. 
Provirus insertion in the common VIS Evil 
A. Southern blot analysis ofPstl-, Pvuii- aodSsti-digestedgenomic DNA ofprimaryCSL tumours. 
Filters were hybridised with fragment 1 (Figure 4B), a eDNA specific for the Evil locus [16]. 
The size marker is depicted in kilobases and an arrow indicates the size of the nonnal allele. All 
tumours, i.e., CSL23, -29, -30, -41 and -95 contain rearrangements in the Evil locus, 
representing the leukemic subpopulation. 
B. Schematic representation of the genomic structure of the Evil locus (PII:Pvull, B:BamHI, S:Sstl, 
P:Pstl, H:Hindiii). The first three exons of the Evil gene are indicated by black boxes. The 
location and orientationofprovirusesin the Cas-Br-MMuLV-inducedprimaryCSL tumours and 
NFS cell lines [17] are depicted by arrows. 
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Discussion 
Cas-Br-M MuL V -injected newborn NIH/Swiss mice developed detectable leukemias by 
approximately 140 to 400 days post inoculation. I'viost of these were myeloid leukemias 
(59%), although T -cell (21 %) and mixed T-cell!myeloid (21%) leukemias were found. 
These results differ somewhat from other studies. Cas-Br-M induced a wide spectrum 
of hematopoietic neoplasias in NFS/N mice, including T -, pre-B- and B-celllymphomas 
as well as erythroid, myeloid and megakmyocyticleukemias [ 17, 46]. Bergeron eta!. [ 18, 
20, 44} reported the developmentofmainlynon-T, non-B-celllymphomas in NIH/Swiss 
mice after injection with Cas-Er-E MuLV. In contrast, we observed T -cell and myeloid 
leukemias in the same mouse strain. The major difference between the two studies is that 
Bergeron used a molecular clone NE-8, described by Jolicoeur eta!. [47], whereas we 
inoculated a biologicallyclonedCas-Br-M MuL V stock obtained by limiting dilution [30] 
in the same mouse strain. In contrast to our studies, Bergeron et a!. observed frequent 
insertions ofCas-Br-E MuL V in Flil [18, 20, 44], whereas these investigators observed 
no Cas-Br-E provirus insertions in either Evil J/Cb2 or in Evil2 loci (personal 
communication E. Rassart). In fact, only Mink Cell Focus Fonningretroviral integrations 
were identified in Evil] and Evil2 [22], suggesting the presence of amphotropic virus 
contaminant in the Cas-Br-M stock, which is absent in Cas-Br-E. [48, 49] In addition, 
no rearrangements of c-Myb were detected in either study, indicating that the c-Afyb locus 
is a frequent target for Moloney- and Friend MuL V [3, 23-25], but not for Cas-Br-type 
viruses. The results from these studies together reemphasize that different retroviruses 
or even subclones of a particular retrovirus may result in proviral integration in distinct 
loci, thereby determining the development of selective types of leukemia or lymphoma 
[2, 3]. 
More males then females developed leukemia following Cas-Br-M MuLV-injection. In 
fact, seven female mice did not develop any hematological malignancy at all even 13 
months after inoculation. Moreover, male mice developed leukemia more rapidly than 
females did. Gender related sensitivity to tumour inducing agents in rodents has been 
documented in several tumorigenic conditions before. For instance, female animals have 
been reported to be more sensitive to certain tumour inducing agents or viruses [50, 51}, 
whereas other studies have demonstrated a higher tumour incidence in males following 
exposure to radiation [52, 53]. As an interesting parallel to our study, the radiation-
induced tumours, showing greater susceptibility in male mice, represent cases of acute 
myeloid leukemia [52, 53]. Explanations to clarify these gender-specific differences are 
mainly based on speculation, including possible differences in sensitivity of certain 
tumour cells to gender-specific honnones [50, 53]. Although, gender-specific leukemia 
development is currently not one of the purposes of our investigations, the difference in 
sensitivity between male and female mice to Cas-Br-M MuLV-induced leukemia 
progression is intriguing and requires further study. 
Retroviral insertions in the Evi I locus occurred in myeloid, erythroid or mixed myeloid!T-
cell leukemias (19% (14174)). These results are in agreement with many reports showing 
that Evil is a proto-oncogene mainly involved in myeloid leukemia progression [5, 20, 
44, 45]. In humans, EVIl has shown to be mutated in acute myeloid leukemias with 
chromosome 3q26 abnormalities [4] and in certain cases of myelodysplastic syndrome 
[54], a preleukemic disease characterised by a severe anemia. Overexpression of Evil in 
32Dcl3 cells has been shown to interfere with granulocytic differentiation of these cells 
when stimulated with G-CSF [26]. In addition, Kreider eta/. [27] demonstrated a block 
of erythroid differentiation by Evil in vitro. Possibly, Evil interferes with GAT AI. a 
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transcription factor that is indispensable for erythropoiesis [55, 56]. Recent studies with 
Evil transgenic mice also support this hypothesis, i.e., a defective erythropoiesis as a 
result of Evil overexpression [57]. In this study, we show that Evil retroviral 
integrations frequently occur in leukemic blast cells expressing not only myeloid, but also 
erythroid specific markers, i.e., ER-MP2l and TER119. These observations support the 
hypothesis that one of the major effects of aberrantly expressed Evi 1 in hematopoietic 
precursors is a block of erythropoiesis. 
In contrast to Evil proviral insertions, retroviral integrations in Evil J!Cb2 (12% (9/74)) 
and Evi 12 (20% (15/74)) are not lineage-restricted. The observations that Evill/Cb2 and 
Evil2 mutations occurred in T -cell leukemias as well as in myeloid leukemias, suggest 
that retroviral insertions in those loci may have occurred early in hematopoiesis, i.e., in 
primitive hematopoietic stem cells. Subsequently, additional mutations, e.g., Evil 
retroviral insertions, may detcnnine whether myeloid or lymphoid leukemias evolve. 
Leukemia initiation and progression involves aberrant expression of multiple genes [58]. 
Two or more VISs have frequently been shown to be present in one particulartumour or 
tumour cell line. For instance, Hoxa and Pbxl-related genes in myeloid leukemias [1 OJ, 
c-Myc and M-CSF in a monocyte tumour [59], IL-3, SCL and Hoxh8 in myeloid WEHI-
3B(D') cells [60],IL-3 or GM-CSFandc-Myb in WEHI-274cells [61], IL-3 and GM-CSF 
in in vivo-passaged FDC-PI cells [62], p53 and PUI in erythroleukemias [63], and Flil 
andp53 in non-T-, non-E-cell leukemias [20]. These data indicate that leukemogenesis, 
like oncogenesis in general [64, 65], is indeed a multistep process involving mutation of 
multiple oncogenes [58}. The simultaneous occurrence of different VISs in the same 
infected animal suggests a similar mechanism underlying mmine leukemogenesis. 
Evil l/Cb2 and Evil2 insertions frequently coincided in the same leukemias suggesting 
that the Cb2 in Evil 1 and the currently unknown Evil2-target oncogene cooperate in 
leukemia development. Here we demonstrateretroviral integration in Evil and Evil] !Cb2 
in two cases, i.e., CSL13 and -23. In fact, aberrant expression of Evil and EviiJICb2, as 
a result of retroviral insertions in both loci has been demonstrated in the myeloid cell line 
NFS78 [21]. These results suggest that in certain cases of myeloid leukemia these two 
proto-oncogenes may collaborate in hematopoietic transfommtion. This hypothesis will 
be directly assessed in vivo by cross-breeding of Evil- and Cb2-transgenic mice that we 
have recently generated (unpublished results). Evil also appears to collaborate with an 
Evi 1 2-related proto-oncogene since three leukemias contain insertions in both these loci, 
i.e., CSL13, -29 and -93. Two common VISs, which frequently coincide are Evil l/Cb2 
and Evz'l2, i.e., rearrangements were shown in both common VISs in CSLI2, -13, -16,-27 
and 97. Although the target gene in Evil2 is currently unknown, the data obtained so far 
are highly suggestive for collaboration of Cb2 and a protooncogene at the Evil2-Iocus in 
leukemia progression. In one leukemia, CSL13, three loci, Evil, Evill !Cb2 and Evil2 
harbour Cas-Br-M provirus, which may imply that indeed three or maybe more genetic 
defects are required for full leukemic transfonnation [64]. 
Interestingly, in 18 of the 26 cases retroviral insertion was observed in only one locus, 
i.e., Evil, Evil] or Evil2 and in 48 cases we did not identify any retroviral insertion in 
the loci that we studied. These results suggest that many unknown candidate target genes 
for Cas-Br-M provirus are still waiting to be discovered in our panel of leukemias. Large-
scale isolation of retroviral flanking sequences is currently being canied out in our series 
of leukemias using inverse PCR procedures. Nucleotide sequence analysis and differential 
probing to griddedhigh density filters from a BAC library will be caniedout to identify 
novel common integration sites and new (collaborating) proto-oncogenes. These studies 
may result in the definition of complementation groups of transfonninggenes which may 
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provide insight into the defects that may occur in different signalling pathways leading 
to full malignant transformation of hematopoietic cells. 
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Abstract 
Proto-oncogenes in retrovirally induced myeloid mouse leukemias are frequently 
activated following retroviral insertion. The identification of common virus 
integration sites (VISs) and isolation of the transforming oncogene is laborious and 
time-consuming. We established a rapid and simple PCR based procedure, which 
facilitates the identification of VISs and novel proto-oncogenes. Complementary 
DNA fragments adjacent to retrovirus integration sites were selectively isolated by 
applying a reverse transcriptase reaction (RT) using an oligo(dT)-adapter primer, 
followed by PCR using the adapter sequence and a retrovirus long terminal repeat 
(LTR) specific primer. Multiple chimeric eDNA fragments suitable for Southern and 
Northern blot analysis were isolated. 
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Results and Discussion 
Retroviral insertional mutagenesis is a powerful method to isolate proto-oncogenes 
from retrovirally induced leukemias and lymphomas (reviewed in [1]). A common 
VIS, which marks the position of a possible proto-oncogene, is characterised by 
retroviral insertions within corresponding genomic loci of various independent 
tumours and visualised by Southem blot analysis with probes flanking the actual VIS. 
Unknown flanking DNA sequences have been detennined by genomic cloning [2], 
inverse PCR [3], biotinylated DNA labelling followed by PCR [4] and other PCR 
based methods [5, 6]. However, these methods cany cetiain disadvantages. Isolation 
of VIS flanking cellular DNA fragments by genomic cloning requires the 
establishment of DNA libraries, which is time-consuming and the libraries have to be 
made for every individual tumour or cell line. The PCR based methods consist of 
critical ligation [3], tailing [ 6] or biotinylating steps [ 4]. 
Several mechanisms are known by which retroviral sequences affect normal gene 
expression [ 1]. Promoter activation as well as enhancement by proviral integration 
within the 3' untranslated region requires that the viral LTR and the cellular gene are 
in the same transcriptional orientation [1]. As a result of these integrations 
transcription may be initiated from the retroviral L TR promoters and terminated by 
poly( A) signals of cellular genes (Figure 1 A). Consequently, retrovirally initiated 
chimeric mRNA transcripts consist of a 5' leader derived from the viral L TR [2, 7] 
and a 3' poly( A) tail of a cellular gene. The overall RT-PCR based method to isolate 
these chimeric cDNAs is schematically shown in Figure lA. Poly(A)+ RNA was 
purified using oligo(dT) cellulose columns (Phannacia) from a panel of Cas-Br-M 
MuLV-induced murine myeloid leukemia cell lines (NFS22, NFS56, NFS58, NFS60 
and NFS78) [8]. First-strand eDNA was obtained by reverse transcriptase (RT) 
reactions at 37'C with 3[.lg poly(Af RNA, I unit RNAguard (Phannacia) and 100 
units of SuperScript RT (Gibco) in 50mM Tris-HCl (pH 8.3), 75mM KCl, 3mM 
MgC!, ,lmM DTT, 0.5mM dNTP' and 40mM ohgo(dT)-adapter primer (5'GTC GCG 
AAT TCG TCG ACG CG(dT)ts3'). The integrity of the poly(Af RNA and first-
strand eDNA synthesis was verified by PCR (! OmM Tris-HCI (pH 8.3), 50mM KCI, 
!.5mM MgCl,, 150[.<M dNTP' and 2.5 units of Tag-polymerase (Phannacia), 1 min at 
94°C, 1 min at 50°C and 3 min at 72°C (25 cycles)) with human f3-actin specific 
primers, highly homologous to murine 13-actin and located in two separate exons 
(MB6: 5'CTG GAC TTC GAG CAA GAG AT3' and MB7: 5'TCG TCA TAC TCC 
TGC TTG CT3'). Fragments of 433 bp were amplified with the ~-actin primers solely 
in the presence of reverse transcriptase (Figure lB). Subsequently, PCRs (1 min at 
94'C, 1 min at 58'C and 3 min at 72'C (30 cycles)) were performed on the RT-
reactions of the NFS cell lines by using the LTR-specific primer (pLTRl: 5'GGG 
TCT CCT CAG AGT GAT TG3 ') and the adapter primer (adapter: 5'GTC GCG AA T 
TCG TCG ACG CG3'). Fragments of different size, 0.1 to 2.5 kb, were detected in all 
cell lines tested (Figure 1B). No DNA fragments were amplified if PCR was not 
preceded by eDNA synthesis, indicating that only transcribed fragments were 
amplified. Fragments were cloned into the EcoRV site ofpBluescript SK+ (Stratagene, 
La Jolla, CA) and the viral origin of the cDNAs was confinned by sequence analysis 
(Figure lC). No cDNAs were detected entirely consisting of viral sequences but, as 
expected, 100% of the cDNAs contained LTR sequences at the 5' end. The eDNA 
sequences were compared with the database of the National Center for Biotechnology 
Infonnation (NCBl) to identify possible homologous sequences. VISs were detected 
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within the murine homologue of the hERG gene [9}, which encodes a transcription 
factor, involved in AML t(l6;21) [10] and within the promoter region of the mouse T-
cell receptor y chain near the V g6 gene [ 11]. 
The basis of inse1iional mutagenesis to identify proto-oncogenes is the isolation of 
common VISs in independent tumours or tumour cell lines. Southern blot analysis of 
one fragment, derived from NFS22, is shown in Figure 2A. Rearrangements in 
various independent cell lines, i.e., NFS22, NFS58, NFS60 and NFS78, were 
detected. A partial restriction map and the orientations of the proviruses were 
established (Figure 2B) using the Southern blot data. The orientation and location of 
the proviral DNAs in NFS58, NFS60 and NFS78 implicated that fragment 1 was 
localised in the commonly rearranged Evil locus [7, 12], within intron 2 of the Evil 
gene. Northern blot analysis showed that this intron due to proviral integration is 
highly expressed in NFS22 and NFS78 (Figure 2C), which could be expected from 
the orientation of virus integrations in NFS22 and NFS78 (Figure 28). In myeloid 
leukemias the Evil gene is frequently activated due to viral integration within the 
murine gene [7] and in human AMLs due to translocation involving chromosome 
3q26 [13]. Transcripts initiated from the retroviral promoter were selectively 
amplified. The existence of a poly(A) signal (AATAAA) (70%) and more than 15 
adenine residues (55%) at the 31 end of all eDNA fragments (data not shown) may 
suggest that eDNA synthesis regularly initiated at mRNA poly(A) tails. It is however 
possible that eDNA synthesis initiates at A-rich sequences. In fact, the isolated Evil 
eDNA represents a sequence located Y within a cellular gene. Nevertheless, the 
isolation of eDNA fragments will eventually facilitate the identification of target 
genes in the leukemias (Figure 2C). eDNA fragments which did not show homology 
with known genes will be used for Southern blot screening purposes to search for new 
common VISs. The fact that three out of thirteen cDNAs represent known genes of 
which two (Evil and Erg) have been demonstrated to be involved in myeloid 
leukemia [10, 13] suggests that the described method is powerful for the rapid 
identification of novel common VISs and proto-oncogenes. 
Figure l. RT-PCR based method to isolate eDNA fragments t1anking VlSs. 
A. Schematic representation of the strategy to rapidly amplify eDNA fragments adjacent to virus 
integration sites. Viral insertions in a cellular gene may generate abemmt nLE<NAs initiated 
through transcription from the viral promoter located on the lung terminal rcpca: (LTR). -:-he 
aberrant mRNA is polyadenylated downstream of the cellular polyildenylation signal 
(AAT AAA). eDNA is synthesised by reverse transcription using an oligo(dT)-adapter primer 
which primes on the poly(A) tails or A rich sequences (3'RACE: 3' rapid amplification of eDNA 
ends). Using the adapter primer and an L TR specific primer (pLTRl) the cellular DNA 
fragments flanking the VIS are amplified by PCR. 
B. RT-PCR (adapter/pLTRl) on poly(Ar RNA isolated from Cas-Br-M MuLV-induced myeloid 
leukemia cell lines NFS22, NF$56. NFS58. NFS60 and NFS78 (+RT). i\s a control PCR \vas 
carried out on poly(A)" RNA samples without the addition of reverse transcriptase (~RT). The 
integrity of the isolated poly(Ar RNA and the first-strand eDNA was confirmed by IZT -PCR 
with f)-actin primers (M:marker). 
C. Sequence analysis of dO\vnstream of the L TR primer located MuL V LTR-specific sequences. 
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The arrows (5'-TTTCA''NN-3') indicate the general fusion site of viral and cellular eDNA in 
both A and C. The eDNA sequence depicted in this figure is identical to the murine EST 
(DDB.I/EMBL/GenBank accession no. W97251). 
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A. Southern blot analysis (Pvuii and Bam HI digest) of a panel of retrovirally induced leukemic cell 
lines NFS22, NFS58, NFS60, NFS78, NFS6l and NFSI07 hybridised with fragment l. 
B. Limited restriction map of the Evi 1 locus with the site and orientation of viral integrations, 
indicated by arrows, in the leukemic cell lines NFS22, NFS58, NFS60 and NFS78 (Pll:Pvull; 
B:BamHL S:Sstl; P:Pstl; H:Hindiii). The black boxes indicate the 5' end exon structure of the 
Evil gene [7, 12]. 
C. Northern analysis of the cell lines NFS22, NFS31, NFS36, NFS56, NFS58. NFS60, NFS61, 
NFS78 and NFS I 07 probed with fragment I. 
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Abstract 
The identification of common virus integration sites ( c VIS) in retrovirally induced 
tumours in mice provides a powerful strategy to isolate novel transforming genes. 
Applying virus LTR-specific inverse-PCR and RT-PCR combined with automated 
sequencing on Cas-Br-M Murine Leukemia Virus (MuLV) induced myeloid 
leukemias, 126 virus integration sites were cloned. Using locus- and LTR-specific 
primers, a nested-PCR/Southem-blotting procedure was developed on genomic DNA 
from a large panel of MuL V -induced leukemias, to analyse whether a particular virus 
insertion represented a cVIS. In fact 39 out of 41 integrations analysed this way 
appeared to represent a common virus integration. We recognised 6 previously cloned 
cV!Ss, i.e. Evil, Hoxa7, c-Myb, Cb2/Evill, Evi12, and His] and 33 novel common 
insertions, designated Cas-Br Virus Integration Site (Casvis). Among this group we 
found integrations in or near genes encoding nuclear proteins, e.g. Dnmt-2, Nm23-M2, 
Ctbpl or Erg, within receptor genes, e.g. Cb2 or mrcl, novel putative signalling or 
transporter genes, the ringfinger-protein gene Midi and a panel of genes encoding 
novel proteins with unknown function. The finding that 39 out of 41 integrations 
analysed represented a cVIS, suggests that the majority of the other virus insertions 
that were not yet analysed by the PCR!Southem- blotting method are located in a 
cVIS as well and may therefore also harbour novel disease genes. 
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Introduction 
Genes responsible for leukemic transformation are frequently located near non-
random chromosomal translocations [1, 2]. However, in approximately 50% of the 
clinically diagnosed myeloid leukemias no cytogenetic abnonnalities have been 
detected. Furthennore, in a number of cases that do carry a cytogenetic abnonna1ity 
[3-5] the genes located near the breakpoints are still unknown. Moreover, since 
leukemia is believed to be a multi-step process, aberrant expression of different 
disease genes affecting multiple pathways are required to obtain full leukemic 
transfom1ation [ 6, 7]. An alternative procedure to identify leukemia disease genes is 
the cloning of common vims integration sites ( c VIS). This approach has proven to be 
a sensitive tool to identify novel proto-oncogenes as well as tumour-suppressor genes. 
In fact, several genes located near chromosomal breakpoints or otherwise aberrantly 
expressed in human hematopoietic malignancies have been identified through 
retroviral insertional mutagenesis in murine leukemias or lymphomas as well, e.g. 
Evil [8, 9], Evil (NFI) [10-12], Evi6 (Hoxa9j [13, 14], Bell (Cyclin Dl) [15, 16], N-
Myc [17, 18], and Erg [19, 20]. A major assumption in studies ofMuLV-induced 
leukemias is that proviral integration is essentially random and that common sites of 
integration are observed in tumour samples due to selection of rare cells with proviral 
insertions in these common sites. The selective pressure is provided by the expression 
of the target gene nearby [6, 7]. Although one might suspect that common as well as 
non-common VISs will be present in a leukemia, it is at present unclear which 
percentage of VISs in a patiicular tumour represents common sites of integration. In 
this study, we developed a high-throughput procedure to clone nove! cVISs on a 
large-scale to answer this particular question. 
Until recently, the identification of cVISs has been a laborious procedure. In order to 
isolate cVISs and potential disease genes on a large scale PCR approaches were 
previously established, e.g. an inverse PCR (IPCR) and a RT-PCR based procedure 
[20], [21 ]. Making use of lPCR and subsequent automated DNA sequencing 
investigators identified VISs on a large scale using AKXD- or BXH2-vims-induced 
leukemias [22, 23]. By comparison of every virus flanking fragment with sequences 
in the GenBank of the National Center for Biotechnology Information 
(www.ncbi.nlm.nih.oov, NCB!, Bethesda, MD, USA) and with the nucleotide 
sequences of each of the other cloned vims insertions, a significant number of novel 
common integration sites and potential disease genes were identified. On the other 
hand, a large number of virus insertions were found only once. Although these 
insertions had frequently taken place in key regulatory genes, commonality could not 
be shown using this approach. Here we present a strategy in addition to the PeR/high-
throughput sequencing protocol, to not only identify large numbers of virus 
integration sites, but also rapidly define whether a vims insertion represents a cVIS. 
Swiss mice infected with Cas-Br-M MuLV may develop myeloid or lymphoid 
malignancies as the result of retroviral insertion in disease genes [24, 25]. Classical 
cloning procedures resulted in the identification of several disease genes in Cas-Br-M 
MuLV-derived tumours, e.g. Evil, Evil 1/Cbl or Evil2 [8, 26, 27]. Large scale !PCR 
and RT-PCR was perfonned utilising DNA or mRNA from 28 primary ~as-Br-M 
MuLV induced myeloid leukemias in _Swiss mice (CSL) [28] and 15 retrovirally 
induced myeloid cell lines [29, 30]. Vims-flanking fragments were cloned, sequenced 
and subsequently compared to the Celera Discovery System (Contents of May 2002) 
(wvvvv.celera.com, Celera Genomics, Rockville, MD, USA) and to NCBI Genbank. 
To investigate whether these sites represented cVISs, we developed a nested PCR 
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strategy on genomic DNA from 107 leukemias, by applying LTR-specific and 
fragment-specific primers followed by a Southern blotting protocol with an additional 
set of radio-labelled L TR- and fragment-specific oligonucleotides. Applying this 
approach, we were capable of defining whether and how frequent a virus insertion 
occurred in other leukemias. In addition to six previously identified cVISs we 
identified a large number of novel common virus insertions. The exact mouse and 
human chromosomal localisation were defined and in most of the cases the potential 
target genes in these loci could be identified. 
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Materials and Methods 
Primary leukemias and cell lines 
The NIH-Swiss derived Cas-Br-M MuLV induced primary tumours used in this study 
are: for IPCR: CSL 13, 16, 20, 22, 26, 30-33, 65, 71, 78, 82, 90, 91, 93, 111, 117, 123, 
201,203,204,212,221,227,228,237 and 239; and for RT-PCR: CSL 201 and 203. 
[28]. Cells isolated from leukemic spleens were stored vitally in aliquots in liquid 
nitrogen. The following leukemia cell lines were utilised in this study: for IPCR: DA 
24, and NFS 22, 36, 56, 58, 60, 61, 78, and 124; and for RT-PCR: DA 1, 2, 3, 8, 33, 
and NFS 22, 36, 58, 61, 78, 107, and 124. [31]). These cell lines were cultured in 
RPM! plus 10 % fetal calves' serum (FCS) (GIBCO Life Technologies Inc., Gent, 
Belgium) and 10 Units of mouse IL3. The frequency of virus integrations was 
detennined both on cell lines (DA l-3, 8, 13, 24, 25, 28, 29, 31, 33, and NFS 22, 36, 
56, 58, 60, 61, 78, 107, and 124), and primary leukemias (CSL 11-17, 19, 21-23, 25-
27,29, 31-33, 35, 36, 38, 39, 41, 43,45-51, 53-61, 63-72, 74-83, 85, 87-109, 114, 
117, and 123). 
IPCR and RT-PCR 
Isolation of genomic DNA was carried out exactly as described previously [27]. Five 
~g of genomic DNA was digested with Sau3A, Pvull or Sst! (GIBCO Life 
Technologies Inc., Gent, Belgium). The products were treated with T4-ligase (GIBCO 
Life Technologies Inc.), which resulted in the formation of circularised products. 
Subsequently we perfonned an IPCR strategy using primers specific for the Cas-Br-M 
MuL V L TR. For the Sau3A digested/ligated fragments, the first PCR reaction was 
carried out with primers pLTR4 (5' -CCG AAA CTG CTT ACC ACA-3') and pLTR3 
(5'-GGT CTC CTC AGA GTG ATT-3'), followed by a nested PCR using pLTR5 (5'-
ACC ACA GAT ATC CTG TTT-3') and pLTR6 (5'-GTG ATT GAC TAC CCG 
CTT-3') Cycle conditions for both PCRs were 15" at 94'C, 30" at 57'C, and 2' at 
72oC for 10 cycles, and an additional20 cycles following the conditions 15" at 94°C, 
30" at src, and 2'30" at 72oC. Reactions were performed using Expand High 
Fidelity PCR System (Roche, Mannheim, Germany). For Pvull and Sst! digested 
genomic DNA, the circularised DNA was amplified using primers pLTR7 (5'-GAC 
TCA GTC TAT COG AGO AC-3') and pLTRl (5'-CTT OCT OTT GCA TCC GAC 
TGG-3'), and pLTR8 (5'-GTG AGO GOT TOT GTG CTC-3') and 2 (5'-GTC TCG 
CTG TTC CTT GOG AGG-3 ') respectively. The first PCR was performed for 30 
cycles 30" at 94 °C, 1' at 54 oc, and 3' at 72°C. The reaction was carried out with 
Expand High Fidelity PCRsystem (Roche). Nested PCR conditions were 30 cycles of 
30" at 94°C, 1' at 58°C, and 1' at 72oC. This reaction was performed with Taq 
polymerase (Amersham Phannacia Biotech, Roosendaal, The Netherlands). RT-PCR 
was carried out as described previously by Valk eta/. [20]. Briefly, total RNA was 
isolated through a CsCI gradient. First strand eDNA was obtained by reverse 
transcriptase (RT) reactions with an oligo(dT)-adapter primer (5'-GTC GCG AAT 
TCG TCG ACG CG(dT)w3') at 37'C with 5~tg RNA, using the SuperscriptTM 
Preamplification System (Life Technologies, Breda, The Netherlands) according to 
the instructions of the manufacturer. Subsequently, PCRs (1' at 94°C, 1' at 58°C, 3' at 
72°C (30 cycles)) were perfonned on the RT reactions of the leukemias by using the 
LTR specific primer pLTR6 and the adapter primer (5'-GTC GCG AAT TCG TCG 
ACG CG-3'). PCR products were directly cloned into pCR2.1 (Invitrogen, Breda, The 
Netherlands) according to the instructions of the manufacturer and subjected to 
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nucleotide sequencing. Nucleotide sequences were compared to the NCBI database 
for analysis. 
PCR analysis and Southern blot hybridisation 
One Mg of genomic DNA isolated from primary leukemias or cell lines was subjected 
to PCR with primer pLTR1 and a locus specific primer A (Figure 1). Locus specific 
primers of 17 to 21 nucleotides were designed specific for each of the sequences of 
the fragments generated by Inverse- or RT-PCR. Primers were purchased from Life 
Technologies. One [11 of PCR product was transferred to a nested PCR reaction using 
primer pLTR2 and a nested locus specific primer B. Cycle conditions for both 
reactions were I cycle 5' 94"C, 30 cycles 30"94°C, I' Tm, 1 '30"72°C, 1 cycle 5'72"C. 
Tm was specific for each primer and was between 48°C and 62°C. PCR was carried 
out using Taq polymerase (Amersham Phannacia Biotech). PCR products were 
electrophoresed in a 1.5% agarose gel and transferred to Hybond-N+ nylon 
membranes (Amersham Phannacia Biotech) with 0.25 M NaOH/1.5 M NaCl. 
Membranes were hybridised with a 32P-end-labelled locus specific primer C. 
Labelling was carried out using T4kinase (USB, Cleveland OH, USA) according to 
the instructions of the provider. Subsequently, blots were stripped in 0.4M NaOH for 
30 minutes at 45°C, neutralised using 0.2M Tris-HCl, 0.2% SDS, and O.lxSSC for 15 
minutes at 45°C and hybridised with 32P-end-labelled Cas-Br-M MuL V specific 
primer pLTR3. Blots were exposed for autoradiography with a KODAK film and an 
intensifying screen. After 15 minutes of exposure films were developed and analysed. 
Sequencing analysis 
Samples were prepared using the Bd-sequencing kit according to instructions from the 
provider (PE Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) and nucleotide 
sequencing was carried out on an ABI 310 automatic sequencer (PE Biosystems) 
using primers M13forward (5'-GTA AAA CGA CGG CCA GT-3') and M13reverse 
(5'-GGA AAC AGC TAT GAC CAT G-3'). Sequences isolated by IPCR or RT-PCR 
were compared to the data present in the Celera Discovery System (Celera Genomics, 
Rockville, MD, USA, database contents May 2002) and in the GenBank of the 
National Center for Biotechnology lnfonnation (NCB!, Bethesda, MD, USA). The 
exact site of integration was detennined. For insertions found outside a gene, the 
distance between the integration and the most nearby gene was calculated. The 
location on the mouse chromosome was established and the human equivalent was 
deduced by using the human databases of Celera Discovery System (May 2002), 
LocusLink or human mouse homology maps (both www.ncbi.nlm.nih.gov). 
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Figure 1. 
IPCR or RT-PCR was performed on RNA or DNA from cell lines (DA and NFS), or CSL leukemias. 
The resulting virus flanking fragments were subjected to sequence analysis. LTR- and locus-specific 
primers were designed and used in a nested PCR strategy(*), i.e. LTR-1/primer-A PCR, followed by a 
L TR-2/primer-B amplification using genomic DNA from a panel of Cas-Br-M MuLV induced 
leukemias. PCR products were electrophoresed on a !.5% agarose gel and subsequently blotted. Blots 
were first hybridised with locus-specific primer C and exposed to film, and after stripping rehybridised 
with primer LTR3. Bands hybridising with the LTR3 as well as the locus specific primer C (Lanes 
1,2,3,6, and 8) were considered positive, i.e. tumours carrying this particular cVIS. Hybridisation with 
one primer only (lanes 4 and 7) are false positives. In each experiment two or three positive fragments 
were cloned and nucleotide sequenced to confinn specificity. 
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Results 
To clone V!Ss on a large scale, a virus-LTR specific IPCR as well as a RT-PCR were 
applied as complementary approaches using DNA or RNA from 43 myeloid 
leukemias. The IPCR method was carried out on 28 primary leukemias and nine cell 
lines, whereas the RT-PCR based technique was perfonned on 12 cell lines and two 
primary leukemias. The fragments were cloned, subjected to nucleotide sequencing 
and compared to each other and to those present in the Celera and NCBI databases. In 
total 126 unique virus integration sites were identified of which some were found 
more than once in distinct leukemias. Database analyses revealed three different 
groups of virus integrations: i.e. (I) in a gene (65/126), (II) in a known genomic locus 
in the vicinity of a gene (57/126), and (III) in a unknown sequence (4/126) (Table 1). 
We next determined for 41 inserted loci whether they represented a cVIS. This 
concerned 20 integrations from group I and 21 sequences from group II (Table 1). We 
designed locus specific primers for each of the virus insertions and carried out a 
nested PCR reaction using these primers in combination with L TR specific primers on 
genomic DNA isolated from 107 tumours, i.e. 87 primary CSLs, 11 DA cell lines and 
nine NFS cell lines (see Figure 1). The PCR products were run on an ethidium 
bromide stained 1.5% agarose gel, subjected to Southern blot analysis and hybridised 
with locus specific primer-C and pLTR3 (Figure 1). Fragments that hybridised to both 
primers were considered positive. In each experiment, two or more of those positive 
fragments were cloned and sequenced to confirm specificity and to acquire more 
nucleotide sequence infonnation of the loci (Figure 1). 
PCR/Southem strategy was applied on 20 of the 65 integrations from Group I 
(Insertion in a gene). It appeared that 19 of the 20 integrations analysed represented a 
common VIS. These 19 loci, including their frequency, the tumours from which the 
virus integrations were originally isolated, the murine and human chromosomal 
localisation, the NCBI accession numbers of the viral integrations, the Celera protein 
accession numbers, and the (putative) function of the gene products are summarised 
in Table 2. Using the PCR/Southem strategy we identified several previously cloned 
cVlSs, i.e. Evil. Hoxa7. c-Myb, Evill/Cb2. Evil2 and His]. Of the other 13 cV!Ss, 
i.e. Casvis 1-13 a known or a novel putative gene was identified. Three of them, 
Casvis 1,2, and 3, were located in genes encoding nuclear proteins, i.e. Transcription 
elongation factor II, Dnmt2, and Nm23-M2 respectively. We found integrations in tvvo 
genes encoding membrane receptors, i.e. Cb2 and mrc1. Recurrent viral integrations 
were also found in genes encoding the enzyme Hmox2, a tyrosine kinase. 
Furthermore, genes encoding the carrier proteins Slc7a11 and Slc17a5, being sodium-
dependent phosphate transporter-related proteins and the ringfinger protein Midline-1 
were very often inserted by retroviral DNA. Finally a number of genes encoding 
novel putative proteins were identified as frequent common virus integration sites 
(Casvis 11-13 andEvil2). 
In Table 3 common insertion sites are listed in which virus DNA had integrated into a 
genomic sequence at a relative distance from a potential target gene (Group II). Using 
PCR/Southem procedure 19 out of 20 integrations from Group II were identified as 
cVIS (Casvis 14-33). Frequent proviral insertion was found in a locus harbouring the 
transcription regulators Erg and LIM domain binding protein 1, the signalling 
molecule PKCE, the TGF~ receptor and the Rap guanine nucleotide exchange factor. 
In 11 cases the candidate genes encode unknown putative proteins. 
Since our data demonstrate that the majority of virus insertion sites analysed by 
PCR/Southem represent common VISs, suggest that the majority of the remaining 
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integrations should be considered as disease loci as well. Therefore, the remaining 45 
integrations from Group I (insertions in a gene) and 36 insertions from Group II 
(insertion in the vicinity of a potential target gene) are summarised in Tables 4 and 5 
respectively. Of these remaining vims integrations, eight were found more than once 
within the distinct leukemias and were therefore designated Casvis 34-41 (Tables 5 
and 6). 
Table I. Numbers of unique retroviral insertions identified and studied. 
Total in a gene near a gene 
Group I' Group II" 
Virus insertions 126" 65 57 
PCR!Southem analysed!cVIS" 41/39 20/19 21/20 
Not anal sedf 85 45 36 
Sequence comparison: cVISg 8 5 3 
Sequence unknO\Vn 
Group III" 
4 
0 
4 
0 
"Number of unique virus integrations. bGroup 1: Virus integrations in a gene. cGroup II: Virus 
integrations in a genomic sequence in the vicinity of a gene. ctGroup III: No sequences available in 
Celera or NCBI databases. "Number of virus integrations analysed by PCR/Southern protocol and 
number of integrations designated cVIS as determined by this approach. rNumber of virus integrations 
not analysed by PCRJSouthem. gNumber of virus integrations that were found more than once among 
the remaining 85 virus insertion sites and designated cVIS as well. 
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Table 2. Cas-Br M MuLV common virus integration sites (cVIS) locateg~ candidate gene. 
name of gene product frequency retrieved mouse hum NCBI ace no Celera p1·otein function 
VIS (%•) f1·om chrom chrom Casvis" ace no" 
Evil Evil 16~ NFS22 3A3 3q26 NM007963h mCP2223 TR/DNA. binding 
Evi7 Hoxa7 58 CSL82 61:33 7p15-pl4 NM010455b mCP12985 TRJDNA binding 
c-Myb c-Myb 32 CSLI23 10 6q22-q23 Nlvl033597b Xl6389d TR/DNA binding 
Casvis l Transcr. elung. factor Sll 58 NFS107 4C6 1 p32 AF432356 mCP22410 TRJONA binding 
Casvis2 Dnmt2 35 CSLI6 ?AI 10pl5.l AF432357 mCP2357 TR/DNA binding 
CasvisJ nm23-M2 9 CSL22 liD 17q21.3 AF43?358 mCP14lll TR/DNA binding 
Casvis4 Tyrosine kinase 24 CSL30 II E2 17q25.3 AF432370 mCP 18961 signalling 
Evil] Cb2 11" CSL 78 4D3 lp36 X93168. b mCP3324 receptor 
Casvis5 mrc I 3 CSLlll 21\. I lOp 13.1 AF432359 mCP2323 receptor 
15 
" 
FS61 3C 4q28-q32 AF432387 mCP21827 transpmter 
7 CSL31 9 El 6ql4-ql5 AF432364 mCPll743 transpmter 
30 NFS22 5Bl 4pl6.3 AF432377 mCP3901 ___ <_nmsporter 
4 N <S78 16A I 16p 13.3 AF4J2383 mCP86495 enzyme 
55 < :SL20 X Xp22 AF432365 Nlvi0\0797* ring finger 
protein 
Evil2 putative protein 17~ NFS I 07 lOC l 12q24.2 AF091114 mCP28980 unknown 
His! His! 3 NFSI24 28 2ql4-q21 U10269° mCP42656 unknown 
Casvisll putative protein XP051927 47 CSL26 19Cl 10 AF432372 mCP2702 unknown 
Casvis 12 putative protein 28 CSL91 131\.2 unknown AF432366 mCP 15205 unknown 
Casvisl3 putative protein 3 CSLll7 1Cl.3 unknown AF432379 mCP74740 unknown 
CVISs are ordered according to the (putative) function of the potential target genes. The frequency of integrations were determined by a PCR/Southern blotting 
approach (sec Figure I) in a panel of 107lcukcmias. The cell lines or leukemias from which the original virus-llanking fragment was isolated are listed. The newly 
assigned NCB! accession numbers for the cloned viral flanking nucleotide sequences and the Celcra protein accession numbers arc presented. 
CVISs arc designated Casvis = Cas-Br-M MuLV common Yin1s Integration liite, TR =Transcription Regtdator. 
"The sequences in the GenBank, National Center for Biotechnology Information (NCBI), Bethesda, MD, USA: www.ncbi.n_lm.nih.2ov will become (;!Vl.lilable 
tln·ough the accession numbers in May 2003. b These accession numbers represent the original nucleotide sequences submitted to the NCBI by others previously.~ 
Accession numbers from Celcra discovery system were tl:om May 2002. It should be noted that the mouse assembly of Celcra discovery system is dynamic and will 
be improved over time.<~Rcpresents a NCBI accession number. No accession number was present in the Celera Discovery System.~The frequency of Evil, Evil 1 
and Evi 12 was dctennincJ by Southcm blotting instead of the f>CR/Southern procedure l20, 27l 
Table 3. Cas-Br M MuLV cVISs lm:ated in the vicinity ora candidate gene. 
name of 
VIS 
Casvis14 
Casvisl5 
Casvisl6 
Casvisl7 
Casvisl8 
Casvis19 
Casvis20 
Casvis21 
Casvis22 
Casvis23 
Casvis24 
Casvis25 
Casvis26 
Casvis27 
Casvis28 
Casvis29 
CasvisJO 
Casvis31 
Casvis32 
Casvis33 
candidate gene product frequency retrieve mouse hum chrom NCBI Cclcra protein function 
(%) d fmm chrom ace no Casvis ace no 
Erg____ 2§_ NFS22 16C4 21q22.2 AF432389 mCPl7313 TRJDNA binding 
LIM domain binding I 24___ CSL90 19Q__ 10q24 AF43)373 mCPI5411 TR/DNA binding 
Ctbp I 14___ DA 1 5B I 4p 16 AF432388 mCP3953 TR/DNA binding 
Calmodulin-like protein 16 NFS22 13Al 10ptcr-pl3 AF43236J mCP19315 signulling 
FLJ13159 13 NFS22 IAJ 6q12-q13 AF432362 mCP22J09 signalling 
PKC epsilon 26 NFS22 17E4 2p21 AF432368 mCP43026 signalling 
rap guanine nucl exchange 41 CSL82 11 B 1.3 5q31.1 AF432374 mCP81 048 signalling 
ractor 
Gaba !\receptor theta 19 CSL91 XA7.1 Xq28 AF432367 mCP80542 receptor 
TGF beta receptor I 22 CSLJO 4A5 9q22 AF432381 mCP5773 receptor 
leucinrichrcpcatprotein 19 CSL26 9F2 3p21.33 AF432375 mCP74372 unknown 
putative protein 31 NF$78 IH4 I AF432390 mCP90066 unknown 
putativcprotein 22 ______ CSLJI IIC __ !7q23.3 AF432376 mCP8515l unknown 
putativeprotcin II CSLI!l !OD2 2ql4 AF432378 mCP43253 unknown 
A Y007814 (KIAAII99- 49 D/\24 7D2 15q24 AF432360 mCP7266 tmknown 
related) 
NAS hypothetical protein 55 CSL22 7C l5q24-q25 AF432363 mCP89034 unknmvn 
putative protein 22 CSL26 lSD I 8q24.2 AF432371 mCP60729 unknown 
NAS hypothetical protein 17 NFS36 II E I 17q24 AF432369 mCP75468 unknown 
hypothetical prot XP072192 32 CSLJO 15B3.1 unknown AF432380 mCP43832 unknown 
pttlatiYe protein 9 CSL26 l5Fl 12ql3 AF432382 mCP83599 unlmown 
KIAA1053 6 NFS124 148 14 i\F432391 mCP89924 unknown 
distance 
50kb 
Skb 
6kb 
9kb 
8kb 
JOkb 
3kb 
7kb 
7kb 
!Okb 
8kb 
8kb 
24kb 
60kb 
40kb 
32kb 
12kb 
4kb 
9kb 
ISkb 
Proviral integration occurred within a certain distance of a gc11c. Distances between proviral inse1iions and potential target genes are presented in the last column. For further 
explanations, see Table 2. 
Table 4. Cas-Br-M MuLV insertions within candidate genes not further analysed by directed PCR!Southem. 
name of VIS gene product 1·etrievcd mouse hum chrom NCB I ace Celera protein function 
evi2 
from chrom no ace no 
Jdp2 NFS56 1203 14q24.3 AF432405 mCP3269 TRJDNA binding 
FLJ13479 NfS78 7F3 22ql3 AF432406 mCP10439 TRJDNA binding 
Mal-related CSL204 17E3 2p2J -22 AFS\7726 mCP23717 TRION A binding 
Satbl CSL212 402.2 3p23 AF517735 mCP16222 TR/DNA binding 
Rgll DAI lGI lq24 AF432408 mCP3029 signalling 
Mapk8ip CSL204 l7A3.2 16p13.3 AF517729 mCP23126 signalling 
nfl CSL204 IIBS 17qll.l AF517717 mCP\3469 signalling 
KIAA0766 CSL204 9F2 3p~_l.33 AF517724 mCP37661 __B,gnal!ing 
GGI-62-like CSL221 JA I 8q2l.ll AF517722 mCP 15006 signalling 
myotonin protein kinase CSL32 12F2 lq32 AFS I 7703 mCP 14279 signalling 
Serine/Threonine kinase CSL65 1 A 1 unknown AF517705 mCP70592 signalling 
Gng2 ···-- CSL204 14Al 1..±9l.L_ AF517725 mCP4814 --~igl·talling 
Frapl CSL212 4E1 lp36.2 AF517710 mCP\9396 signalling 
Lyl08 CSL13 11-12.3 lq21? AF517697 mCP\591 lg-receptor 
Tnfrs I 7 CSL239 16Al 16p 13.3 AF517740 mCP6894 receptor I cell cycle 
regulator 
Vomeronasal receptor 1C2 DAl 7Al 19q13.4 AF432410 mCP57640 receptor 
Lysosomal ass trammembr NFSI24 12E 8q22.1 AF432396 mCP50469 transpmter 
prot 4 beta 
Monocarboxylate CSL20 I lOBI 6q22 AF5177l5 mCP33645 transporter 
transporter -related 
ATP-binding cassellc C4 CSL20 1 14E4 13q32 AF517712 mCP80048 transpmter 
Slcl6a6 CSL201 !lEI 17q25 AF517737 mCPI1951 transporter 
ribonuclease E CSL32 12/\1.1 lp36.1 AFS\7704 mCP86146 enzyme 
Ran bindingJ~rotein 11 __ CSL71__ 1302.1 5pl2 AF432402 mCP10629 enzyme 
Sarcosine dehydrogenase _ CSL203 _ 2A3 9q34 AF517734 mCP50903 enzyme 
Snurf CSL237 unknown 15q 11.1 AF517740 mCP7451 splicing factor 
Apobec2 CSL227 17C 6pl2 AF517731 mCP12180 RNA processor 
NOLP4 NFSS8 2Hl 20qll.l- AF517747 mCP18257 nucleolar protein 
qll.23 
Casvis34 (3)" 
Immunoglobulin heavy CSL31 unknown unknown AF517702 mCP19302 immunoglobulin 
chain var reg 
clpx CSL203 9B/C l5q22 AF517714 mCPIIIIS chaperone 
VampS NFS60 6Cl 2p 12-pl 1.2 AF517748 mCP61898 membrane protein 
HSA-C CSL32 lOBI 6q21 AF432384 mCPll896 unknown 
BC003324 CSL3l SF 12 AF432400 mCP12901 unknown 
NAS hypothetical protein NFS78 2Fl 2 
NAS hypothetical protein NFS36 17E3 llql3.2 
SH3domain interacting DA33 2C2 2q24-32 
protein 
Hypothetical protein 
XP 058389 
Ring finger protein 24, 
goliath-like 
CSL212 
CSL137 
14A2-3 10 
2Fl 20pl3-p21 
putative protein CSLlll 18E3 12pl3 
putative protein CSL237 13D2.3 5qll 
putative protein CSL9l 2H3 20ql3.1-13.2 
AF517753 mCP49705 unknown 
AF5!7745 mCP70914 unknown 
AF432412 mCP1909\ mlknown 
AF517727 mCP4840 unknown 
AF517736 mCP17978 unknown 
AF432404 mCP35136 unknown 
AF5!7718 mCP27678 unknown 
AF432403 mCP28479 unknown 
Casvis 35 (2)" put(;ltive protein DAI 17E3 llql3.2 AF432393 mCP71055 mlknown 
Casvis 36 (2)" putativep~(ltein NFS78 2Cl.l ?q23 AF432394 mCP20051 unknown 
Casvis 37 (2/ putative protein CSL237 28 2q22 AF517719 mCP49332 unknown 
putative grotein CSL20 IH4 1 AF5!7699 mCP35212 unknown 
putative protein CSL123 14E2.1 l3ql4.3-q21.1 AF5!7696 mCP88467 unknown 
putative protein CSL227 IOA3 6q23 AF5!7709 mCP59156 unknown 
Proviral integration occurred within certain genes. "Integrations in Casvis 34-37 were found in more than one distinct leukemia. The number of independent leukemias in 
which these integrations were detected is between brackets in the tlrst column. No virus insertion name was given yet for inse1tions found only once. For fbrther explanations, 
see Table 2. 
Table 5. Cas-1:3r-M MuL V insertions in the vicinity of a candidate gene but identified once. 
name of VIS 
Myc 
candidate gene product retrieved mouse hum chrom NCBI ace Cclcra protein function distance 
from Ch!"OIIl no ace no 
Casvis 
Myc DA24 150 I 8q24.12- AF517716 mCP14505 TlUDNA binding 50kb 
24.13 
Ddxl9 NFS60 REI 16g22.1 AF517751 mCP7335l TR/ONA binding 3kb 
Pscdl DA8 IIE2 17g?5 AF43?409 mCP18847 signalling 6kb 
Src homology domnin CSL212 6Cl 2p 11.1 AF517720 mCP61938 signalling lk 
containing prot 
Pps CSL228 1185 17 13 .AF517732 mCP13369 sign~~~ 7kb 
Pyridoxine kinase CSL2 \1. 17 A3.J 2lq22.3 AF517739 m~P5282 ~IQ_lalling 2kb 
Ankyrin repeat containing CSL212 I 11:33 17p 12 .AF517730 mCP13813 signa1li11g 1 kb 
protein 
TNFalph<~ J'ifSSH 1_7_Bl__ 6p21.3 AF51774)~Pll847 ~tokine 
vomeronasal receptor IC6 NfS78 13A2 6p21.3 AF432407 mCP34098 receptor 
lowdensitylipoprotein CSL212 2Al 2q24-q31 AF517711 mCP51218 receptor 
receptor-related 
Pah 
Rho GTP;~se-activating 
rotein 
CSL123 
DAI 
lOCI 12q22-q24.2 AF517695 mCP4545 enzyme 
6E2 12 Af517744 mCP6091 0 enzyme 
IOkb 
2kb 
27kb 
30kb 
32kb 
--------'lzC~C-''C. ____ CSL 16 1002 12q 15 AF43239H mCP23874 enzyme 9kb 
Casvis 38 (3)" 
G x5 CSL221 
1.21 CSL22 
RpsiS 
ribosomal protein Lll 
ribosomal protein PO 
Elastase 
Slc7a 1 
phuspl1olipid-tmnsporting 
ATPasc related 
CSL31 
CSL7l 
CSL20l 
CSLI3 
CSL212 
NFS61 
13A2 6p21.2 AF517719 mCP22123 enzyme 
4AS l7q 12-q21 .AF517700 mCP53488 ril:Jgsomal protein 
SES l9pl3.3 AF517701 mCP19940 ribosomal protein 
12A I. lp36.l AF517707 mCPS7152 1·i.Q9somal protein 
21-11 18 .AF517733 mCP30352 ribosomal protein 
ISFI 12q 12 AF432397 mCP9570 protein 
metabolism 
5G3 13ql2 A.F517738 mCP18766 transp01ier 
3!\.3 3 AF517749 mCP3736 transporter 
putfltive protein CSLJ6 2Cl.l 2 AF5!7698 mCP49486 DNA. repair 
Mcp CSL33 1H5/H6 lq32 AJ-<"432386 mCP15315 complement 
15k 
5kb 
5kb 
30kb 
7kb 
6kb 
24kb 
3kb 
26kb 
40kb 
Casvis 39 (3)" 
Cas vis 40 {2/' 
Casvis 41 (2)" 
Kir5.l NFS6l l!El!E2 17q23.l-
q24.2 
activation 
AF432395 mCP33805 ion channel 
Actgl NFSI07 llE2 !7q25 AF43241! mCPl8943 cytoskeleton 
VSP41 DA2 l3Al 7pl4-pl3 i\F517754 mCP3593 unknown 
putative protein NFS58 18C 5q21 AF4323S5 mCP77581 unknown 
putative NAS protein CSL212 9A2 19pl3.2 AF517721 mCP55555 unknown 
putative protein NFS58 12A1.2 2p25 AF517746 mCP78746 unknown 
putative protein CSL203 16B5 3q 13. I AF517723 mCP87422 unk.J1mvn 
putative protein NFS124 6FI 9pl3.3 AF5l7728 mCP62222 un1mown 
putative protein CSL201 15Fl 12q 12-q l3 AF517742 mCP83351 unknown 
putative protein NFS I 07 I SO 1/02 unknown AF5l7750 mCP77834 unknown 
putative protein CSL65 12!\ 1.1 2p24 AF5l7706 mCP86238 unknown 
putC~tive protein CSL78 3H2 lq31-32.1 AF5l7708 mCP89319 unknown 
p...!:!_t_ative protein NFS6 t 3A3 3q26 AF5l7752 mCP25237 unknown 
!34kb 
!Okb 
6kb 
6kb 
5kb 
l4kb 
llkb 
25kb 
!3kb 
!Okb 
lkb 
16kb 
22kb 
Provirul integmtion occuned within a certain distance of CJ gene. Distances between proviral insertions and potential target genes are presented in the last column. 
alntegrations in Casvis 38-41 were round in more than one distinct leukemia. The number of independent leukemias in which the integrations were detected is between 
brackets in the ftrst column. For further explanation, see Table 2. 
Discussion 
The identification of c VISs has previously become less labour-intensive through the 
development of various PCR procedures. In the present study we used two distinct 
complementary PCR procedures and applied an additional PCRJSouthem strategy 
(Figure 1) to further increase the speed of identifying novel cVISs. Using these 
techniques we identified 126 virus integration sites in Cas-Br-M MuL V induced 
myeloid leukemias and determined that 39 of 41 insertions analysed represented a 
common VIS. Based on these findings, it may be deduced that of the other virus 
integration sites a comparable high percentage may in fact represent cVISs as well. 
PCRJSouthern blotting analysis in the panel of leukemias using locus- and LTR-
specific primers should assure whether this is indeed the case. The detection of 
previously cloned cVISs and their corresponding leukemia genes (Evil, Hoxa7, c-
Myb, Cb2/Evill, His 1 and Evil2) indicates that the PCR/Southern based technique 
that we applied is reliable. It also emphasises the significance of the novel cVISs 
found, and warrants further exploration of the strategy to clone the large number of 
c VISs and disease genes that remain to be identified in leukemia and lymphoma. 
The frequency of proviral insertions is sometimes exceptionally high, e.g. 58% for 
Hoxa7 and Transcription elongation factor SII or 55% for Midline-f. Many other 
insertions were found at frequencies between 10 and 30%. In fact only a minority of 
common integrations were found at a frequency lower than I 0%. The most likely 
explanation for these high frequencies is that these retrovirally-induced leukemias are 
oligoclonal [23, 32]. In fact, proviral insertion in certain genes (e.g. Nm23-A12 or 
Midi) identified by the PCR/Southern strategy, were undetectable by applying 
classical Southern blotting (data not shown), suggesting amplification of proviral 
integrations present in a minor clone. Since leukemia development is believed to be a 
multigenetic process it will be important to dissect which disease genes frequently 
cooperate in transformation. A thorough analysis of the large series of common 
integrations found in this cohort of leukemias should reveal which disease loci 
frequently coincide. However, oligoclonality does not allow a reliable analysis to 
identify cooperation between disease genes in these virus-induced tumours, a caveat 
also being recognised by other investigators [23, 32]. 
One group of genes frequently targeted by retrovirus comprises the ones that encode 
for nuclear proteins involved in transcriptional control or other nuclear functions. The 
fact that this group of genes is so often subject of mutations in mouse leukemias as 
well as in human disease underlines the critical role these proteins may have in 
development and indicates that mutations in those genes are key-events in leukemic 
transfonnation. Among integrations in previously reported DNA-binding protein 
genes Evil, Hoxa7 and c-Myb, we also found frequent proviral insertions in a region 
in the vicinity of Erg. The latter gene is the murine homologue of human ERG, which 
has been shown to be expressed as TLSIERG fusion gene in human AML with 
translocation t(l6;2l)(pll;q22) [19]. 
The high-throughput search for novel cVIS provides a unique opportunity not only to 
clone novel transforming genes but may also lead to the identification of new disease 
pathways that have not previously been implicated in leukemia. Several novel 
potential disease genes have been identified as frequent proviral targets in our screen, 
which may relate with novel pathways. Among these are the Mid-I gene encoding the 
Midline- I ringfinger protein, which is mutated in patients with Opitz-syndrome [33] 
and Nm23-M2 a gene of which a human homologue has been identified as a critical 
gene in lymphoma development. A large set of common virus insertion sites were 
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identified harbouring novel genes, encoding for putative proteins, with unknown 
function. Each of these novel disease loci may become of interest following further 
cloning, characterisation and functional screening using in vitro and in vivo models. 
Obviously, the PCR based strategies used are highly sensitive and almost every 
insertion that was found represented a common VIS. It is possible that certain VISs, 
particularly the ones found less frequently (<5%) have been pulled out due to the high 
sensitivity of our approach, and may not resemble disease loci. However, additional 
approaches are required anyway to further select for the critical genes that play a 
major role in leukemic transfonnation. An important question to be answered in the 
near future is whether the genes identified in our in vivo functional screens are of 
importance for the development of human disease. As a final filter, high-throughput 
nucleotide sequencing, real-time PCR and gene-array analysis should prove the role 
ofthese genes in the development of human AML. 
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Chapter 5 
Nm23-Ml, -M2, and -M3, members ofthe nucleoside 
diphosphate kinase family of genes, are frequent proviral 
targets in Cas-Br-M MuL V induced leukemias in mice 
Marieke Joosten, Fokke Lindeboom, Antoinette van Hoven-
Beijen, Yolanda Vank:an-Berk:houdt, Bob Lowenberg, Marieke 
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Abstract 
Nm23-M2 was recently identified as a common virus integration site in Cas-Br-M 
MuLV induced mouse leukemias. Nm23-M2 is one of the eight members of the highly 
homologous family of nm23-genes, which can be divided into two groups. One group 
contains the genes nm23-Ml to M4, which are 44% to 88% similar in amino acid 
sequence. The second group, consisting of nm23-M5 to A18, shares far less homology 
with the first group or with each other (3% to 30%). Nm23-Ml and nm23-M2, which 
share the highest homology, are located in tandem on mouse chromosome 11. Here 
we demonstrate by PCRJSouthem blotting that nm23-Ml and nm23-M3 were frequent 
targets of proviral insertion as well. The other five members of this family appeared 
not to be located in a common virus insertion site. This indicates that multiple but not 
all members of the nm23-family may be involved in leukemic transformation. Since 
all members of the nm2 3 family of genes contain nucleoside diphosphate kinase 
(NDPK) activity, and only three of the members may act as a disease gene, it is 
possible that another function these three genes may have in common is responsible 
for their transforming activity. Our findings that nm23-Ml, -M2, and M3 are frequent 
proviral targets in mouse leukemia and the fact that the human equivalents of nm23-
Ml and -M2 are reported to be abnormally expressed in certain cases of leukemia or 
lymphoma, predicts a role for these genes in leukemia development. Experiments 
using the in vitro 32D system revealed that aberrant expression of nm23-M2 did not 
affect neutrophilic differentiation, a major characteristic of myeloid leukemia. Studies 
using alternative models should demonstrate how abnormal expression of the nm23 
genes may affect myeloid development. 
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~3 IN MOUSE LEUYEMIA 
Introduction 
Nm23-M2, also indicated as NDPK-B, is a member of a gene-family containing a 
]!UCleoside !!iP.hosphate Jiinase domain capable to convert GDP to GTP. The nm23 
family is highly conserved throughout species: nm2 3 genes are not only found in 
mammals, but also in Zebrafish [1], Drosophila melanogaster (awd, abnormal wing 
discs) [2] and Dictyostelium discoideum [3]. The nm23 family consists of 8 members 
that are all found in human and mouse [ 4]. This high conservation suggests an 
important role for the nm23-genes in basic cellular processes. In addition to the kinase 
domain, nm23-M2 possesses a DNA binding domain by means of which it is able to 
regulate c-Myc expression in a positive way [5]. This transactivation of c-Myc has 
been shown to be independent of the NDPkinase activity [6]. 
Ninety-eight percent of the nm23-M2 amino acid sequence corresponds to the 
composition of the human homologue nm23-H2, located on chromosome 17q21.3 in 
tandem with the homologous isofonn nm23-Hl [7]. Nm23-Hl and nm23-H2 are 
designated differentiation inhibitory factors, a function that is independent of their 
NDPkinase activity [8). Enhanced expression of nm23-Hl was reported to be 
associated with hematopoietic malignancies in man [9, 1 0]. Interestingly, high 
expression levels of the human homologue nm23-H2 are associated with a poor 
prognosis in AML-M2, -M4, and -MS [11]. 
Recently, the gene nm23-M2 was found to be a common virus integration site (VIS) 
in primary mouse leukemias. Genes identified through retroviral insertional 
mutagenesis have been reported to play an important role in human leukemia as well. 
Examples are Evil [12, 13], Erg [14, 15], NFI [16-18], N-Myc [19, 20], or Bell 
(Cyclin DI) [21, 22]. Proviral integration in a common virus insertion site may result 
in abnormal expression of the target gene. Insertion of the provirus 5' as well as 3' of 
a particular gene usually results in enhanced gene expression, while integration into 
the coding region may result in expression of aberrant (active or inactive) protein [23, 
24]. Previous observations demonstrating that high Nm23 expression associates with 
aggressive leukemias and lymphomas [9-11] together with our finding that nm23-M2 
is a frequent target for proviral insertion in mouse disease, suggest a direct role for 
nm23 genes in malignant development of hematopoietic tissues. 
To further investigate the importance of nm23-M2 and other family members in 
transfonnation of hematopoietic precursor cells we first studied the exact distribution 
of viral insertion in the nm23-M2 gene locus. We next investigated whether any of the 
other family members (nm23-Ml through -M8) are located in a common virus 
insertion site as welL To study the effect of abenant expression of nm23-M2 on 
myeloid development, the gene was introduced into the 32D/G-CSF-R model. Our 
data demonstrate that of the eight different family members, nm23-Ml, -M2 and -M3 
are frequent targets for retroviral insertion, whereas in the loci containing the nm23-
M4 through -M8 genes no viral insertions were detectable. None of the other family 
members have been shown to be involved in leukemia development. Using the 32D 
model a clear role for nm23-M2 in leukemia development was not identified yet. 
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:Materials and .Methods 
PCR analysis and Southern blot hybridisation 
The frequency of virus integrations was detennined on primary leukemias (CSL 11-
17, 19,21-23,25-27,29,31-33,35,36,38,39,41, 43,45-51,53-61,63-72,74-83,85, 
87-109, 114, 117, and 123). To detect virus insertions in the 5'region of the gene, 1 ~Lg 
of genomic DNA from these leukemias was subjected to PCR with primer pLTRl and 
a gene-specific primer A. lJ..1.l of PCR product was transferred to a nested PCR 
reaction using primer pL TR2 and a nested gene-specific primer B. Cycle conditions 
for both reactions were 1 cycle 5' 94'C, 30 cycles 30"94'C, 1' Tm, 1 '30"72'C, 1 
cycle 5'72°C. Tm was specific for each primer combination and was between 48°C 
and 62°C. PCR was carried out using Tag polymerase (Amersham Pharmacia Biotech, 
Roosendaal, The Netherlands). PCR products were electrophoresed in a 1.5% agarose 
gel and transferred to Hybond-N+ nylon membranes (Amersham Pharmacia Biotech) 
with 025 M NaOH/1.5 M NaCL Membranes were hybridised with a 32P-end-labelled 
locus specific primer C. Labelling was carried out using T 4kinase (USB, Cleveland 
OH, USA) according to the instructions of the provider. Subsequently, blots were 
stripped in 0.4M NaOH for 30 minutes at 45°C, neutralised using 0.2M Tris-HCl, 
0.2% SDS, and O.lxSSC for 15 minutes at 45'C and hybridised with 32P-end-labelled 
Cas-Br-M MuLV specific primer pLTR3. Blots were exposed for autoradiography 
with a KODAK film and an intensifying screen. After 15 minutes of exposure films 
were developed and analysed. Nm23-M2 was analysed for the presence of proviral 
insertions in both 5'and 3'gene region, and in both orientations of the virus. For these 
experiments, primer combinations 1-A, 2-B, 3-C, 1-D, 2-E, 3-F, 4-A, 5-B, 6-C, 4-D, 
5-E. 6-F were used (see also Figure 1 ). The sequences of the primers used for the 
detection of vims integrations in the different nm23 genes are present in Table l. All 
primers were obtained from Gibco Life Technologies (Breda, The Netherlands). 
Sequencing 
Samples were prepared using the Bd-sequencing kit according to instmctions from the 
provider (PE Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). Nucleotide 
sequencing was carried out on an ABI 310 automatic sequencer (PE Biosystems) 
using primers Ml3forward (5'-GTA AAA CGA CGG CCA GT-3') and Ml3reverse 
(5'-GGA AAC AGC TAT GAC CAT G-3'), 
Cells 
32D/G-CSF-R-cells were cultured in RPM! 1640 medium (GibcoBRL., Life 
Technologies, Breda, The Netherlands) supplemented with 10% FCS and 10 ng/ml 
murine IL3 at a concentration of2x105 cells/ml. For experiments, cells were washed 
twice with HBBS (Gibco BRL.) and seeded in RPM! 1640 medium without any 
additives. Factor stimulation was with lOOng/ml IL3, lOng/ml G-CSF. 
Nm23-A12 expression constructs 
eDNA ofnm23-M2 (NCB! accession number X68193) was cloned in the pBluescript 
KS vector. A triple HA-tag was added 5' of the startcodon of the introduced sequence. 
Artificially introduced Neal and BspHI restriction sites were used to isolate HA-nm23 
and HA-LBD. Fragments were blunted by adding 1 U of Alkaline Phosphatase 
(Roche, Mannheim, Germany) for 15' at 37°C. Subsequently the fragments were gel-
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Table 1: Primer sequences used to detect integrations in nm23 genes. 
Gene primer A primer B pl"imer C primer D primer E primer F 
Nm23-Ml ATGATCTCGCCCA CATCAGGClTGA"l' GTACGCTCACTGT 
CCAGCC GGCAATG TGGCC 
Nm23-M2 TCGCCCACCAGG TGCACGCCATCTG CCAACCTCG/\GCG G1\ TGGCTTTTCTGG CATCCC/\CTG/\C CAGTTCCAAAGTC 
CCGCGC GCTTO T/\CCTTCATTG ACAOAGCTC AOGATGGATC TTTAT 
Nm23-M3 CCCGCCCOGGTG OAGGTT AGCAAA AGCACCAGACAGA 
CTCAC GATGGT TCATG 
Nm23-M4 GCAGGCACTGAA GCACAACAGCGC GACGCGCCCGAAA 
AGCGTG CCCiCAG 1\GGC 
Nm23-M5 CCTCTTCTTTGTC TGGCTTGATAAG CTACATATATCTG 
AACAAC GGCTAG AGGCAG 
Nm23-M6 GCATCAGGCTTG GTGTGAGCTGGA GGACTTCGCAAGA 
ATCAGG GAGCTTG TGGAG 
Nm23-M7 GACAGGCTCTCA CGAGGATGCAAC GAAGAGAAGGCGT 
TACTGC GCCGGC CAATAAC 
Nm23-M8 GTTCAGCA.ACAT CAAGTTCTGACTA CTGACTGTAGCTG 
CTCATC TTGACG GACTTC 
LTR primer 1 primer 2 primer 3 primer 4 pl"imcr 5 primer 6 
CTTGCTGTTGCAT CiTCTCGCTGT"rCC GGTCTCCTCAGAG ACCAC/\G/\TATC GTTCCTGACCTTG CCCTATTCTCAGT 
CCGACTGG TTGGGAGG TGATT CTGTTT ATCGAAC TCGGTA 
Virus integrations in genes from the nm23-gene hnnily were detected by a nested IJCR-Southern blotting technique. For proviral insertions in the 5'regim1 or the genes, 
primers A to C were used together with LTR primers 1, 2. and 3. For virus integrations in the nm23-M2 gene, both 3'cmd 5'regions were checked for integrations in two 
orientations (5'3'and 3'5'), using also primers D, E, and F, and LTR primers 4, 5, and 6. All primer sequences are given 5'to 3'. 
c--l;",.~·T2,F 
purified and inserted into the blunted EcoRI site of the eukaryotic expression vector 
pLNCX. 
Preparation of retrovirus and transduction of32D cells 
The retrovirus producer Phoenix-E cells were split to 2x106/ml 24 hours prior to 
transfection. Chloroquine was added to each plate 5 minutes before transfection at a 
final concentration of 25~LM. I O[!g DNA was transfected in the cells by the calcium 
phosphate coprecipitation technique. Chloroquine was removed 9 hours after 
transfection and fresh medium was added to the cells supplemented with I 0% foetal 
calf serum (FCS, Gibco Life Technologies) and !Ong/ml murine IL-3. The 
supematant was collected from the cells 48 hours post-transfection. 2.5x105 32D/G-
CSF-R cells were repeatedly transduced with 1.5 ml supematant on retronectin coated 
plates. The cells were replaced from these plates 48 hours after transduction and the 
virus was removed by washing the cells three times with phosphate-buffered saline 
(PBS, Gibco Life Technologies). The transduced 32D cells were maintained in RPMI 
1640 medium (Gibco Life Technologies) supplemented with 10% FCS and 10 ng/ml 
murine IL-3 at a concentration of 2xl05 cells/mi. Cells were subjected to limiting 
dilution to obtain monoclonal cell populations. The infected 32D clones were induced 
to terminally differentiate by shifting them from IL-3 supplemented medium to 
medium containing lOng/ml G-CSF. Cytospins stained with May-Griinwald Giemsa 
and cell counting were done daily. 
Western blotting 
Samples of 32D/G-CSF-R-cells were taken at time points 0, 2, 4, 6, 7, 8, and 9 days 
during differentiation. Cells were washed twice with ice-cold phosphate-buffered 
saline with lOmM NaV04 . Subsequently, cells were spun down and lysed by 
incubation for 10 minutes at 4'C in Lysis buffer (20mM Tris pH7.4, 150 mM NaCl, 
I% NP40, 0.1% SDS, 0.5% Sodium deoxycholate, 5 mM EDTA). Insoluble material 
was removed by centrifugation for 15 minutes at lOOOOxg at 4 °C. Following 
separation on 12.5% PAGE and Westem blotting, filters were incubated with the 
nm23-M2 antibody (Seikagaku, Falmouth, MA, USA). Immune complexes were 
detected with horseradish peroxidase-conjugated goat-anti-rat IgG semm (Santa Cruz, 
Santa Cruz, CA, USA, catalogue #32006), followed by an enhanced 
chemoluminiscence reaction (NEN® Life Science Products, Zaventem, Belgium). 
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Results 
Proviral insertions 5' and 3' of the nm23-M2 gene 
f ,_.-
!_,[', 
We previously identified by inverse PCR a proviral insertion in the promoter 
sequence of nm23-M2. Directed PCR further demonstrated that the 5' region of 
nm23-M2 is a common site of proviral insertion. To study the frequency of proviral 
integrations in the nm23-M2 locus we designed a directed nested-PCR protocol 
applying LTR specific and locus specific primers followed by a Southern blot 
approach using additional LTR and locus specific primers (Figure 1 ). Proviral 
insertions were found in the 5' as well as 3' area of nm23-M2 (Figure 1). The 
insertions of the provirus occurred in the 5'3' as well as in the 3'5' orientation and 
were detected in 56% of the primary leukemias studied. 
6 5 4 1 2 c B A D E F 4 5 6 3 2 1 
Figure l. Schematic representation of the nm23-M2locus. 
A PCR-Southem blotting approach was used to detect proviral insertions in the 5' and 3' regions of 
nm23-M2. Primers are depicted. For analysis of the 5' region of nm23-M2 LTR primers 1, 2, and 3 and 
nm23-M2 primers k B, and C were used to identify proviral insertions in the 5'3' orientation, and 
L TR primers 4. 5, and 6 in combination with the before mentioned nm23-M2 primers were used to 
detect integrations in the 3'5' orientation. For proviral insertions in the 3' region of the gene primers D. 
E, and F together with LTR primers 4, 5, and 6 resulted in identification of insertions in the 5"3' 
orientation, whereas with L TR primers I, 2. and 3 integrations in the opposite direction were 
demonstrated. Proviral insertions were found in the 5' as well as 3' area ofnm23-M2. The insertions of 
the provims occurred in the 5'3' as well as in the 3'5' orientation and were detected in 56% of the 
primary leukemias studied. In the figure the percentage of occurrence of each type of integration is 
annotated. 
Proviral insertions are present 5' ofnm23-MJ, M2 and M3 
Nm23-M2 is part of a highly homologous family of nm23 genes. The amino acid 
comparison between the different nm23 homologues is shown in Figure 2A. The 
nm23-family can be divided into two groups. One group containing the first four 
members (nm23-M1, -M2, -M3 and -M4) between which homologies vary from 44% 
to 88% in mice (Figure 2B) and from 58 to 88% in human (data not shown). The 
expression of these genes is ubiquitous although variable in place and time during 
development [4]. The proteins from the second group containing the other members 
(nm23-M5, -M6, -M7 and -MS) share far less homology with the first group or with 
each other i.e. 3% to 30% in mice (Figure 2B) and 25% to 45% in human (data not 
shown). Nm23-M5, M7, and -M8 are mainly expressed in the testis, nm23-M6 is 
ubiquitously expressed [4]. 
Nm23-M2 shares the highest homology (88%) with the nm23-M1 family member. 
Interestingly, nm23-Ml and nm23-M2 are located in tandem on mouse chromosome 
ll with a separation of approximately 3.8kb between the 3' end ofnm23-M2 and the 
5' mRNA start ofnm23-MI (Figure 3). We investigated whether nm23-M1 was also a 
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Figure 2. Amino acid comparison between the 8 murine nm23 family members. 
A. Visual comparison of the 8 nm23 genes. Identities are on a black background and similarities 
are on a gray background. 
B. Homologies ('Yo identity) between all 8 murine nm23 genes. 
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Figure 3. Nm23-M 1 and nm23-i\12 localisation in the mouse genome. 
Nm23-Afl and nm23-i\12 are located in tandem on mouse chromosome !I with a separation of 
approximately 3.8kb benveen the 3' end ofnm23M2 and the 5' mRNA start ofnm23-Ml. 
frequent target of proviral insertion. PCR/Southem blotting analysis using specific 
LTR primers and primers in ex on 1 from nm23-M 1 revealed that 48% of the primary 
CSL leukemias contained a VIS in the 5' area of the nm23-MI gene. 
Since both nm23-M2 and Ml were frequent targets of proviral insertion, it was 
worthy to investigate which of the remaining nm23-family members should also be 
considered as potential leukemia disease genes. Therefore we designed prin1ers ln aU 
other known nm23-genes to search for integrations in the 5' regions (sequences 
annotated in Tablel ). In 20% of the primary CSL leukemias proviral insertions had 
taken place 5' of the nm23-lvf3 or DR-nm23 gene. None of the other nm23-genes 
appeared to be located in a common vims integration site. 
Overexpression ofnm23-JU2 in 32DIG-CSF-R cells 
The 32D/G-CSF-R system has been shown to be a valuable model to study the effect 
of aberrantly expressed disease genes on neutrophilic differentiation. We generated 
nm23-M2/pLNCX expression constructs to which aHA-tag was cloned in frame 5'of 
the murine nm23-M2 eDNA. HA-nm23-M2 was introduced into 32D/G-CSF-R and 
Westem blotting analysis demonstrated the presence of the ectopic protein (Figure 
4A). In vitro cultures using IL3 or G-CSF were carried out using five HA/nm23-M2 
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expressing as well as five vector control 32D clones. All ten clones were fully 
dependent on growth factors and no differences in proliferative response were 
observed in response to either IL3 (data not shown) or G-CSF (Figure 4B). HA-nm23-
M2 expressing as well as vector control 32D/G-CSF-R lines fully differentiated 
towards neutrophils in the presence of G-CSF (data not shown). So far, no differences 
were observed between the two distinct groups of clones. 
Expression ofnm23-M2 in 32DIG-CSF-R-cells during differentiation 
Expression of endogenous nm23-M2 is downregulated during differentiation of the 
erythroid progenitor cell line Ill! (Chapter 6). To investigate whether nm23-M2 
expression decreases during granulocytic differentiation of the murine myeloid 
32D/G-CSF-R-cell line, the cells were induced to terminal differentiation using G-
CSF. Total protein was isolated from cells in different stages of differentiation and 
analysed by western blotting. Nm23-M2 protein levels did not decrease significantly 
following 9 days of culture of 32D/G-CSF-R with G-CSF (Figure 5). 
A B C 
A HA!nm23-M2 
2 3 4 5 
pLNCX 
--<o-HNS A 
-<>-HNS C 
---m-HNS D 
-<>-HNSE 
-o-pLNCX 1 
---tr-pLNCX2 ! 
_,_.pLNCX 3 
--fl-}-pLNCX4 
-D-pLNCX 5 
; ' 
Days of culture on G-CSF 
Figure 4. 
A. Western blot showing expression of the HA tagged nm23-M2/pLNCX expression constructs 
in 320/G-CSF-R (A to E). No nm23-M2 message was present in the pLNCX control 
transfectants (I to 5). 
B. No differences in proliferation were observed in 32D[G-CSF-R/HA-nm23-M2] cells 
compared to control clones in response to G-CSF. 
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Figure 5. Nonnal expression of nm23-M2 during differentiation of32D/G-CSF-R cells. 
Western blot demonstrating that nrn23-M2 protein level did not decrease significantly following 9 days 
of culture of32D/G-CSF-R with G-CSF. Staining for actin was used as a control for equal loading. 
Discussion 
The gene nm23-M2 was identified as a common VIS in murine primary leukemias. 
Integrations had taken place both 5' and 3' of the coding sequence of the gene in 
different retrovirally induced leukemias in mice. In addition we showed that the two 
most closely related homologues ofnm23-M2, i.e. nm23-Ml and nm23-M3 were also 
frequent targets for proviral insertion, the other five nm23 family members (M4 
through MS) were not, Although these data clearly suggest a role ofnm23-Ml, M2 or 
M3 in leukemic transformation, aberrant expression ofnm23-M2 into 32D/G-CSF-R-
cells did not have an effect on the proliferative response or neutrophilic differentiation 
of these cells, 
Proviral integrations 5' or 3' of a gene usually result in an overexpression, suggesting 
that high uncontrolled expression of the gene may be a critical event in leukemic 
transformation. High expression of the nm23 genes or their products has not been 
demonstrated in our retrovirally derived leukemias (unpublished data). The main 
reason for this cavity is that the tumours that are obtained from these mice are 
oligoclonal [25, 26]. The proviral insertions are therefore most likely present in only a 
certain percentage of leukemia cells in a particular mouse and high gene expression is 
most likely masked, The idea that high expression of nm23 genes may indeed be 
critical in leukemia progression comes from human studies. High expression of 
NM23-H2, the human homologue ofmu23-M2, has been shown to be associated with 
a certain group of poor-risk myeloid leukemias [11, 27]. Furthermore, high expression 
of NM23-H1 has convincingly been shown to be associated with poor-risk 
lymphomas [9, 10]. In vitro or in vivo models should further elucidate how aberrant 
expression ofnm23-M1, M2 or M3 may play a role in leukemia development. 
One such model is the 32D in vitro system These 32D cells expressing the G-CSF-R 
can be maintained in vitro using IL3, but differentiate towards mature neutrophils in 
the presence of G-CSF, The model has been successfully used to demonstrate the 
transforming ability ofe,g, Evil, Myb, Cb2 or a mutated fonn of the G-CSF-R [28-
31], Introduction of the nm23-M2 gene into the 32D-wt cells however, did not at all 
affect the proliferative capacity of the cells nor did it interfere with neutrophilic 
differentiation. Several possible explanations may explain this particular finding. It is 
possible that nm23-M2, like many other transforming genes, is oncogenic only in 
conjunction with other proto-oncogenes. This particular gene should then be 
introduced in 32D/G-CSF-R cells as welL It could also be that in the 32D cells the 
signalling pathway involved in the regulation of nm23-M2 expression is already 
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defective. This could explain our finding in figure 5 showing that nm23-M2 protein 
levels are not downregulated during granulocytic differentiation of 32D cells. Other 
studies have nicely demonstrated that nm23 protein levels are normally 
downregulated during development [32]. Another possibility is that nm23 genes do 
not disturb granulocytic development but that they interfere with development of 
other lineages. AML is not only characterised by a block of neutrophilic 
differentiation, but also by a lack of mature cells of other differentiation lineages. 
Since the incapability of other hematologic precursors to develop may also be the 
result of genetic defects, we are currently investigating whether nm-23-M2 may 
interfere with erythroid development using an in vitro erythroid differentiation model. 
The nm23-genes are part of an evolutionary highly conserved gene family. Eight 
distinct members were identified of which the nm23-lr11 and nm23-lvf3 members were 
originally identified in tumour tissue. Nm23-Ml was identified in a murine melanoma 
celi line [33]. Nm23-i\13 \Vas isolated from differential screening of a blast-crisis CML 
eDNA library [34]. The original identification of nm23-H2 was based on sequence 
homology with nm23-Hl [35]. All other nm23-genes have been found by screening of 
EST sequences in databases [36-38]. Since integrations were found in nm23-M I, 
nm23-M2, and nm23-M3 genes and not in the other five family members, it is likely 
that the transforming capacity of these genes is not caused by an uncontrolled 
nucleoside diphosphate kinase activity. Studies on nm23-M2 have demonstrated that 
besides a nucleotide diphosphate kinase activity the protein was also capable to act as 
a c-A1yc-transactivator, indicating that these proteins may indeed possess other 
functions [5]. Since the Myc-transactivation capability was not ascribed to nm23-M 1 
or M3, we suggest that the transfom1ing ability of these three nm23 homologues may 
be caused by yet another specific function that these three family members have in 
common. 
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Abstract 
Recently the gene nm23-M2 was found to be a common virus integration site, 
suggesting that this gene plays a role in leukemia development. Using a second 
approach to identify genes that may be involved in leukemogenesis, i.e. high 
throughput screening of cytokine induced genes by micro-array analysis, again nm23-
M2 was identified. Northern blot analysis of nm23-M2 expression did not reveal 
alterations in mRNA levels behveen growth factor stimulated cells and controls. 
However, it was found that polysome binding of nm23-M2 mRNA is growth factor 
dependent, indicating a translational control of gene expression. Nm23-M2 polysome 
binding as well as protein expression declined during differentiation of the erythroid 
progenitor cell line I/11, indicating a change of translation of nm23-M2 during 
erythroid maturation. Regulation of nm23-M2 polysome binding was shown to be 
PI3K dependent, while inhibition of the MEKIERK pathway did not result in a 
reduction in polysome association. Moreover, it was found that nm23-M2 transcript 
started with a Terminal Oligopyrimidine (TOP) tract, a stretch of pyrimidines that is 
present in many translationally controlled genes. Comparison of expression of nm23-
M2 with other translationally regulated genes demonstrated that nm23-M2 behaves 
like other TOP-containing genes. These data together indicate that PBK targets like 
nm23-M2 are likely involved in renewal induction, suggesting a mechanism by which 
mn23-M2 may be involved in leukemogenesis. 
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Introduction 
Hemopoietic progenitors can be induced to undergo renewal divisions or they may 
differentiate into mature cells [1, 2]. This balance is controlled by proteins inherently 
expressed in the cells, including transcription factors, in concert with molecules that 
transmit signals in response to extracellular factors like growth factors, cytokines and 
hormones [3, 4]. Recently we described how human and murine erythroid progenitors 
can be induced to undergo renewal divisions in presence of erythropoietin (Epo ), stem 
cell factor (SCF) and dexamethasone (dex), whereas they undergo terminal 
differentiation upon stimulation by Epo in absence of SCF [5, 6]. Leukemic 
alterations disturb the balance between expansion and differentiation as they 
constitutively mimic processes involved in renewal. For instance, the v-ErbB 
oncogene, encoded by the avian erythroleukemia virus (AEV) appeared to mimic the 
synergistic effect of Epo plus SCF induced signal transduction [6], which induces 
factor independent renewal divisions. Genes normally expressed under conditions of 
cell renewal, i.e. induced in presence of Epo plus SCF, and downmodulated during 
tenninal differentiation are candidate genes to be upregulated in leukemia. 
A direct approach to identify disease genes in hematopoietic malignancies is the 
characterisation of virus insertion sites in retrovirally induced leukemia. Genes 
recurrently targeted by retroviruses in experimental mouse leukemia models often 
appeared to be involved in human leukemia, either activated by translocations (e.g. 
Evi [7, 8], Erg [9, 10], NFJ [11-13] and N-Myc [14, 15]) or by point mutations (e.g. 
Bcll(CyclinDJ) [16, 17]). 
We have started to make an inventory of genes that may have a role in 
leukemogenesis, employing two different approaches, i.e. 1) high throughput 
screening of cytokine induced genes by means of micro-array analysis [18-20] and 2) 
identification of leukemia promoting genes by retroviral insertional mutagenesis. 
In a recent screen of retroviral integration sites, 9 % of the samples in a panel of 
primary CSL leukemias harboured integrations in the nm23-M2 gene [21]. Nm23-M2, 
or NDPK-B, is a member of a gene-family containing a n_ucleoside !!.iJ!hosphate 
]iinase domain able to convert G-protein bound GDP to GTP [22-24]. Nm23-M2 also 
possesses a DNA binding domain by means of which it is able to regulate c-myc 
expression [25]. Nm23-M2 has 98% amino acid identity with the human homologue 
nm23-H2, located on chromosome 17q21.3 in tandem with the isofonn nm23-Hl [26]. 
Nm23-H1 and nm23-H2 are considered differentiation inhibitory factors, a function 
that is independent of its NDPkinase activity [27]. Enhanced expression ofnm23-Hl 
was reported to be associated with hematopoietic malignancies in man [28, 29]. 
Gene expression may be controlled at the transcriptional as well as at the translational 
level. Nuclear transcribed mRNAs contain a cap-structure (m 7 GpppN) at their 5 'end. 
Eukaryote initiation factor 4E (eiF4E) binds the cap structure and fonns a complex 
with other translation initiation factors [30]. This complex scans the mRNA until it 
encounters an ATG-startcodon in a favourable sequence environment [31, 32]. 
Subsequently the initiation factors dissociate and a 60S ribosomal subunit associates, 
and protein synthesis starts. Structural elements in the UTRs can render translation 
dependent on cell type, developmental stage or environmental conditions. Such 
structures may consist of a terminal oligopyrimidine-(TOP)-tract, repeats fanning 
dsRNA stretches that require RNA helicase activity, structures that are stabilised by 
conditional binding of proteins, or upstream A TGs and ORFs that require recruitment 
of the translation machinery to an internal ribosomal entry site (IRES). In such 
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situations, specific cellular signals, e.g. phosphorylation of proteins involved in 
recruitment may be required for mRNA translation. Signalling pathways known to 
regulate translation following growth factor stimulation include the MEKIERK 
pathway, resulting in activation of p90RSK and MNK-1,-2, and PBKIPKB which 
activates mTOR and S6kinase [33]. 
Genes upregulated upon growth factor stimulation may be actively involved in 
preserving cell growth, while inhibiting differentiation. In the present study, we 
carried out micro-array analysis, using eDNA derived from growth factor stimulated 
(Epo plus SCF; representing renewal conditions) versus factor deprived erythroid 
precursor cells. In order to identify genes that are differentially expressed either at the 
transcriptional or at the translational level, eDNA prepared from polysomal mRNA 
was used. Here we demonstrate that expression of the nm23-M2 gene, previously 
identified as a common virus integration site, was differentially expressed in factor 
stimulated cells. Furthennore, nm23-M2 protein expression was shown to be down 
regulated during erythroid differentiation. To study whether nm23-M2 expression was 
regulated at the transcriptional or at the translational level, nm23-M2 Northern 
analysis was perfonned using mRNA fractions blotted after sucrose gradient isolation, 
separating polysomal from non-polysomal mRNA. We report that although mRNA 
transcripts from the nm23-M2 gene in erythroid progenitors are constitutively high, 
polysome binding of nm23-M2 mRNA, suggesting protein expression control, is 
regulated at the level of translation initiation. Polysome binding of nm23-M2 in 
erythroblasts is strictly dependent on Epo/SCF signalling to PI3K. Cloning of the full 
5'UTR of nm23-M2 revealed that it contains both a TOP-sequence and an inverted 
repeat which may both be crucial for translation regulation. 
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Materials and Methods 
Cells 
Ill! cells were cultured in StemPro medium supplemented with 0.5U/ml Epo, (Ortho-
Biotech, Tilburg, The Netherlands), 100 ng/ml SCF (Amgen, Breda, The Netherlands) 
and 10- 6M dexamethasone (Sigma-Aldrich, Zwijndrecht, The Netherlands) as 
described [6]. To analyse cellular signalling mechanisms, cells were washed twice 
with HBBS (Gibco BRL., Life Technologies, Breda, The Netherlands) and seeded in 
Iscove's medium without any additives. Factor stimulation was with 5U/ml Epo, 
200ng/ml SCF. 
RNA isolation and Northern blot analysis 
Isolation of total RNA and Northern blot analyses was perfonned as described by 
Chomczynski eta!. [34] with minor modifications [35]. Isolation of polysomal RNA 
by sucrose gradient fractionation was perfonned essentially as described [36]. Cell 
extracts were prepared by lysis at 4°C in extraction buffer (10 mM Tris-HCl, pH 8.0, 
140 mM NaCI, 1.5 mM MgCI2, 0.5% Nonidet-P40, 20 mM dithiothreitol, !50 ~g/ml 
cycloheximide, I rnM phenylmethylsulfonyl fluoride and 500 U/ml RNAsin), and 
nuclei were removed by centrifugation (12000 g, 10 s, 4 °C). The supernatant was 
supplemented with 665 ~g/ml heparin and and centrifuged (12000 g, 5 min, 4'C) to 
eliminate mitochondria. The supernatant was layered onto a 10 ml (ATLAS 
hybridisation and Northerns) or 4 ml (Taqman analysis) linear sucrose gradient 
(15-40% sucrose [w/v] supplemented with 10 mM Tris-HCI, pH 7.5, 140 mM NaCI, 
1.5 mM MgC12, 10 mM dithiothreitol, 100 ~g/ml cycloheximide, and 0.5 mg/ml 
heparin) and centrifuged in a SW41Ti rotor (Beckman, Palo Alto, CA, USA.) 38000 
rpm, 120 min, 4°C, or in a SW50Ti rotor 42000 rpm, 60 min, 4°C without brake. 
Fractions (550 ~I) were collected and digested with I 00 ~g proteinase K in I% 
sodium dodecylsulfate (SDS) and 10 mM EDTA (30 min, 37'C). RNAs were then 
recovered by phenol-chloroform-isoamyl alcohol extraction, followed by ethanol 
precipitation. RNAs were analysed by electrophoresis on denaturing 1.2% 
formaldehyde agarose gels and subsequent Northern blotting (using Hybond-N+ 
membranes; Amersham Phannacia Biotech, Roosendaal, The Netherlands). These 
gels indicated that fractions 1-11 (10 ml gradient) and 1-4 (4 ml gradient) contain 
nonpolysomal and subpolysomal mRNA, while fractions 13-20 (10 ml gradient) and 
5-8 (4 ml gradient) consisted ofpolysomal RNA. The latter fractions were pooled for 
array hybridisation and Taqman analysis respectively. As probes we used a 612 bp 
nm23-M2 eDNA fragment, or cDNAs containing the entire ORF of piml or c-jun. 
After hybridisation, filters were scanned on a phosphor-imager and signals were 
quantified by Phosphorlmaging (Molecular Dynamics, Sunnyvale, CA, USA.) 
Poly( A/ mRNA isolation and eDNA synthesis 
Total RNA from sucrose gradients was pooled into 1:\vo major fractions: free RNA 
and polysome-bound RNA. RNA was quantified by UV-absorbance. Poly(Af mRNA 
was purified from isolated total RNA (25-30 !-'g) with the oligotex rnRNA minikit 
(Qiagen Gmbh, Hilden, Gennany) according to the manufacturer's recommendations. 
Equivalent amounts of poly A.,. RNA (1-2 !-lg) were reverse transcribed into eDNA 
using 2 1-'1 CDS primers provided by the ATLAS kit. RNA was denatured (7', 65'C; 
7' on ice), RNAsin (lOU), DTT (lOmM), nucleotides (IOOnM each) and buffer 
supplied with the enzyme plus 100 U SSII* Reverse Transcriptase (Gibco) were 
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added and the reaction was put at 42"C for 1.5 hours. Subsequently RNA was 
degraded in 0.3M NaOH at 65"C for an hour, which was stopped by adding Tris 
pH7.5 to 20mM and HCl to neutralise the NaOH. CDNA was precipitated in the 
presence of glycogen (Boehringer) and dissolved in 15 [.ll H20. I 111 was used in a 
random labelling reaction (Random primed labelling kit, Roche) using 32P-dATP. 
After removal of free nucleotides the 32P-incorporation was measured in a Cherenkov-
counter and the same amount of counts was used in hybridisations of a single 
experiment [18, 37]. 
Microarray hybridisations 
Hybridization of AtlasTM eDNA arrays (588 mouse eDNA probes; Clontech 
laboratories, Palo Alto, CA) was performed basically as recommended by the 
manufacturer, with the modifications described below. Filters were prehybridised for 
8h at 68°C in 10 ml ofprewarmed ExpressHyb plus denatured sheared salmon spenn 
DNA, both provided by the kit. Subsequently, 6 x I 0 7 dpm of denatured radioactive 
eDNA (kept 5 min at 95"C without denaturing solution and thereafter chilled on ice) 
were added and hybridised for 20 hours. Filters were washed three times at 68°C in 
200 ml of 2 X sse I I %SDS for 40 min. Thereafter the filters were washed again 
three times in 0.2 x SSC I 0.5% SDS for 20 min and subjected to phosphor-imaging 
(Molecular Dynamics). 
Western blotting 
I/11 cells were factor deprived and stimulated as described above. Samples were 
taken at regular intervals and processed as described before [38]. Following 
separation of proteins on 10% PAGE and Western blotting, filters were incubated 
with the nm23-M2 antibody (Seikagaku, Falmouth, MA, USA). Immune complexes 
were detected with horseradish peroxidase-conjugated goat anti rat IgG antiserum 
(Santa Cruz, Santa Cruz, CA, USA, catalogue no #2006), followed by an enhanced 
chemoluminescence reaction (NEN® Life Science Products, Zaventem, Belgium). 
Isolation and cloning of the 5 'untranslated region of nm23-M2 
A nested PCR was performed on an oligo-d(T)-primed eDNA library of primary 
erythroblasts (a gift from Walbert Bakker, Institute of Hematology, Erasmus 
University, Rotterdam, The Netherlands). The library was ligated into the lambda 
ZAP express® vector (Stratagene, Amsterdam, The Netherlands). The first PCR (45" 
at 94"C, I' at 57"C, and I' at 72"C; 25 cycles) was performed using the Ml3 reverse 
primer (5'ACA GGA AAC AGC TAT GAC CTT G3') in the vector in combination 
with pN6 (5'TCG CCC ACC AGG CCG CGC3') in nm23-M2 on SOng of eDNA. I f.ll 
ofPCR product was transferred to the nested PCR (45" at 94"C, 1' at 56'C, and 2' at 
72'C (30 cycles)). The T3 primer (5'AAT TAA CCC TCA CTA AAG GG3') in the 
vector and pN8 (5'TGC ACG CCA TCT GGC TTG3') in nm23-M2 were used for 
this reaction. Subsequently, the final products were cloned directly into pCR2.1 
(Invitrogen, Breda, The Netherlands) according to the instructions of the 
manufacturer. Nucleotide sequencing was carried out using the Bd-sequencing kit 
according to instructions from the provider (PE Biosystems, Nieuwerkerk a/d IJssel, 
The Netherlands) Sequencing was carried out on an ABI 3l 0 automatic sequencer (PE 
Biosystems) using the M13forward primer (5'GTA AAA CGA CGG CCA GT3'). All 
primers were obtained from Life Technologies (Breda, The Netherlands). 
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Primer pairs 
Gene-specific primers corresponding to nm23-M2 (NCBI accession number X68193), 
YB-1 (X57621), rpS4 (M73436), eEF-1~2 (BC023139), F1i-1 (X59421) and aTUB4 
(M13444) were obtained from Life Technologies. The sequence of the primers used 
for the amplification ofnm23-M2 were: forward 5'TGG CCA ACC TCG AGC GTA 
C3', reverse 5'TTG AGC CCC TCC CAG ACC A3'; YB-1, forward 5'TGC AGG 
AGA GCA AGG TAG AC3', reverse 5'TGG TGG ATC GGC TGC TTT TG3'; rpS4, 
forward 5'TAG CGC AGC CAT GGC TCG TG3', reverse 5'TCA TCT CCA GTC 
AGG GCA TAC3'; eEF-!p, forward 5'ATG GGA TTC GGA GAC CTG AA3', 
reverse S'TCA GCA GGT GGT GGA CCA GA3'; Fli-1, forward S'TGC AGC CAC 
ATC CAA CAG AG3', reverse S'TGA AGG CAC GTG GGT GTT AG3'; and 
aTUB4, forward S'TGC AGC GTG CTG TGT GCA TG3', reverse 5'TCC TCT CGA 
GCC TCA GAG AA3'. 
Real-time PCR 
The real-time PCR assay involves TaqMan technology (PE Applied Biosystems 
Model 7700 sequence detector), which combines rapid thermocycling with on-line 
fluorescence detection of the PCR products. The reactions were performed in a 
volume of 25 111 of a mixture containing 4 111 of the respective eDNA dilution, primers 
at 5 [.tM and 12.5 !ll of2X SYBR green PCR Master mix (PE Biosystems) containing 
Amplitaq Gold® DNA polymerase, reaction buffer, dNTP mix with dUTP, passive 
reference and the double stranded DNA (dsDNA)-specific fluorescence dye SYBR 
green I. Samples were placed into a 96-well plate, capped and placed into the TaqMan 
sequence detector. The amplification program consisted of 1 cycle of 50°C with 2-
minutes hold (AmpErase UNG incubation), I cycle of 95'C with I 0-minutes hold 
(AmpliTaq Gold Activation), followed by 40 cycles of denaturation at 95'C for 15 s, 
annealing at 62°C for 30 s and extension at 62°C for 30 s. All the different primer 
pairs have the identical optimal PCR annealing temperature. Acquisition of the 
fluorescence signal from the samples was carried out at the end of the elongation step. 
To confinn amplification specificity the PCR products fonn each primer pair were 
subjected to agarose gel electrophoresis. 
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Results 
Nm23-M2 expression is regulated by control of translation 
Similar to primary erythroid progenitors, the erythroid cell line I/11 proliferates in 
presence of erythropoietin (Epo), Stem cell factor (SCF) and dexamethasone (Dex), 
while the cells undergo tenninal differentiation into enucleated erythrocytes in the 
presence ofEpo and insulin [6, 18]. We are interested in genes whose expression is 
induced by Epo plus SCF as these genes may be actively involved in maintaining cell 
expansion while inhibiting differentiation. As signal transduction may control 
activation of both transcription and translation, we used polysome bound mRNA, 
derived from I/11 erythroid cells factor deprived and stimulated with Epo, SCF or Epo 
plus SCF, to screen ATLAS filters containing 588 eDNA probes (see material and 
methods, [18]). In this screen we found nm23-M2 to be upregulated by Epo or SCF 
(Figure lA). The highest expression was observed when cells were stimulated with 
Epa plus SCF. To validate the results, we tested total RNA derived from cells that 
were factor deprived and similarly stimulated by Epo, SCF or Epo plus SCF for 
nm23-M2 expression on a Northern blot containing total mRNA. Surprisingly, we did 
not detect altered expression, although the Epa-target gene Piml was upregulated by 
Epo and the SCF-target gene c-Jun was upregulated by SCF (Figure lB). 
Subsequently we hybridised Northern blots containing fractions of subpolysomal and 
polysome bound RNA with the nm23-M2 probe. Quantitative analysis showed that in 
absence of factor, less than 20% of all nm23-M2 mRNA is present in the polysome 
bound fractions. Upon stimulation with Epo 53% of nm23-M2 mRNA shifts into the 
polysome bound fractions. In the presence of SCF 64% and in the presence of Epo 
plus SCF 78% of the nm23-M2 mRNA was found in the polysome bound fractions 
(Figure lC). These data suggest that expression ofnm23-M2 is controlled at the level 
of translation initiation rather than by control of transcriptional activation. The highest 
percentage of polysome binding by nm23-M2 transcripts occurs following stimulation 
by the combination ofEpo and SCF. 
Loss of polysomal association of nm23-M2 mRNA and decrease of protein levels 
during erythroid differentiation 
Previous studies reported nm23-M2 protein expression to be downregulated in 
myeloid [39] and in erythroid differentiation [40]. Our finding that the highest 
percentage of polysome-bound nm23-M2 mRNA was observed when stimulated with 
Epo plus SCF is in agreement with these findings. To investigate whether nm23-M2 
downregulation was due to a change in translation, we studied nm23-M2 mRNA 
polysome binding in I/11 cells during tenninal differentiation. I/11 cells were shifted 
from medium supplemented with Epo, SCF, and dexamethasone to medium 
supplemented with Epo and Insulin. Westem blotting shows that nm23-M2 protein is 
dowmnodulated between 36 and 48 hours upon differentiation induction (Figure 2A). 
This corresponds to the differentiation stage in which I/11 cells stop to divide and 
start to accumulate hemoglobin [6, 18]. On Northern blots containing fractions of 
subpolysomal and polysomal mRNA derived from cells at different stages of 
differentiation, the nm23-M2 mRNA shifted significantly to the subpolysomal 
between 20 and 48 hours after differentiation induction (Figure 2B). 
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Figure 1. Nm23-M2 polysome association is induced by mitogenic signals. 
Clone Ill! erythroblasts were factor deprived and subsequently left unstimulated (NF) or stimulated 
with Epo (5U/ml), SCF (100 ng/ml) or both (Epo/SCF) for two hours. A. polysomal mRNA was 
hybridised to ATLAS filters (see materials and methods). Arrows indicate spot C4c, nm23-M2, to be 
induced by Epo and SCF. B, Total RNA of cells similarly treated was used to generate a Northern blot, 
which was hybridised to probes representing nm23-M2, piml, c-jun and c-myb (in all cases probes 
comprised full ORF). Surprisingly, nm23-M2 expression was not induced, thoughpiml expression was 
induced by Epo (E) and Epo plus SCF (ES) and c-)un was expressed by SCF (S) and Epo plus SCF 
(ES). C, Separate fractions of RNA isolated from the sucrose gradient (concentration gradient indicated 
below) were tested for expression of nm23-M2. The first fractions contain subpolysomal RNA, the 
latter fractions contain RNA recovered from polysomes. The percentages indicated at the right 
represent the percentage of nm23-M2 mRNA present in polysomes (fraction ll and above) under the 
respective conditions. 
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Figure 2. Nm23-M2 translation is downregulated upon differentiation induction. 
Lfll cells were induced to differentiation. A, cells were harvested at times indicated and derived protein 
samples were analysed for nm23-iYf2 expression on Western blots. Expression of Actin served as a 
loading control. In erythroid cells, the anti-nm23-M2 antibodies we used recognise two proteins with 
almost similar electrophoretic mobility. Nm23-M2 is the faster migrating protein. B, Polysome-bound 
mRNA was isolated at various time points after differentiation induction. RNA isolated from 20 
distinct fractions of a sucrose gradient was tested for nm23-M2. Nm23-M2 message in proliferating 
cells is present in the polysome-bound and unbound RNA fractions. After 6 hours a slight shift of 
nm23-M2 to polysome bound mRNA is present. Twenty hours after differentiation induction the signal 
starts to move to the non-polysome bound fraction. After 48 hours the differentiating cultures have 
become stationary and the nm23-M2 signal is present in the subpolysomal fractions. 
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Cytokine regulated polysome binding ofnm23-M2 mRNA is PI3K dependent 
The signalling routes that may be involved in growth factor stimulated translational 
control are the MEK/ERK pathway resulting in activation of p90RSK and MNK-1,-2, 
and the Pl3K/PKB pathway activating mTOR and S6kinase [33], To test whether 
these pathways are involved in growth factor induced polysome association ofnm23-
M2 mRNA, we factor-depleted and subsequently SCF-stimulated 1/llcells in absence 
and presence of the PBK-inhibitor LY294002, the mTOR inhibitor rapamycin and the 
MEKl inhibitor PD98059. In presence of the PBK inhibitor L Y294002 polysome 
association of nm23-M2 mRNA was completely abrogated, whereas in the presence 
of the MEK inhibitor PD98059 the distribution of the nm23-M2 transcripts was 
identical to the untreated SCF-control samples (Figure 3). Rapamycin only weakly 
reduced polysome association ofnm23-M2 rnRNA following SCF treatment. 
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Figure 3. Translation ofrun23-M2 occurs in a PBK dependent way. 
A culture of 1111 cells was factor deprived for 4 hours and subsequently stimulated with SCF (100 
ng/ml) in absence of low molecular weight inhibitors, or in combination with the PBK inhibitor 
LY294002 (15~M), MEK inhibitor PD98059 (25f!M), or the mTOR inhibitor Rapamycin (20ng/ml) for 
two hours. Separate fractions of RNA isolated from the sucrose gradient (concentration gradient 
indicated below) were tested for the presence of nm23-M2. Nm23-M2 message in the SCF stimulated 
cells is mainly present in the polysome associated fractions. Incubation with PD98059 does not have an 
effect on the polysome association of nm23-M2 mRNA. Incubation with LY294002 causes a major 
shift of the nm23-M2 signal to the subpolysomal fractions. Rapamycin has a similar, though less 
evident effect on the nm23-M2 mRNA. 
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Nrn23-M2 rnRNA starts with a Terminal Oligopyrirnidine (TOP) tract and contains a 
inverted repeat 
Translation regulation may occur through specific sequences and structures present in 
the 5'- and/or 3'-untranslated region (UTR) of the mRNA. The 5'UTR sequence of 
nm23-M2 available in the public databases did not contain any sequence known to be 
involved in translational control. We obtained 5' fragments ofnm23-M2 eDNA from 
a eDNA library by PCR. Fragments of approximately 170 bp, primed from the ATG 
in nrn23-M2 to the 5'cloning site of the vector were isolated and cloned. Three 
independent clones were sequenced, which all started at their 5' site with a pyrimidine 
stretch of 14 nucleotides respectively. Terminal Qligogyrimidine (TOP) tracts are 
structures known to be essential in the control of translation of several genes [ 41]. In 
addition, we observed a 9bp inverted repeat (indicated as a stem-structure in Figure 
4). Modelling of the 5'UTR, using the digital program RNA structure 3.6 [42], 
indicated that this inverted repeat was able to fonn a structure with a free energy of 
approximately -15.4 kcal/rnole (Figure 4). Mapping of the novel 5'cDNA sequence to 
genomic DNA revealed that the extra 90 nucleotides in the mRNA are located on a 
separate exon which precedes the second exon from which the nm23-M2 open reading 
frame starts. 
-15.4 kcaVmol~ GC 
UA 
CG 
GC 
GC i 
UCCCUCCUCUCUCCGCGCCGACCCACCGGCUUUCGGACCAUGGCCA 
Exon 1 
i M - A -
I Exon 2 
214 nt intron 
Figure 4. The 5'untranslated region ofnm23-M2 contains a TOP-tract and an inverted repeat. 
The 5'UTR of nm23-M2 was cloned by RT-PCR from a eDNA library ofl/11 cells. Three independent 
clones were sequenced. The eDNA of nm23-M2 started with a stretch of pyrimidines (underlined 
italics). The 5'UTR contains a 9 nucleotides inverted repeat, creating a potential stem-loop stmcture as 
indicated with a predicted free energy of -15.4 kcal/mole. Within the gene, the TOP and potential 
stem-loop sequence are separated from the translation start site by an intron of 214 nt (indicated by an 
aJTOW below the sequence). The start of the protein coding region is marked in bold and the encoded 
amino-acids are written below in the !-letter code. 
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SCF/Epo and PI3K dependent polysomal association of RpS4, EFJ{J2, YBI and 
nm23-M2 mRNA 
To relate the observed inhibition of translation initiation by L Y294002 to the TOP-
tract and/or the inverted repeats, we compared regulation of nm23-M2 polysome 
association with several other rnRNAs wich appeared to be upregulated as determined 
by our Atlas screen, i.e. (i) ribosomal protein S4 (rpS4) [20] and elongation factor 
lB2 (EF1~2) [20], two mRNAs with an exemplary TOP-tract but no other S'structure, 
(ii) YB 1 a mRNA which also harboured an inverted repeat in its 5 'UTR but does not 
contain a TOP-tract, (iii) FLI-1 a mRNA subject to translational regulation but via 
distinct mechanisms, and (iv) alpha-tubulin as control mRNA. The cells were treated 
as described above, subpolysomal and polysomal fractions were isolated and pooled 
into two fractions and transcribed to eDNA. Real-time PCR (Taqman, PE) was 
performed to quantitatively determine mRNA expression (Figure 5). RpS4, EFI {32, 
YBJ and nm23-M2 showed significant polysome association following Epo/SCF 
stimulation (more than 8-fold). Furthennore, nm23-M2, rpS4, EFI{J2 and YBJ showed 
very similar behaviour in that polysome association was almost completely abrogated 
by L Y294002 and largely reduced by rapamycin. In contrast, Epo/SCF induced a 
minor increase in polysome association of Fli-1 or a.-tubulin (less than 2-fold) and 
the presence of L Y294002 or rapamycin hardly affected polysome association by 
these particular transcripts. Apparently, the TOP-sequence (rpS4, EF1~2 and nm23-
M2) and inve1ied repeats (YBl and nm23-M2) similarly render translation dependent 
on PI3K activity. 
Figure 5. Real Time PCR. 
A culture of Ill! cells was factor deprived for 4 hours and subsequently left unstimulated(-) or 
stimulated with Epo (5U/ml) and SCF (100 ng/ml) for two hours. Real-time PCR was perfonned on 
eDNA isolated from polysome bound and non-polysome bound RNA from these cells. For six 
translationally regulated genes the response to growth factor stimulation and to the PI3K inhibitor 
LY294002 or the mTOR inhibitor Rapamycin was measured and compared to the effect on the 
unstimulated cells. 
A. Nm23-M2 mRNA, containing a TOP-tract and an inverted repeat in the 5'UTR, showed a large 
increase of ribosome binding upon growth factor stimulation. This increase \vas almost 
completely vanished when incubated with LV. Rapamycin did inhibit this binding, but not as 
much as L Y. 
B. The TOP-containing rpS4 mRNA showed a less big increase than nm23-M2 and YB-1 upon 
growth factor stimulation. L Y and Rapamycin were both able to reduce this effect, though L Y 
had a larger impact than Rapamycin. 
C. The translation elongation factor eEF-11)2 that only holds a TOP tract shows a similar response 
to growth factor stimulation and inhibition ofPI3K and mTOR as rpS4. 
D. YB-1, containing an inverted repeat in its 5'UTR, responded in the same fashion to growth 
factor stimulation as nm23-M2, Blocking of the signalling intermediates demonstrated that there 
was no increase of polysome binding after incubation with L Y, and only a minor increase upon 
mTOR inhibition. 
E. Fli-1, that is translationally regulated through an lRES, demonstrated an increase of mRNA~ 
polysome binding when stimulated with Epo and SCF, but no clear effect of both LY and 
Rapamycin was detected. 
F. Approximately 50% of the mRNA of the control mRNA alpha-Tubulin is already bound to 
polysomes in the unstimulated cells. Stimulation with growth factors resulted in an increase of 
this fraction. No obvious inhibition resulting from the presence of L Y or Rapamycin was found. 
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Figure 5. Real Time PCR. 
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Discussion 
Expression of the putative oncogene nm23-M2 in erythroid progenitors was found to 
be controlled by the mitogenic factors Epo and SCF. Nm23-M2 gene transcription is 
constitutively high, while mRNA translation appeared strictly controlled by pathways 
dependent on PBK and mTOR. The mn23-M2 starts with an oligopyrimidine tract 
and contains an inverted repeat, structures known to invoke control of translation by 
growth factors [41, 43]. 
To stimulate cell proliferation growth factors need to activate multiple processes, 
required for cell cycle progression. To allow cell growth, regulation of translation is 
as important as transcriptional control. Growth factors enhance expression of 
translation factors like initiation- and elongation factors and ribosomal proteins [ 44, 
45]. They do so by inducing mRNA specific translation rather than gene transcription, 
which ensures a very rapid response. Many translation factors are encoded by mRNAs 
containing a TOP-sequence [41], which causes inhibition of translation in absence of 
growth factors and nutrients and enhances translation in presence of growth factors. It 
is crucial that the very first nucleotide following the cap structure is a pyrimidine and 
a stretch of 5 pyrimidines is sufficient to execute its function (41]. A TOP-sequence 
generally contains a similar proportion of C and U residues. Furthennore, a TOP-tract 
is followed by a GC-rich sequence and no upstream AUGs should be present. The 
nm2 3-M2 TOP-sequence consisting of 5 U and 9 C residues meets these 
requirements. The mechanism by which a TOP-sequence inhibits translation is not 
known. Overexpression of the cap-binding protein eiF4E in general overcomes the 
requirement for growth factors to translate TOP-mRNAs, which suggested that 
activation of e!F4E by phosphorylation and/or release of e!F4E from 4E-BPs may be 
required. However, a recent report suggests the existence of a factor that actively 
inhibits translation by binding to TOP-sequences [46]. 
Other structural motives present in UTRs may also be critical regulators of growth 
factor-dependent translational control of gene-expression. Nm23-M2 contains an 
inverted repeat able to form a stem-loop structure. However, the free energy of this 
stmcture (-15.4 kcalimole energy as calculated by RNA structure 3.6 [42]) is too 
small to impair scanning by the initiation complex and can easily be resolved by 
eiF4A. The stmcture may, however, be stabilised by an interaction with RNA-binding 
proteins. The stem-loop structure in ferritine, the iron response element, is stabilised 
by a protein whose association is controlled by iron binding [43]. Similarly, the 
potential stem-loop structure in nm2 3-M2 may be stabilised by a protein whose 
association is dependent on its phosphorylation status. On the basis of the presented 
data it can not be decided whether both the TOP-sequence and the inverted repeat 
contribute to translation control. Comparison with known TOP-mRNAs that contain 
no other regulatory domains show that growth factor-dependence of nm23-M2 mRNA 
translation is even more strict than that of ribosomal protein S4 and elongation factor-
} f3. This suggests that both potential control mechanisms in the nm23-M2 5 'UTR may 
contribute to its translational controL 
PI3K controls nm23-M2 mRNA polysome association 
Translation of most TOP-mRNAs, is under the control of S6kinase. Activation of 
S6kinase occurs through phosphorylation by mTOR and PI3K-dependent pathways, 
which target separate domains of S6kinase. The translation of nm23-M2 is fully 
repressed upon inhibition of PI3K. Inhibition of mTOR by rapamycin appears less 
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complete. However, translation of EF1]3 and S4 is also less efficiently repressed by 
rapamycin. Therefore, the effectiveness of L Y294002 compared to rapamycin may be 
specific for the erythroid progenitors and the conditions used, rather than for the 
nm23-M2 mRNA. In erythroid progenitors, the cooperation of Epo and SCF induces 
renewal divisions and delays differentiation [47]. Inhibition of PBK abrogates 
renewal and induces differentiation [6], while inhibition of the MEK/ERK pathway 
does not affect the balance between expansion and differentiation. This indicates that 
PBK-targets like nm23-M2 may be involved in renewal induction. Enhanced activity 
of PBK and its downstream targets is also cmcial in tumours induced by v-p3k, the 
oncogene present in avian sarcoma virus 16 (ASV16) [48] and in Friend spleen focus-
fanning virus induced erythroleukemia [49]. We showed that nm23-M2 mRNA 
translation is controlled by Epo/SCF-induced PI3K-activity in erythroid progenitors, 
but we do not know whether the same mechanisms are used to control mRNA 
translation during differentiation. 
The nm23 jilmily and malignant transfOrmation 
Enhanced expression of the nm23 family of genes has been detected in a variety of 
malignancies [50-54] and frequently correlated with a poor differentiation stage of 
certain tumours [50]. Some studies examined nm23 mRNA levels, others investigated 
protein levels but seldom the relation between mRNA and protein levels was studied. 
Therefore, it is not clear whether abberrant control of nm23-M2 mRNA translation is 
involved in enhanced protein expression in malignancy. Most likely transcriptional as 
well as translational control mechanisms regulate nm23-M2 expression. In the 
retrovirally induced mouse leukemias the large majority of the integrations occur in, 
or just upstream of the 5 'UTR. The retroviral L TR may act as a promoter enhancer 
element. However, in the leukemias tested, virus integration often resulted in a fusion 
transcript in which the translational control elements of nm23-M2 (TOP-sequence and 
repeat) are replaced with viral sequences that ensure rapid scanning of the translation 
initiation complex (data not shown). As a result, the viral integrations may render 
nm23-M2 expression independent of growth factor availibility. Unfortunately, it 
appeared impossible to isolate polysome-associated mRNA from primary leukemias. 
Therefore the effect of virus integration on translational regulation ofnm23-M2 in the 
leukemias containing LTR-nm23-M2 fusion transcripts could not be determined. 
Moreover, the oligoclonal nature of the leukemias renders protein expression assays 
difficult to interpret. 
Oncogenesis and translational control 
Control of translation initiation via mRNA-specific mechanisms is increasingly 
recognised as a potentially important control level in lineage determination, cell 
survival, proliferation and differentiation. Overexpression of elF4E, the limiting 
factor in translation initiation, is in its own tumourigenic [55-57]. In addition, the 
expression of many potential oncogenes appears to be controlled at the level of 
translation since it allows rapid changes in protein levels. Expression of AML 1 is 
regulated through usage of alternative promoters coupled with IRES-mediated 
translation control [58]. An IRES is also present in the 5'UTR of c-Myc. In several 
bone marrow samples from patients with multiple myeloma there is aberrant 
translational regulation of c-myc and this correlates with a C-I mutation in the c-myc-
IRES (59]. FLI-1 is expressed as two protein isoforms generated by alternative 
translation initiation from two highly conserved in-frame initiation codons [60]. 
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Overexpression of the proto-oncogene Fli-1 is associated with multiple virally 
induced leukemias in mouse, and the human counterpart is translocated in Ewing 
tumours [ 61]. 
Several mechanisms for retrovirally induced malignant transformation have so far 
been identified, ranging from activation of transcription to mRNA stabilisation or 
gene inactivation. Data presented in this paper suggest that an important mechanism 
may so far have been underestimated: the replacement of untranslated sequences in 
the mRNA encoding a potential oncogene, such that translation is no longer 
controlled by e.g. growth factors. 
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Abstract 
Objective. The gene encoding the peripheral cannabinoid receptor, Cb2 is located in 
the common virus integration site Evil] and is associated with hematopoietic 
malignancies in mice. To determine the effect of Cb2 overexpression on 
hematopoietic development in vivo, Cb2 transgenic mice were generated. 
Materials and Methods. A Cb2 expression vector was constructed containing a Cb2 
eDNA fragment cloned into the 14kb Sea-l (Ly-6£.1) gene. Two transgenic lines in 
which Cb2 expression is controlled by the Sea-l promoter, were generated and the 
effect on hematopoietic development was studied. The expression of Cb2 rnRNA or 
protein was studied by means of RNase protection analysis and ligand binding assays, 
respectively. Leukemic predisposition was investigated by injecting newborn 
transgenic as well as control animals with a retrovirus, i.e. Cas-Br-M Murine 
Leukemia Virus (Cas-Br-M MuL V). 
Results. Although increased expression of the Cb2 gene was observed in 
hematopoietic tissues, a follow-up of more than one year did not reveal any 
hematological defect. Interestingly, infection of newborn pSca-l/Cb2 transgenic mice 
with Cas-Br-M MuL V revealed that significantly more transgenic mice developed 
leukemia than virus treated control littennates. Since these studies provide evidence 
for the cooperative potential of Cb2 in leukemia progression, we wished to identify 
genes that may collaborate with Cb2 in leukemic transfonnation. Our study suggests 
that Evil, another common target for proviral integration in mouse leukemias may be 
overexpressed in virus-induced leukemias inpSca-J!Cb2 transgenic mice. 
Conclusions. These data indicate that hematopoietic precursor cells that express high 
levels of Cb2 possess increased susceptibility for leukemia development and that Cb2 
and Evil might collaborate in leukemogenesis. 
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Introduction 
Cb2, the gene encoding the peripheral cannabinoid receptor has been shown to be a 
frequent target for proviral integration in retrovirally induced leukemias [1, 2]. In 
mice, the protein-coding region of Cb2 is located on a single ex on of approximately 4 
kb (exon-2). Two non-protein coding first exons have been identified, i.e. exons-lA 
or 1B, previously designated exon-1 and exon-1 \ respectively [1]. In cells expressing 
exon-IA/exon-2 mRNA, e.g. in thymocytes or in the majority of myeloid cell lines, 
no or only low levels of the peripheral cannabinoid receptors are detectable [3]. In 
contrast, in spleen cells expressing both transcripts high receptor numbers are present, 
suggesting that protein expression is the result of translation from the exon-1B/exon-2 
Cb2 mRNA transcript. Interestingly, retroviral insertion in Cb2 in mouse leukemia 
may cause expression of exon-lB/exon-2 transcripts and consequently lead to high 
receptor numbers [3]. These results indicate that Cb2 receptor overexpression may be 
a critical step in tumour progression in retrovirally-induced leukemias. 
I o study the effect of Cb2 overexpression on hematopoiesis in vivo and investigate its 
role in hematopoietic malignancies, Cb2 transgenic mice were generated in a FVB/n 
background. A construct was made with the Cb2 gene, i.e. exon-lB/exon-2 under the 
control of the Sea-l (Ly-6E.l) promoter [4]. Genes controlled by regulatory elements 
of the Sea-l gene will be expressed in primitive hematopoietic cells, as has previously 
been shown for LacZ [5] as well as for Evil [6]. 
Retroviral insertions in Cb2 occur in mice that develop leukemia with a long latency, 
after Cas-Br-M Murine Leukemia Virus (Cas-Br-M MuLV) infection, suggesting that 
a Cb2 defect is one of a series of mutations, leading to full transfonnation. To study 
the transforming potential of Cb2 and investigate whether aberrant expression in 
marrow precursor cells may be part of the multigenetic process of leukemia 
progression, pSca-1 /Cb2 transgenic mice were treated with retrovirus in analogy with 
other transgenic mouse models [7, 8]. Transgenic mice as well as FVB/n background 
control animals were inoculated with Cas-Br-M MuL V. This combination was chosen 
since Cas-Br-M MuLV, which is a N-tropic retrovirus, only rarely causes 
development of leukemias in non-susceptible FVB/n control mice [9]. On the other 
hand, we recently reported that transgenic animals. e.g. Evil transgenics, are 
susceptible for leukemia induction using this virus [6]. Thus, inoculating Cas-Br-M 
MuL V into FVB/n mice may particularly result in the development of leukemia in 
case other defects have been introduced. Our data demonstrate enhanced 
susceptibility to Cas-Br-M MuLV-induced tumour formation of pSca-J/Cb2 
transgenic mice as compared to retrovirus-treated control littennates as well as non-
treated Cb2-transgenics. To investigate in those leukemias whether Cb2 would 
cooperate with other established transforming genes, we studied the abnormal 
expression of Evil, another common VIS targeted by Cas-Br-M MuLV in mouse 
leukemias. The data presented suggest cooperation between Cb2 and Evil in leukemia 
progression. 
103 
Materials and Methods 
Generation and propagation of pSca-l/Cb2-transgenic mice 
A Cb2 expression vector was constructed containing Cb2 exon-lB/exon-2 eDNA 
under the control of regulatory elements of the murine Sea-l (Ly6E.l) gene (Figure!). 
The EcoRI!BamHI eDNA fragment encompassing the complete coding region was 
isolated and filled in with the Klenow fragment of DNA polymerase I. The resulting 
fragment was cloned into the Clai site ofpL6Cla (a gift from Dr. E. Dzierzak, Dept of 
Cell Biology and Genetics, Erasmus University, Rotterdam, The Netherlands) to yield 
pSca-l/Cb2. The plasmid pL6Clal contains the full-length 14-kb Sea-l (Ly-6E.l) 
gene [5]. The proper orientation of the Cb2 eDNA insert was verified by restriction 
enzyme analysis. Transgenic mice were engineered according to standard techniques 
[10]. Briefly, a linearised DNA fragment of 15.5 kb in length was derived by Not! 
digestion of pSca-1/Cb2 (see above) and purified by means of 0.8 % agarose gel 
electrophoresis and electro-elution. This DNA fragment was microinjected into the 
most accessible pronucleus of (FVBxFVB) fertilised mouse eggs. These eggs were re-
implanted into pseudo-pregnant BCBA female foster mice. Transgenic mice were 
identified by Southern blot analysis of tail-derived DNA according to standard 
procedures [II]. In short, DNA was isolated, digested with Bglll, electrophoresed in a 
0.6% agarose gel and transferred to Hybond-N- nylon membranes (Amersham 
Phannacia Biotech Benelux, Roosendaal, The Netherlands) with 0.25 M NaOH/1.5 M 
NaCL Membranes were hybridised with a random-primed 32P-labelled 1.2-kb Cb2 
eDNA probe [1]. Transgenic founder mice were bred with nonnal FVB mice to 
establish transgenic lines. All mice were maintained under standard conditions and 
treated according to institutional animal health care and use guidelines. 
RNase protection analysis 
Total cellular RNA was prepared from spleen and thymus by homogenising tissue 
cells in 4M guanidium thiocyanate, followed by phenol-chlorofonn extraction and 
isopropanol precipitation [11]. The RNA samples were subjected to an RNase 
protection assay, essentially as described by the supplier (Promega, Leiden, The 
Netherlands). For this purpose a 249 bp Cb2 eDNA fragment (See Figure I) was 
cloned into a pBluescript II SK + vector and linearised by using Hindiii. To study 
Evil mRNA expression a 350 bp antisense riboprobe was used as described 
previously [6]. For comparison of the signals a radiolabelled GAPDH riboprobe was 
synthesised [12]. RNA probes were synthesised using T3 or T7 polymerase. For each 
incubation, 10 [lg mRNA was suspended with radiolabelled RNA probe (15.000 cpm) 
in 30[!1 of hybridisation buffer. The samples were heated to 85 °C for 5 minutes and 
after hybridisation of overnight at 50°C digested with RNase One (Promega, Leiden, 
The Netherlands) and electrophoresed in a 6% polyacrylamide-8 M urea sequencing 
gel. After running, the gels were dried and exposed for autoradiography with a 
KODAK film and an intensifying screen. 
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Figure 1. Generation of pSca-1 /Cb2 transgenic mice. 
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A. Schematic representation of the 14 kb Sea-l transgenic construct. A 1.2 kb Cb2 eDNA was 
cloned into the genomic construct giving pSca-I/Cb2 (See Materials and Methods). 
Abbreviations used: Bg, Bg!II; E, EcoRl; [C], Clai lost upon subc\oning. Locations of probes B 
and C are indicated. 
B. Southern blot analysis of Bg!II-digested tail DNA frompSca-l!Ch2 transgenic lines #3 and 19 
and non-transgenic FVB control animals. Blots were hybridised with a exon-18/exon-2 total 
eDNA probe C. 
C. RNase protection using probe B (See Figure lA and 4A) on 10 f.lg total mRNA from spleen (S) 
or thymus (Th) isolated from pSca-J/Cb2 transgenic (line# 3) and control FVB mouse. 
D. Expression of Cb2 ligand binding sites using [3H]-CP55,940 on spleen cells isolated from two 
pSca-J/Cb2 transgenic mice and one FVB control mouse. 
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lV!embrane preparation and f H}-CP55, 940 binding assays 
Frozen cell and tissue pellets were kept at -80°C lll1til use. For binding assays, pellets 
were tl1awed and suspended in assay buffer (50 mM Tris-HCI pH 7.0, I mM EDTA, 3 
mM MgCl2, containing 0.1% BSA (Serva, Heidelberg, Germany). Membrane 
suspensions were homogenised and centrifuged at lO,OOOxgav for 10 min (4°C). Pellets 
were then resuspended in 5 ml in assay buffer and homogenised using a Potter-
Elvejhem homogeniser. Suspensions were finally resuspended in assay buffer at a final 
membrane concentration equivalent to 106 cells/rnl. 
For binding experiments 160 ).ll membrane suspension (1 06 cells/ml) was incubated in 
96-well plates (flat bottom plates, Greiner, Frickenhausen, Gennany) with 20 ~1 ['H]-
CP55,940 (165~Cilnmol) (DuPont-New England) in a saturable concentration of 1 nM 
and 20 ).ll assay buffer for total binding or assay buffer containing 1o-6M non-labelled 
CP 55,940 to assess non-specific binding. Mixtures (200 ).ll final volume) were 
incubated at 30°C for 50 min after which suspensions were filtrated over Unifilter GF/B 
plates using a Filtennate-196 Harvester (Packard, Meriden, CT, USA) and washed 
twice for 5 sec with 200 ~Ll ice-cold washing buffer (50 mM Tris-HCl pH 7.0, 
containing 0.25% BSA). Subsequently, filtration plates were sealed at the bottom, after 
which 25 )11 scintillation fluid (Microscint-0; Packard) was added per well, 
radioactivity was cotmted in a TopCount scintillation counter (Canberra Packard 
Central Europe GmbH, Schwadorf, Austria) and the Bspecific was detennined. 
In vitro colonyfOnnation 
Bone marrow cells were harvested by crunching femurs and tibia of Cb2 transgenics 
and non-transgenic FVB control mice. Single cell suspensions were washed twice in 
HBSS (HANKS'; GIBCO Life Technologies Inc., Gent, Belgium) and resuspended in 
a-minimum essential medium (_ -MEM; GIBCO Life Technologies Inc., Gent, 
Belgium). Percoll fractionated bone marrow cells [13] were plated at 1 x 104 cells/ml 
in 35-mm dishes (Falcon® 3001; Becton Dickinson, Plymouth, England) in 
methylcellulose media (Methocult GF M3434; Stem Cell Technology, Vancouver, 
BC, Canada) supplemented by 15% FCS (GIBCO Life Technologies Inc., Gent, 
Belgium), 2 mM L-glutamine, with G-CSF (lOU/ml), !L3 (lOU/ml), Epo+SCF 
(3U/ml, 100ng/ml resp), or without additional growth factors. For erythroid colony 
development 10-4 mol!l hemin was added to the cultures. Dishes were incubated at 
37°C in 5% C02• Assays were perfonned in triplicate. Colonies were counted at day 7 
(G-CSF-derived colonies), and day 14 (BFU-E-derived and IL3-derived colonies) 
using an inverted microscope. 
Peripheral blood cell counts and bone marrow analysis 
Peripheral blood (PB) was collected in EDTA-coated micro-tubes (SARSTEDT, 
Etten-leur, The Netherlands) by heart or tail puncture. Peripheral blood counts and 
hematological parameters were detennined using an automated blood cell counter 
(Cobas, ABX La France, Montpellier, France). Differential counts of peripheral blood 
and bone marrow cells were performed microscopically on May-Grunwald-Giemsa 
stained smears and cytospins, respectively. Numbers of neutrophils, lymphocytes and 
platelets are expressed as 109 cells/1 whereas the number of erythrocytes is indicated as 
10 12cells/ I. 
Tumour induction and DNA analysis 
For tumour induction Cas-Br-M MuLV was used to infect 19 Cb2 transgenic mice 
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and 39 non-transgenic littermates. Cas-Br-M MuLV producing NIH 3T3 cells (a gift 
from Dr. J. Hartley, National Institutes of Health, Bethesda, MD, USA) were cultured 
in Dulbecco's modified Eagle's medium (DMEM; GIBCO Life Technologies Inc., 
Gent, Belgium) containing 10% Fetal Calf Serum (FCS). A subconfluent culture of 
Cas-Br-M MuLV-producing NIH 3T3 cells was incubated in 5 ml of culture medium 
for 18 hours at 37°C, in a 75 cm2 culture flask. Newborn mice were injected 
subcutaneously with 100 _l filtered (pore size, 0.22 _m; Nucleopore Corp., 
Pleasanton, CA, USA) tissue culture medium. Mice were sacrificed when moribund. 
Tumour tissues, i.e. bone marrow, spleen and thymus were isolated and cryopreserved 
and stored in liquid nitrogen. For Southern blot analysis tumour spleen DNA was 
digested with BamHI and analysed as described above. A 570 nt Evil specific eDNA 
fragment [14] was used as a probe for hybridisation. 
Immunological staining and.flowcytometric analysis 
Single-cell suspensions of nonnal bone marrow cells and spleen tumour cells were 
analyzed by flow cytometry using a F ACScan flow cytometer (Becton Dickinson and 
Co, Mountain View, CA, USA). Tumour cells were analysed by single staining using 
rat monoclonal antibodies. The following antibodies were used: ER-MP58 (anti-ER-
MP58); Ml/70 (anti-Mac-!) (CDllb); F4/80 (anti-F4/80); 59-AD2.2 (anti-
Thyl)(CD90); KT-3 (CD3); El3161-7 (anti-Sea-l); or MEC14.7 (CD34) [15]. As a 
second step reagent GaRa (Goat-anti-Rat)-FITC (Nordic, Tilburg, The Netherlands) 
was used. Immunophenotyping of percoll separated nom1al bone marrow cells from 
transgenic mice and control littennates was perfonned by flowcytometric analysis 
using double-staining. FITC-conjugated E13161-7 (anti-Sea-l, ED Phanningen, San 
Diego, CA, USA), was combined with PE-conjugated MEC14.7 (CD34, Beckman 
Coulter, Fullerton, CA, USA), 2B8 (anti-c-Kit, Beckman Coulter), 59-AD2.2 (anti-
Thy!, BD Phanningen)(CD90), or Ml/70 (anti-Mac-1, Beckman Coulter)(CDllb). 
Labelling with FITC-conjugated RB68C5 (anti-Grl, ED Pharmingen) was carried out 
in combination with PE-conjugated El3161-7 (anti-Sea-l, BD Phanningen). 
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Results 
Generation of pSca-1 !Cb2 transgenic mice and analysis of transgene expression 
To study the effect of Cb2 over-expression in primitive hematopoietic cells in vivo, 
transgenic animals were generated. Exonl-B/exon-2 Cb2 eDNA was cloned into the 
14 kb genomic DNA fragment containing the Sea-l promoter (Ly-6E.l) (Figure !A). 
The complete construct was injected into pronuclei of fertilised oocytes. By Southern 
blot analysis two transgenic founder animals carrying the Cb2 exon-lB/exon-2 gene 
(lines #3 and #19) were obtained (Figure !B). RNase protection using the Cb2 eDNA 
probe B (Figure lA) revealed excess of Cb2 splice-variant exon-IB/exon-2 mRNA in 
spleen and thymus as compared to control FVB animals (Figure !C). Using ['H]-
CP55,940 the presence of the cannabinoid receptors in spleen was studied (Figure 
!D). Ligand-binding to spleen cells from pSca-l!Cb2 transgenic mice of both lines 
was higher than to spleen cells from control FVB/n mice. 
Analysis of blood and bone marrow cells 
To study the effect of Cb2 receptor overexpression on hematopoiesis we carried out 
standard blood cell analysis as well as bone marrow, spleen and thymus histology. 
Those analyses did not reveal any abnonnality in transgenic animals (data not shown). 
No differences between respectively pSca-J/Cb2 transgenic animals (n=10) and 
control mice (n~lO) were observed in platelet (1228 ± 257 versus 1329 ± 153), 
neutrophil (1.4 ± 0.8 versus 1.9 ± 1.1), lymphocyte counts (9.7 ± 3.4 versus 9.4 ± 2.1), 
expressed as 109cells/Liter or erythrocyte counts (10.8 ± 3.3 versus 11.4 ± 1.9), 
expressed as 10 12 /liter. The values are given as mean± standard deviation. 
To investigate the characteristics of blood progenitor cells ofpSca-l/Cb2 transgenic 
mice more specifically, percoll separated bone marrow cells from two transgenics and 
two control mice were analysed by flow cytometry. Cells were labelled with anti-Sea-
l (£13161-7) in combination with different membrane markers, i.e. anti-CD34 
(MEC14.7), anti-c-kit (2B8), anti-Thy! (59-AD2.2), anti-Macl (Ml/70), anti-Grl 
(RB68C5). The representative experiment shown in Figure 2 demonstrates that no 
differences were observed between the phenotype of transgenics and control litter 
mates in the distribution of these surface markers. 
To investigate whether the expression of the Cb2 trans gene in hematopoietic 
precursor cells had affected the behaviour of immature colony forming cells, colony 
culture were carried out. No clear differences were observed between transgenic mice 
and nonnal control mice in the numbers of IL3 stimulated colonies, G-CSF induced 
granulocytic colonies or EPO/SCF induced BFUe (Table 1). 
Table 1. In vitro colony formation of bone marrow precursors cells. 
Stimulus pScaJCb2 FVB/n 
Nofactor(n-5) 0 0 
IL3(n-ll) 30 + 8 36 + 17 
G-CSF (n- 5) 34 + 15 67 + 21 
Epo/SCF (n- 9) 109•44 97 + 37 
Numbers represent mean colony numbers± SD per 104 percol\-separated bone marrow cells. 
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Figure 2. Immunological analysis of transgenic and control bone marrow cells. 
Percoll separated bone marrow cells were double labelled using the indicated membrane markers and 
analysed by flow cytometry. 
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Increased tumour incidence by Cas-Br-M lvfuLV in pSca-I/Cb2 transgenic mice 
To further investigate the role of Cb2 in leukemogenesis and study its potency as a 
collaborating proto-oncogene in tumour progression, newbom transgenic mice and 
non-transgenic littermates were infected with Cas-Br-M MuLV. Animals were 
monitored for tumour development. Twenty-two months after retroviral infection 11 
of 19 (58%) pSca-l/Cb2 transgenic mice developed hematological malignancies, 
whereas leukemias were observed in only 4 out of 39 (10%) virus-infected control 
animals (Figure 3). Autopsy of moribund animals revealed an enlarged spleen (5-10-
fold enlargement; [6]) in almost all of the cases (Table 2). In one case (CFL 7) a 
thymoma was observed. In cases with a splenomegaly, morphological analysis 
demonstrated high blast percentages in five cases and accumulation of granulocytic 
cells at all stages of differentiation in the other five. Morphologic analysis of bone 
marrow cells showed accumulation of blasts or granulocytic cells as well (Table 2). 
Immunological analysis of the leukemic spleen cells demonstrated the presence of 
primitive membrane n1arkcrs (Sea-l; CD34 and/or ER-MP58) in all cases examined 
(Table 2). In 6 cases monocytic markers were observed and in 3 positivity for 
granulocytic markers (Grl and Mac-1 positivity, but negative for F4/80) was present. 
In one case (CFL 7) the T -cell markers Thyl and CD3 were present. The 
hematopoietic profile as determined by blood smears revealed that most mice were 
severely anemic. Furthermore, in the majority of cases there was a strong reduction in 
white blood cell counts (Table 2). 
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Cas-Br-M MuL V infected pSca-l!Cb2 (n= 19) and FVB (n=39) as \vel! as non-infected pSca-1 !Cb2 
(n=20) and FVB (n=20) were monitored for tumour development. The graph indicates the percentage 
of mice remaining tumour-free (vertical axis) at the indicated ages (horizontal axis). 
Overexpression of Cb2 and the Evil proto-oncogene in pSca-I/Cb2 transgenic 
leukemias 
To investigate whether leukemic organs in transgenic animals expressed high Cb2 
mRNA levels, an RNase protection analysis was performed using probe B, 
representing exon lB + 2. As expected leukemic cells ofpSca-l/Cb2 transgenic mice 
demonstrated high Cb2 mRNA expression (Figure 4A). 
llO 
Leukemic transfonnation is a multistep process involving activation of multiple proto-
oncogenes and/or inactivation of tumour suppressor genes. One of the most 
commonly found retroviral insertions in Cas-Br-M MuLV-induced leukemias is Evil. 
Moreover, in NFS78, a leukemia expressing high Cb2 protein levels as the result of 
retroviral insertion in the gene, Evil mRNA and protein overexpression has been 
demonstrated. RNase protection revealed high Evil mRNA levels in spleen cells from 
6 out of 8 pScal/Cb2 derived leukemias studied (Figure 4B). Southern blot analysis 
using an Evil specific probe [14], on Ssti-digested genomic DNA was carried out on 
5 of those cases (Figure 4C). This analysis demonstrated rearrangements as the result 
of proviral insertion in the Evil-locus in 2 of those cases. These data suggest that 
aberrantly expressed Cb2 cooperates with elevated levels of Evi I in the 
transformation of myeloid precursor cells. 
Table 2. Characterisation of the leukemic pSca I !Cb2 transgenic mice. 
Tumour ' Gross Blood counts Blast Eercentage Immunologv 
pathology2 White3 Red4 Ylarro·w SEleen Mono5 Gran6 T' 
CFL7 T ND ND ND ND + 
CFL\3 s ND ND ND ND 
CFL14 s 3.3 7.8 ND ND 
CFL?3 s ND ND 18* ,, ND ND ND 
CFLJ5 s 2.7 !.I 77 53 ND ND ;-;o 
CFL28 s 7.3 5.5 ND ND + 
CFL29 s 0.6 2.4 87 77 
CFL32 s 3.4 5.2 ND 4* + 
CFL34 s NO ND 16* 0* + + 
CFL37 s 41 11.3 2* 23 NO NO ND 
CFL44 s 4?.6 3.4 46 12 
1The tumors are designated CFL (.(;as-Br-MuLV; EVB background; 1eukemia). 
2The majority of the mice presented with a splenomegaly (S). One mouse had a thymoma (T). 
3White blood cell counts represent numbers X l 09 per liter. 
4Red blood cell counts represent numbers X 1012 per liter. 
5Monocytic marker positivity (Mono), i.e. M 1/70 (Mac 1) or/and F4/80. 
p,-eM 
+ 
ND 
ND 
+ 
NO 
"Granulocytic marker positivity (Gran), i.e. RB68C5 (Grl) and Ml/70 (Mac-1), without positivity for 
F4/80. 
7T-lymphocytic marker positivity (T), i.e. KT-3 (CD3) and 59-AD2.2(Thyl) 
8Precursor marker positivity (Pre), i.e. ER-MP58, E13 161-7 (Scal)or MEC 14.7 (anti-CD34). 
*In the cases with low blast percentages differential counts revealed the presence of 
myelo/granulocytic cells from all stages of differentiation. 
A sample was considered positive for a particular marker when 30% of the cells or more showed 
positive fluorescence [ 15]. 
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Figure 4. Evil mRNA expression in leukemic spleen and marrow isolated from Cas-Br-M MuL V 
treated pSca-J/Cb2transgenic and FVB mice. 
A. RNase protection using probe B on 10 !J.g total mRNA isolated from leukemic spleens. The 
protected Cb2 bands are indicated. NFS 78 mRNA has been taken along as a positive control 
and GAPDH was used as an internal control 
B. RNase protection using an Evil specific RNA probe [6] on 10 !J.g mRNA isolated from 
leukemic spleens or bone marrow*. The protected Evil bands are shown. NFS 78 mRNA has 
been taken along as a positive control and GAPDH was used as an internal controL Evil 
mRNA expression levels were quantified relative to the GAPDH levels, using Gene Tools 
(version 2.10.03 ©1998 Synoptics Ltd, Cambridge, UK). 
C. Southern blot analysis has been carried out to investigate the presence of a retroviral insertion 
into the Evil locus (See Materials and Methods). Southern blot analysis demonstrated the 
presence of a proviral insertion in the Evil locus (arrows). Evil rearrangements (Evi vis) have 
also been indicated in figure 3B (+/-). ND =not done. 
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Discussion 
Previously, Cb2 has been identified as a target for retroviral insertion and it may 
therefore be a proto-oncogene involved in the development of certain mouse 
leukemias. Cb2 retroviral integrations were found in the myeloid cell lines NFS 78 
and NFS107, and in a large panel of primary leukemias that were generated by 
injecting newborn NIH-Swiss mice with Cas-Br-M MuLV [1]. Phenotyping of the 
tumours revealed that virus integrations in Cb2 may occur in myeloid as well as in T-
lymphoid leukemias [ 15]. To study the effect of enforced expression of Cb2 in 
primitive hematopoietic cells transgenic mice were generated using a Sea-l (Ly-6£.1) 
promoter construct. The Sea-l protein is a membrane surface marker expressed on 
hematopoietic precursors as well as on a subset of T -lymphocytes [ 16-18]. pSca-
1/LacZ transgenic mice have previously been generated to study primitive 
hematopoiesis [5]. Recently, we successfully expressed the Evil proto-oncogene in 
the hematopoietic system using the Sea-l promoter construct [ 6]. In this report we 
demonstrate that expression of Cb2 mRNA (RNase protection) and protein (ligand 
binding assay) is high in spleens ofpSca-l!Cb2 transgenic animals. 
Although examples exist, showing that a single defect may result in a severe 
hematological abnonnality [19-21], other transgenic models reveal that additional 
genetic lesions may be required for progression towards leukemia or lymphoma [22-
24]. During follow-up of more than one year Cb2 transgenic mice did not develop 
leukemia or another apparent hematological defect. The lack of significant 
hematological effects caused by Cb2, as determined by hematological and 
immunological analysis and in vitro colony cultures (Figure 2 and Table 1), may be 
due to the choice of the Sea-l promoter, which functions in a small population of 
primitive hematological precursors [5]. In addition, it is possible that enforced 
expression of Cb2 alone is not sufficient to cause hematological defects. Previous 
studies have demonstrated that Cb2 is a frequent target of retroviral insertion. 
Leukemias with Cb2 abnonnalities arise with long latency, suggesting that multiple 
'hits' in time are required for full transfonnation of hematopoietic precursors [15]. In 
order to investigate the role of Cb2 as a collaborating oncogene, Cb2 transgenics were 
infected with Cas-Br-M MuLV. Significantly more pSca-l/Cb2 mice developed 
leukemia than non-transgenic control mice indicating that Cb2 transgenic mice indeed 
carry a higher susceptibility for Cas-Br-M Mul V -induced tumour formation. 
Detennination of the phenotype of these leukemias revealed a large variation present 
between the distinct tumours. Since in the FVB control population only 4 mice 
developed leukemia, a comparison between phenotypes in this setting is not reliable. 
However, primary leukemias that were generated previously by infecting newborn 
NIH-Swiss mice with Cas-Br-M MuLV demonstrated a similar spectrum of 
phenotypes [15]. 
"Vle decided to investigate which other transfonning genes may collaborate with Cb2 
in leukemic transformation. Overexpression of the peripheral cannabinoid receptor as 
the resutt of virus inse1iion in Cb2 has been demonstrated in the myeloid precursor 
cell line NFS 78 ([l, 3]. Interestingly, in this cell line the Evil gene is also highly 
transcribed as the result of proviral integration [25] (Figure 4). RNase protection 
using RNA from leukemias derived frompSca-J/Cb2 transgenics revealed high Evil 
mRNA levels in 6 out of 8 cases studied. In 2 out of 5 Evil mRNA expressing 
leukemias a virus insertion was observed by means of Southern blot analysis. In three 
cases high Evil mRNA levels were found whereas no retroviral insertion in the Evil 
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locus was observed. It is possible that in these leukemias retroviral insertion took 
place in the Fim-3 locus, which is located approximately 90 kb upstream of Evil[26]. 
In the murine leukemic cell lines DA3 and DA34 virus integrations in the Fim-3 
region result in over-expression of Evil [26]. On the other hand, it is also possible 
that Evi 1 is overexpressed by other mechanisms. Interestingly, preliminary results 
obtained from real-time RT-PCR studies in human AML, demonstrate that EVIl is 
expressed in at least 5% of de novo AML cases without a 3q26 abnommlity [27]. No 
matter the mechanism, the observed association of increased Cb2 and Evil gene 
expression may be suggestive for a cooperative action between these two genes in 
leukemic transformation. Breeding of Cb2 transgenic animals with Evil-mutant mice 
possibly followed by retroviral infection should provide further documentation of the 
cooperative action of these two genes in leukemia progression. 
Primary leukemias containing an integration in Cb2 displayed a myeloid or a T-
lymphoid phenotype [15]. In contrast, the leukemias from the pSca-J!Cb2 mice 
mainly exhibit a myeloid phenotype. It is unlikely that the Sea- 1 promoter construct 
employed for ectopic expression of Cb2 selects for myeloid malignancies rather than 
for a T -lymphoid disease. The discrepancies could be the result of the genetic 
differences of the mouse strains used in these different studies. Animals with NIH-
Swiss background were previously injected with Cas-Br-M MuLV for the 
identification of novel virus integration sites in leukemia [15], whereas FVB mice 
were used in the study presented here. 
It is currently unclear by which mechanism Cb2 may be involved in leukemic 
transformation. Cb2 encodes a G0.i-coupled peripheral cannabinoid receptor. This 
receptor, like other G,ti-coupled seven transmembrane receptors, may be involved in 
chemoattraction. Myeloid precursor cells overexpressing Cb2 migrate in a trans-well 
assay, when stimulated v;rith the endogenous ligand 2-arachidonoylglycerol (2-AG) 
[3]. Altered migration in vivo as the result of stimulation of the Cb2 receptor may 
cause differences in homing of the cells. Changes in homing of myeloid precursors 
may result in altered regulation of growth and development. Infection of nonnal bone 
marrow precursors with Cb2/EGFP using retroviral vectors may be carried out to 
study the effects of peripheral cannabinoid receptor expression on homing of myeloid 
precursors in vivo. The Cb2 specific antagonist SR144528, when included in these 
experiments, should interfere with altered homing of myeloid precursors in vivo. The 
availability of the Cb2 specific antagonists may also be used to investigate whether 
blocking of the Cb2 receptor on leukemia ce11s, interferes with leukemic progression 
in vivo. Leukemias generated in the pSca-l!Cb2 transgenic mice presented in this 
study may be of value for these investigations. 
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& 
Samenvatting en Discussie (in Dutch) 
Summary and Discussion 
Leukemia is characterised by an accumulation in the bone marrow of non-functional 
blood cells arrested at a particular stage of differentiation. In the process of normal 
hematopoiesis, errors may occur as the result of mutations in the DNA of 
hematopoietic precursor cells. These genetic lesions may lead to activation of proto-
oncogenes, inactivation of tumour suppressor genes or expression of aberrant gene 
products. The combination of different genetic lesions in a hematopoietic progenitor 
cell may ultimately result in the development of leukemia. An approach to find 
leukemia disease genes is the identification and cloning of common virus integration 
sites in murine leukemias. This approach has proven to be a sensitive tool to identify 
novel proto-oncogenes as well as tumour suppressor genes. 
We used the slow transforming retrovirus Cas-Br-M murine leukemia virus (Cas-Br-
M MuL V) in NIH/Swiss mice to establish a panel of leukemias (Chapter 2). All 
tumours found in leukemic animals were classified by gross pathology, morphology, 
and immunophenotype as well as the incidence of known common virus integration 
sites in murine leukemia virus-induced myeloid malignancies, i.e., Evil [ 1], 
Evill/C b 2 [2], Evi 12 [3], Flil [ 4] and c-Myb [5]. While most of the 
immunophenotyped Cas-Br-M MuLV induced tumours were of myeloid origin 
(58%), also numerous T -cell leukemias (21%) and mixed myeloid/T -cell leukemias 
(21%) were found. The myeloid leukemias and myeloid compartment of the mixed 
leukemias were further characterised by immunophenotyping with stem cell-, 
myeloid- and erythroid-specific antibodies. The known Cas-Br-M MuLV common 
vims integration sites Evil, Evill/Cb2 and Evil2 were demonstrated in 19%, 12% 
and 20% of the cases, respectively, whereas no Flil or c-Myb rearrangements were 
found. Integrations into Evil were restricted to myeloid leukemias, whereas those in 
Evill/Cb2 and Evil2 were identified in myeloid as well as T -lymphoid leukemias. 
This panel of well-characterised Cas-Br-M MuL V -induced hematopoietic tumours 
may be useful for the isolation and characterisation of new proto-oncogenes involved 
in murine myeloid or T -cell leukemias. 
The identification of common virus integration sites and isolation of potential disease 
genes in those loci used to be a laborious and time-consuming procedure. We 
established a rapid and simple RT-PCR based method, which facilitates the 
identification of virus integration sites and novel "leukemia" genes (Chapter 3). In 
addition to the RT-PCR technique, we used an inverse-PCR procedure combined with 
automated sequencing on the Cas-Br-M MuLV -induced primary mouse leukemias to 
isolate novel virus integration sites (Chapter 4). As a result, 126 different virus 
integration sites were cloned. Subsequently, a nested-PCR/Southern-blotting 
procedure was developed on genomic DNA from a large panel of MuLV-induced 
leukemias, to investigate whether a particular virus insertion represented a common 
virus integration site. This analysis was carried out for approximately one third of the 
virus integrations. The majority of the virus integration sites analysed appeared to 
represent a common vims integration site, suggesting that the other vims insertions 
represented common virus integration sites as well and may also harbour novel 
disease genes. Among the novel virus integration sites we found insertions in or ncar 
genes encoding nuclear proteins, novel putative signalling or transporter proteins, a 
ringfinger-protein gene and a panel of genes encoding novel proteins with unknown 
function. The specificity of the two methods described in Chapters 3 and 4 was 
confinned by the detection of previously identified common virus integration sites 
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and their corresponding leukemia genes, e.g. Evil [1, 6], Evi2 [7], Hoxa7 [8], c-Myb, 
Cb2/Evill [2], His] [9], and Evil2 [3]. These findings emphasise the significance of 
the novel common virus integration sites found in our studies. 
Large scale cloning of common virus integration sites and identification of the human 
homologues of the affected genes will serve a clinical interest. Retrospective studies 
in large cohorts of patient samples may demonstrate a correlation between expression 
or mutation of a (novel) transforming gene and prognosis of disease development. A 
representative example of a gene identified as a common virus insertion which may 
also be critical in human AML development is Evil. Murine Evil was identified as a 
common virus integration site in myeloid leukemia [1] (Chapters 2, 3 and 4). EVIl 
encodes a DNA binding protein and is located on human chromosome 3q26 [6]. 
Nonnally the gene is expressed at low levels in hematopoietic tissues, whereas high 
expression was observed in AML and MDS cases carrying a 3q26 abnormality [I 0, 
11}. In a retrospective study, analysing 319 de novo AML patients, Barjesteh Van 
Waalwijk Van Doorn-Khosravani et al. demonstrated applying real-time PCR analysis 
that high EVIl expression occurred in approximately 10% of de novo AML cases. 
EVIl expression appeared independent of the presence of 3q26 abnormalities and was 
highly predictive for unfavourable outcome of treatment [12]. High throughput 
analysis of gene expression through microarray technology allows the simultaneous 
analysis of thousands of parameters within a single experiment. Considering technical 
possibilities this is an even more rapid and pluriform technique than Real-time PCR to 
analyse aberrant expression of genes. Changes in expression patterns resulting from 
transcriptional, posttranscriptional or posttranslational control, and differences in 
subcellular localisation of proteins may be observed using this approach [13, 14]. 
Mutation analysis should provide additional information concerning the role of novel 
leukemia genes in human AML. High throughput sequencing protocols are now 
available to identify mutations in disease genes in AML on a large-scale. It has for 
instance been demonstrated by investigators in our institute that C-tenninal mutations 
in the C/EBPalpha gene in AML with intennediate-risk karyotype predict a good 
prognosis [15]. Patients with C-tenninal C/EBPalpha mutations had remission and 
relapse rates comparable to AML patients carrying a good-risk karyotype (i.e. 
t(15; 17), t(8;21 ), or inv(16)/del( 16) [ 16-18]). Although C/EBPalpha has not been 
identified as a common virus integration site, these data demonstrate the value of 
high-throughput sequencing of candidate genes in leukemia. 
The group of novel common virus integration sites that were identified in Chapter 4, 
contained the nm23-M2 gene. Nm23-M2 is one of eight members of the highly 
homologous family of nm23-genes [19], which can be divided into two groups 
(Chapter 5). One group contains the genes nm23-Ml to -M4, which are 44% to 88% 
similar in amino acid sequence. The second group, consisting of nm23-M5 to -M8, 
share considerably less homology with the first group or among each other (3% to 
30%). Nm23-Ml and nm23-M2, which share the greater homology, are located in 
tandem on mouse chromosome 11. Moreover, the human equivalent of nm23-Ml has 
been reported to be abnormally expressed in leukemias or lymphomas [20, 21]. High 
expression levels of NM23-H2 are associated with a poor prognosis in AML-M2, -
M4, and -M5 [22]. PCR/Southem blotting demonstrated that also nm23-Ml and 
nm23-M3 were frequent targets of proviral insertion. This indicates that multiple but 
not all members of the nm23-family may be involved in leukemic transfonnation. 
Since gene expression may be controlled at multiple levels, a lack of mRNA 
expression regulation does not exclude the presence of altered protein levels. In 
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Chapter 6 it is demonstrated that expression of the gene nm23-M2 may be influenced 
by the hematopoietic growth factors erythropoietin (EPO) and stem cell factor (SCF). 
However, we did not detect altered expression in nm23-M2 mRNA levels between 
growth factor stimulated cells and starved cells by Northern blot analysis. We 
demonstrate, however, that nm23-M2 polysome binding was growth factor dependent, 
indicating a translational control of gene expression by EPO and/or SCF. 
To evaluate how a particular gene may be aberrantly expressed and what its role may 
be in transformation, insight into the mechanism of its normal control and function 
will be of great value. In vivo and in vitro models have been developed to evaluate the 
role of particular genes in development. The nm23-M2 gene may normally be 
expressed in hematopoietic precursors. Regulation of nm23-M2 expression in 
development was investigated in the erythroid progenitor cell line Illl(Chapter 6). 
This precursor cell is capable of differentiating towards mature erythrocytes in vitro 
when stimulated with EPO [23, 24]. We demonstrated in Chapter 6 that association of 
nm23-M2 mRNA with polysomes as well as protein expression decreased during 
EPO induced differentiation of 1111 cells, indicating a change of translation of nm23-
M2 with erythroid maturation. Regulation of nm23-M2 polysome binding also 
appeared dependent on PI3K. Moreover, it was found that nm23-M2 mRNA started 
with a TOP-tract, a stretch of pyrimidines that is often found in translationally 
controlled genes. The data indicate that control of nm23-M2 protein expression may 
occur at the level of translation and suggest that abberant gene expression in 
malignant disease may not only occur by aberrant control of transcription. 
The growth factor dependent 32D myeloid cell line is capable of terminal 
differentiation towards neutrophils following stimulation with G-CSF [25]. In 
previous studies it has been demonstrated that this differentiation model may be of 
great value to study the role of potential disease gene in leukemic transformation. 
Introduction of Evil, Notch], or a truncated fonn of the G-CSF receptor resulted in a 
block of differentiation [26-28]. As described in Chapter 5 we made use of the 32D 
system to investigate the potential role of nm2 3-M2 in myeloid development. In 
contrast to what has been demonstrated with other disease genes, aberrant expression 
of nm23-M2 did not affect neutrophilic differentiation. Adaptation of the cells might 
have caused unresponsiveness to the aberrant protein expression, or the gene may 
have been switched off during cell growth. Inducible systems have been designed to 
avoid such limitations and study the role ofnm23-M2 in altered myelopoiesis. On the 
other hand it is also possible that alternative models are required to study the effect of 
nm23-M2 in transformation. As an alternative, it would be of interest to study the 
effect of uncontrolled expression ofnm23-M2 in the erythroid cell line l/11. 
To investigate the role of a potentially transforming gene in hematopoiesis in vivo 
transgenic mice may be generated as discussed for Cb2 in Chapter 7. Although 
increased expression of the Cb2 gene was observed in hematopoietic tissues, during a 
follow-up of more than one year no hematological defects became apparent. 
Expression of Cb2 alone may not be adequate to cause any hematological 
abnormalities. Taking into account that overexpression of Cb2 in vitro is sufficient for 
blocking the differentiation of myeloid precursor cells [29], it may be more plausible 
that the lack of a direct effect of Cb2 overexpression is due to the choice of the 
promoter used to express the trans gene in the mice. The Sea-l promoter functions in a 
small population of primitive hematologic precursors [30]. To further investigate the 
role of Cb2 receptor in vivo, transgenics could be made under the control of another 
promoter. Alternatively it would be wise to generate inducible and/or conditional 
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constructs to overexpress a potential gene of interest. Cre-recombinase is becoming an 
important instrument for achieving precise genetic manipulation in mice. Using the 
recombinase activity as a genetic activation or inactivation switch, conditional 
transgenic or conditional knock-out mice are currently being created. The Cre protein 
catalyses the recombination between the two loxP recognition sites [31]. For 
conditional trans genesis, the promoter and the coding region of a gene of interest are 
separated by a loxP flanked STOP region, which does not allow any transcription 
initiated from the promoter to read through and include the gene. When this region is 
removed by Cre-mediation, the gene of interest may be expressed. In order to create 
an inducible system, the ere-recombinase may be fused to the LBD of the mutated 
estrogen receptor. In the presence of tamoxifen the ere-fusion protein trans locates 
into the nucleus and will induce the ere-mediated excision [32]. 
Since the eb2 transgenic mice did not develop any hematological defects during a 
long-time follow up, the cooperative potential of eb2 was investigated by infection of 
newborn pSca-J/Cb2 transgenic mice with Cas-Br-M MuLV (Chapter 7). This 
revealed that significantly more virus treated transgenic mice developed leukemia 
than virus exposed control littermates, suggesting that eb2 indeed plays a role in 
leukemia progression. Moreover, Evil overexpression was observed in several 
independent virus-induced leukemias in pSca-I/Cb2 transgenic mice. These data 
would indicate that hematopoietic precursor cells that express high levels of eb2 
possess increased susceptibility for leukemia development. The linked overexpression 
of Cb2 and Evil would suggest collaboration in leukemogenesis. 
This thesis describes the generation of a novel panel of primary mouse leukemias. By 
two ne·wly developed and rapid techniques, common virus integrations sites could be 
identified. The isolation of known cVISs, such as Evil, Njl, Evill/Cb2, and Evi 12 
confirmed the specificity of the methods. Two genes that were found to be a c VIS were 
analysed functionally for involvement in leukemogenesis; i.e. nm23-M2 and 
EviJJ!CbJ. 
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Samenvatting en Discussie 
Leukemic wordt gekenmerkt door een opeenhoping van niet-functionele cellen in het 
beenmerg die tijdens een bepaald stadium in de differentiatie tot staan zijn gebracht. 
In het proces van normale hematopoiese kunnen fouten optreden als resultaat van 
mutaties in het DNA van hematopoietische voorlopercellen. Deze genetische lesies 
kunnen leiden tot activatie van proto-oncogenen, inactivatie van tumorsuppressor 
genen of expressie van aberrante genprodukten. De combinatie van verschillende 
genetische defecten in een hematopoietische voorlopercel kan uiteindelijk leiden tot 
het ontstaan van leukemie. Een benadering om leukemie ziektegenen te vinden is het 
identificeren en kloneren van zogenaamde "common virus integratie sites" in 
leukemieen bij muizen. Het is bewezen dat deze benadering een gevoelige methode is 
die het identificeren van zowel nieuwe proto-oncogenen als tumorsuppressorgenen 
mogelijk maakt. 
Wij hebben gebruik gemaakt van het langzaam transformerende retrovirus Cas-Br-M 
muizenleukemievirus (Cas-Br-M MuLV) om een groep leukemieen te verkrijgen bij 
NIH/Swiss muizen (Hoofdstuk 2). Alle tumoren die gevonden werden in leukemische 
dieren werden geclassificeerd op basis van globale pathologic, morfologie en 
immunofenotype, en ook op basis van bekende common vims integratie sites in 
muizenleukemievims-geinduceerde maligniteiten zoals Evil (1], Evill/Cb2 [2], 
Evil2 [3], Flil [4] en c-Myb [5]. Terwij1 de meeste geimmunofenotypeerde Cas-Br-M 
MuLV gelnduceerde tumoren van myeloide origine waren (58%), werden ook talrijke 
T-ce1 1eukemieen (21%) en gemengd mye1oide/T -ce11eukemieen (21%) gevonden. De 
myeloide leukemieen en het myeloide compartiment van de gemengde leukemieen 
werden verder geanalyseerd met behulp van immunofenotypering met stamcel-, 
myeloid- en erythroid-specifieke antilichamen. De bekende Cas-Br-M MuLV 
common integratiesites Evil, Evill/Cb2 en Evil2 werden in respectievelijk 19%, 
12% en 20% van de gevallen aangetoond, ten:vijl er geen rearrangeringen in Flil en c-
Myb werden gevonden. Integraties in Evil waren beperkt tot myeloide leukemieen, 
terwijl die in Evill/Cb2 en Evil2 gevonden werden in zowel myeloide als T -lymfoide 
leukemieen. Deze groep van goed beschreven Cas-Br-M MuL V -gelnduceerde 
hematopoietische tumoren kan bmikbaar zijn voor het isoleren en karakteriseren van 
nieuwe proto-oncogenen die betrokken zijn bij myeloide ofT -celmuizenleukemieen. 
De identificatie van common vims integratiesites en isolatie van mogelijke 
ziektegenen in deze loci is altijd een arbeidsintensieve en tijdverslindende procedure 
geweest. Wij hebben een snelle en simpele methode ontwikkeld, die gebaseerd is op 
RT-PCR, en die de identificatie van virus integratiesites en nieuwe "leukemiegenen" 
vergemakkelijkt (Hoofdstuk 3). Als aanvulling op de RT-PCR techniek hebben we 
een inverse-PCR procedure toegepast in combinatie met geautomatiseerde 
sequentiebepaling op de Cas-Br-M MuLV gelnduceerde primaire muizenleukemieen 
om nieuwe common virus integratiesites te isoleren (Hoofdstuk 4). Als resultaat 
werden 126 verschillende virus integratiesites gekloneerd. Vervolgens werd een 
interne PCR-Southem-blot procedure ontwikkeld op genomisch DNA van een grote 
groep muizenleukemievirus gelnduceerde leukemieen, om te onderzoeken of een 
bepaalde virus integratie ook een common integratiesite vertegenwoordigde. Deze 
analyse werd uitgevoerd op ongeveer een-derde van de virus integratie sites. De 
meerderheid van de virus integratiesites die geanalyseerd werden, bleek een common 
integratie site te vertegenwoordigen. Dit suggereert dat de andere virus integratiesites 
ook common zijn en nieuwe ziektegenen kunnen bevatten. Onder de nieuwe virus 
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integratiesites vonden wij inserties in of nabij genen die coderen voor kemeiwitten, 
nieuwe potentiele signaal- of transporteiwitten, een ringfinger-eiwitgen en een groep 
genen die voor nieuwe eiwitten met onbekende functies coderen. De specificiteit van 
de methodes die in Hoofdstuk 3 en 4 beschreven worden werd bevestigd door de 
detectie van eerder beschreven common vims integratiesites en hun correponderende 
leukemiegenen, zoals Evil [I, 6], Evil [7], Hoxa7 [8], c-Myb, Cb2/Evill [2], His! [9] 
en Evil2 [3]. Deze bevindingen benadrukken de significantie van de nieuwe common 
vims integratiesites die gevonden zijn in onze studies. 
Het op grate schaal k]oneren van common vims integratiesites en identificeren van de 
humane homologen van de aangedane genen dient een klinisch belang. Retrospectieve 
studies in grate cohorten met patientenrnateriaai kunnen een correlatie tussen 
exprcssie of mutatie van een (nieuw) transformerend gen en de prognose van de 
ziekteontwikkeling aantonen. Een representatief voorbeeld van een gen dat 
geldentificeerd is als een common vims integratiesite die ook kritiek kan zijn in de 
ontwikkeling van humane AML is EVI 1. Muizen-Evil was geidentif1ceerd als een 
common vims integratiesite in myeloide leukemic [I] (Hoofdstukken 2, 3 en 4). EVJJ 
codeert voor een DNA-bindend eiwit en is gelegen op humaan chromosoom 3q26 [6]. 
Normaalgesproken wordt dit gen op een laag niveau tot expressie gebracht in 
hematopoietische weefsels, tenvijl hoge expressie gezien is in gevallen van AML en 
MDS die een 3q26 afurijking had den [ 1 0, 11]. In een retrospectieve stu die waarin 319 
de novo AML patienten geanalyseerd wcrden, toonden Barjesteh Van Waalwijk Van 
Doorn-Khosravani et al. door middel van real-time PCR analyse aan dat hoge EVIl 
expressie in ongeveer I 0% van de de novo AML gevallen voorkwam. EVIl expressie 
leek onafhankelijk te zijn van de aanwezigheid van 3q26 afvvijkingen en was in hoge 
mate voorspellend voor een ongunstige uitkomst van de behandeling [12]. "High 
throughput" analyse van genexpressie via mica-array technologic maakt gelijktUdige 
analyse van duizenden parameters mogelijk binnen een enkel experiment. Rekening 
houdend met technische mogelijkheden is dit een nog snellere en meer plurifonne 
teclmiek dan Real-time PCR analyse om aberrante expressie van genen te analyseren. 
Veranderingen in patroon die het resultaat zijn van transcriptionele, 
posttranscriptionele of posttranslationele controle en verschillen in subcellulaire 
lokalisatie van eiwitten kan door middel van deze benadering bestudeerd worden [13, 
14]. 
Mutatie analyse zou aanvullende informatie betreffende de rol van nieuwe 
leukemiegenen in AML moeten brengen. High-throughput sequentie protocollen zijn 
nu beschikbaar om op grote schaal mutaties in ziektegenen in AML te identificeren. 
Het is bijvoorbeeld aangetoond door onderzoekers van ons instituut dat C-tenninale 
mutaties in het C/EBPalpha gen in AML met gemiddeld-risico karyotype een gunstige 
prognose voorspellen [15]. Patienten met C-terminale C/EBPalpha mutaties hadden 
remissie en relapse cijfers die vergelijkbaar waren met die van AML patienten met 
een gunstig-risico karyotype (bijv. t(15;17), t(8;21), of inv(l6)/del(16) [16-18]). 
Hoewel C/EBPalpha nooit geidentificeerd is als een common virus integratie site, 
tonen deze data de waardc van high-throughput sequentiebepaling van kandidaat-
leukemiegenen aan. 
De groep van nieuwe common virus integratie sites die geidentificeerd werden in 
Hoofdstuk 4, bevatte het nm23-M2 gen. Nm23-lvf2 is een van de acht leden van de 
zeer homologe familie van nm23-genen [19], die onderverdeeld kan worden in twee 
groepen (Hoofdstuk 5). Een groep bevat de genen nm23-Ml tot en met -M4, die 44% 
tot 88% gelijk zijn in aminozuurvolgorde. De tweede groep, bestaand uit nm23-M5 tot 
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en met ~M8, delen aanzienlijk minder homologie met de eerste groep, maar ook met 
elkaar (3% tot 30%). Nm23-lvfl en nm23-M2, die het meest homoloog zijn, liggen in 
tandem op muizenchromosoom 11. Ook is gepubliceerd dat de humane equivalent van 
nm23-Ml abnormaal tot expressie gebracht wordt in leukemieen en lymfomen [20, 
21]. Hoge expressie van NM23-H2 is geassocieerd met een slechte prognose in AML-
M2, -M4 en -MS [22]. PCR/Southern blotting heeft aangetoond dat ook in nm23-MI 
en -i\13 frequent provirale insertie optreedt. Dit geeft aan dat meerdere, maar niet alle 
leden van de nm23-familie betrokken zouden kunnen zijn in leukemische 
transfonnatie. 
Aangezien genexpressie op meerdere niveaus gecontoleerd kan worden, sluit een 
tekort aan mRNA expressie regulatie niet uit dat er sprake kan zijn van een 
veranderde eiwitexpressie. In Hoofdstuk 6 wordt aangetoond dat expressie van het 
gen mn23-M2 belnvloed kan worden door de hematopoietische groeifactoren 
erythropoietine (EPO) en stam eel factor (SCF). Toch konden wij door middel van 
Northern blot analyse geen veranderde expressie van nm23-M2 mRNA aantonen 
tussen groeifactor gestimuleerde cellen en gestarveerde cellen. Wij tonen echter aan 
dat binding van nm23-M2 aan polysomen groeifactor afhankelijk is, wat aangeeft dat 
er sprake is van translationele controle van genexpressie door EPO en/ofSCF. 
Om te evalueren hoe een bepaald gen abenant tot expressie gebracht kan worden en 
wat zijn rol in transformatie kan zijn, is inzicht in het mechanisme van normale 
controle en functie van grate waarde. Er zijn in vivo en in vitro modellen ontwikkeld 
om de rol van bepaalde genen in de ontwikkeling te onderzoeken. De expressie van 
nm23-M2 kan nonnaal zijn in hematopoietische voorlopercellen. Regulatie van 
nm23-M2 expressie gedurende ontwikkeling werd onderzocht in de erythroide 
voorlopercellijn I/11 (Hoofdstuk 6). Deze voorlopercel kan in vitro tot een volwassen 
erythrocyt differentieren na stimulatie met EPO [23, 24}. In Hoofdstuk 6 tonen wij 
aan dat zowel de associatie van nm23-M2 mRNA met polysomen als de 
eiwitexpressie omlaag gaat gedurende EPO-geinduceerde differentiatie van I/ 11 
cellen. Dit geeft aanwijzingen voor een verandering in nm23-M2 translatie tijdens 
erythroide maturatie. Regulatie van mn23-M2 polysoombinding lijkt ook afbankelijk 
te zijn van PI3K. Bovendien is gevonden dat het nm23-M2 mRNA met een TOP-tract 
begint, een rij pyrimidines die vaak in translationeel gereguleerde genen gevonden 
wordt. De data duiden erop dat controle van nm23-M2 eiwitexpressie op het niveau 
van translatie kan gebeuren en suggereren dat abenante genexpressie in maligne 
ziekten niet aileen kan optreden door aberrante controle van transcriptie. 
De groeifactor afhankelijke myeloide cellijn 32D kan volledig uitrijpen tot een 
neutrofiele granulocyt volgend op stimulatie met G-CSF [25]. In voorheen 
uitgevoerde studies is aangetoond dat dit differentiatiemodel grote waarde kan hebben 
voor bet bestuderen van de rol van mogelijke ziektegenen in leukemische 
transfonnatie. Introductie van Evil, Notch 1 of een verkorte vonn van de G-CSF 
receptor resulteert in een blokkade van differentiatie [26-28]. Zoals beschreven in 
Hoofdstuk 5 hebben wij gebmik gemaakt van het 32D systeem om de mogelijke rol 
van nm23-lvf2 in myeloide ontwikkeling te onderzoeken. In tegenstelling tot wat voor 
andere ziektegenen aangetoond is, heeft aben·ante expressie van nm23-M2 geen 
invloed op neutrofiele differentiatie. Een mogelijke verklaring hiervoor is dat 
adaptatie van de cellen ervoor gezorgd kan hebben dat zij geen reactie vetionen op de 
aberrante eiwitexpressie. Een andere oorzaak zou kunnen zijn dat het gen 
uitgeschakeld is gedurende celgroci. Om dergelijke beperkingen te vennijden zijn 
induceerbare systemen ontworpen om zo de rol van nm23-M2 in veranderde 
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myelopoiese te bestuderen. Aan de andere kant is het ook mogelijk dat andere 
modellen nodig zijn om het effect van nm23-M2 op transfonnatie te bestuderen. Als 
altematief zou het interessant zijn om het effect van ongecontroleerde nm23-M2 
expressie in 1111 cellen te onderzoeken. 
Om de rol van een potentieel transformerend gen in hematopoiese in vivo te 
onderzoeken kunnen transgene muizen gemaakt worden, zeals beschreven voor Cb2 
in Hoofdstuk 7. Alhoewel toegenomen expressie van het Cb2 gen in hematopoietische 
cellen waargenomen werd, werden er geen hematologische defecten gezien gedurende 
een follow-up van meer dan een jaar. Expressie van Cb2 aileen zou niet adequaat 
kunnen zijn om hematologische a:furijkingen te veroorzaken. Rekening houdend met 
het feit dat overexpressie van Cb2 in vitro voldoende is om de differentiatie van 
myeloide voorlopercellen te blokkeren [29], is het meer aannemelijk dat het gebrek 
van een direct effect van Cb2 overexpressie te wijten is aan de keuze van de gebruikte 
promoter om het transgen tot expressie te brengen in de muis. De Seal-promoter 
functioneert in een kleine populatie van primitieve hematologische voorlopers [30]. 
Om de rol van de Cb2-receptor in vivo verder te onderzoeken zouden transgenen 
onder de controle van een andere promoter gemaakt moeten worden. Als altematief 
zou het verstandig zijn om induceerbare en/of conditionele constructen te maken om 
een gen van interesse tot expressie te brengen. Cre-recombinase wordt meer en meer 
een manier om preciese genetische manipulatie in muizen te bewerkstelligen. Gebruik 
makend van de recombinase activiteit als genetische activatie of inactivatieswitch, 
worden op dit moment conditionele trans gene of conditionele knock-out muizen 
gecreeerd. Het Cre-eiwit katalyseert de recombinatie tussen de twee loxP 
herkenningsplaatsen [31]. Voor conditionele trans genese worden de promoter en de 
coderende regio van een gen van interesse van elkaar gescheiden door een loxP 
geflankeerde STOP regia, zodat geen transcriptie toegestaan wordt vanaf de promoter 
waarbij het gen gelncludeerd wordt. Als deze regia venvijderd is door middel van Cre 
tussenkomst, kan het gen van interesse tot expressie worden gebracht. Om een 
induceerbaar systeem te creeren, kan de Cre-recombinase gefuseerd worden aan de 
LBD van de gemuteerde oestrogeen receptor. In aanwezigheid van tamoxifen 
verplaatst het Cre-fusie-eiwit zich naar de celkem en zal de Cre gemedieerde excisie 
induceren [32]. 
Aangezien de Cb2-transgene muis gedurende een lange follow-up tijd geen 
hematologische stoomis ontwikkelde, werd de samenwerkende potentie van Cb2 
onderzocht door pasgeboren pSca-I/Cb2 transgenen te infecteren met Cas-Br-M 
MuL V (Hoofdstuk 7). Dit liet zien dat significant meer transgenen die behandeld 
waren met het leukemievirus leukemie ontwikkelden dan controlemuizen, wat 
aanduidt dat Cb2 inderdaad een rol speelt in leukemievoortgang. Bovendien werd 
overexpressie van Evi I gezien in verschillende onafhankelijke virus gei:nduceerde 
leukemieen bij pSca-I/Cb2 transgenen. Deze data zouden kunnen betekenen dat 
hematopoietische voorlopercellen die Cb2 hoog tot expressie brengen een verhoogde 
mogelijkheid bezitten voor ontwikkeling van leukemie. De samenhang tussen 
overexpressie van Cb2 en Evil zou een samenwerking in leukemogenese kunnen 
aanduiden. 
Dit proefschnft beschrijft de ontwikkeling van een nieuwe groep primaire 
muizenleukemieiin. Via twee nieuw ontwikkelde en snelle technieken konden common 
virus integratiesites geidentificeerd worden. De isolatie van bekende common virus 
integratiesites, zoals Evil, Nfl, Evill/Cb2, en Evil2 bevestigt de specificiteit van de 
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methoden. Twee genen die gevonden werden als common virus integratiesite werden 
functioneel geanalyseerd voor betrokkenheid blj leukemogenese, i.e. nm23-M2 en 
Evill/Cb2. 
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acute lymphoblastic leukemia 
acute myeloid leukemia 
basepair 
Cas-Br-M virus integration site 
Cas-Br-M MuLV FVB Leukemia 
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common virus integration site 
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stem cell factor 
the incredible man 
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thrombopoietin 
virus integration site 
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afdeling Hematologic van harte bedanken, en een aantal mensen in het bijzonder. 
Mijn co-promotor Ruud Delwel, de beste supervisor die ik me maar kon wensen. 
Ruud, jij wist aan de meest tegenvallende resultaten nog een positieve draai te geven. 
Heel erg bedankt voor je begeleiding door alle jaren been. 
Mijn promotor Bob LOwenberg wil ik bedanken voor zijn steun en opbouwende 
kritiek tijdens alle werkbesprekingen en refereeravonden. Bob, dankjewel voor bet 
laatste zetje dat nodig was om dit boekje te voltooien. 
Mijn naamgenoot Marieke von Lindern heeft een enorme bijdrage geleverd aan het 
nm23 werk. Marieke, dankje voor je tomeloze enthousiasme. 
Professor Hagemeijer, professor Hoeijmakers en professor Oosterhuis wil ik 
bedanken voor het kritisch doorlezen van mijn proefschrift. 
De Delwel-groep, jullie hebben door de jaren been bewezen een echte supergroep te 
ZlJn. 
Mijn paranimfen Yolanda Vankan, Marion van den Broek en Antoinette van Hoven 
staan met reden naast mij vandaag. Yolanda, wat hebben we altijd fantastisch 
samengewerkt. Het is een korte zin, maar hij drukt precies uit hoe het altijd was. 
Marion, jou wil ik bedanken voor de gezellige werksfeer en de buitengewone 
hulpvaardigheid: als de tijdsplanning weer eens in de soep liep was daar altijd jouw 
helpende hand die nog wel even mini's kon picken ofprobejes afdraaien. Antoinette 
van Hoven is de laatste jaren ook van onschatbare waarde geweest voor mij. 
Antoinette, het was in no-time duidelijk dat ik een mazzelaar was met jou als maatje 
op het nm23-project. 
Sandra Verbakel, ik ben blij dat je er weer bent. Dankjewel voor de kweektips die je 
altijd bereid was te geven. Dominik Spensberger: I like your ironic sense of humour, 
and thank you so much for the wonderful flowers on my last official day in the lab. 
Fokke Lindeboom: bedankt voor je bijdrage aan hoofdstuk 5 en veel succes met het 
verder onderzoeken van nm23. Eric van den Akker, bedankt voor de punten op de i's 
van hoofdstuk 4. Marjolein Tas, Claudia Erpelinck, Sahar Khosravani en Nazik 
Rayman: jullie wil ik bedanken voor de prettige samenwerking, ook al was het kort. 
Tijdelijk Delwelletje Yvonne Jenniskens heeft tijdens haar HLO-afstudeeronderzoek 
vele (inverse) PCRs gedaan. Yvonne, ik wil je voor over een aantal jaren alvast veel 
succes wensen in je eigen aio-schap (?). 
Met mijn goede vriendinnen Meritxell Alberich Jordi en Marieke Mossink heb ik ook 
buiten het lab veel tijd doorgebracht. Thank you so much for always being there when 
I needed you, for all the fun we had and no doubt will have in the future. 
Buitenlabse activiteiten waren er altijd genoeg: vooral de "kolonistenclub" is nog 
steeds een regelmatig terugkerend event. Gert-Jan van de Geijn, Geert Westerhuis, 
Joanna Prasher: dankjulliewel voor aile gezelligheid. 
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Mensen van de "G"-groep: Ivo Touw had altijd suggesties ter verbetering van bet 
onderzoek. Ivo, dank je dat je ook vandaag weer blijk geeft van je interesse. Sigrid 
Oomen, het was zeker heel gezellig op (en rand) de ASH in New Orleans! I would 
like to thank Alister Ward for being such a nice colleague during the three years of his 
presence on the lab. Ook Stefan Erkeland wil ik bedanken voor de nuttige 
opmerkingen tijdens werkoverleg. 
Montserrat Blitzquez Domingo has performed valuable experiments on the nm23-
study. Thank you for that, Montse. Uit dezelfde groep wil ik Thamar van Dijk 
bedanken voor het delen van de computer. Ik hoop dat je nieuwe kamergenoot Jos 
Verstappen wel gaaf vindt. 
Bij mevrouw Venneij-Keers (afdeling Plastische Heelkunde) heb ik de eerste stappen 
op het onderzoekerspad gezet. Dankuwel voor deze mogelijkheid en voor de 
begeleiding bij bet schrijven van mijn eerste artikel. 
Mijn tweede stappen zette ik als student bij Peter Valk. Peter, ik bewonder je 
nauwkeurigheid. Als ik niet bij jou was afgestudeerd, was ik nooit aan een aio-baan 
begonnen. 
Karola van Rooyen heeft aldie jaren hele mooie figuren en dia's voor me gemaakt. 
Karola, bedankt voor je koelbloedigheid als de stress me weer eens te veel werd. 
Jeanne Vlasveld wil ik bedanken voor aile gepleegde telefoontjes en verstuurde faxen, 
brieven en e-mails zodat ik op de juiste wijze door het promotietraject ben geloodst. 
Ans Mannens en Eveline van Heese hebben gezorgd voor een toegankelijk en 
hulpvaardig secretariaat op de afdeling. Veel dank daarvoor. 
De bijdragen van Nico de Both, Walbert Bakker, Rudi Hendriks en Pictcr Leenen zijn 
belangrijk geweest voor de totstandkoming van dit proefschrift. I also would like to 
thank Monja Lunghi, Elaine Dzierzak, Evan Parganas, Florence Boulm6, Bianca 
Habermann, Ernst MUllner, and Hartmut Beug for their contribution to the work. 
Mijn ouders, mijn zusje en haar vriend, "schoonouders", "zvv·agers" en hun 
vriendinnen wil ik bedanken voor hun belangstelling door de jaren been. 
en Tim. Allereerst zal ik rechtzetten dat jij hebt uitgerekend dat de mannelijke muizen 
uit hoofdstuk 2 significant eerder leukemie kregen dan hun vrouwelijke soortgenoten. 
En dat is niet de enige bijdrage die je hebt geleverd aan de totstandkoming van dit 
boekje. Dank jewel voor aile steun en liefde die ik van je heb gekregen. 
Marieke. 
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